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Angiotensin converting enzyme (ACE) is a zinc metalloprotease comprised of two 
homologous, catalytically active domains (90% active site identity and 60% sequence 
similarity).  The C-domain is responsible for blood pressure regulation via angiotensin I 
cleavage while the N-domain inactivates an antifibrotic peptide Acetyl-Ser-Asp-Lys-Pro 
(AcSDKP).  Since selective N-domain inhibition will result in AcSDKP accumulation, it shows 
promise for the treatment of fibrosis without affecting blood pressure.  Low bioavailability, 
however, precludes the use of currently available N-selective ACE inhibitors in a clinical 
setting.   
 
Inhibition of ACE by a phosphinic, peptidomimetic compound, 33RE, was characterized using 
a continuous assay with quenched fluorogenic substrate.  The N-domain displayed 
nanomolar (Ki = 11.21±0.74nM) and the C-domain micromolar (Ki = 11 278±410nM) 
inhibition, thus 1000-fold selectivity.  Residues predicted to contribute to selectivity based 
on the N-domain-33RE co-crystal structure were subsequently mutated to their C-domain 
counterparts. S2 subsite mutation with resulting loss of a hydrogen bond drastically 
decreased 33RE affinity (Ki = 2794±156nM) yet did not entirely account for the selectivity.  
Additional substitution of all unique S2’ residues, however, completely abolished N-selectivity 
(Ki = 10 009±157nM). Interestingly, these residues do not directly bind 33RE.  All mutants 
were therefore subjected to molecular dynamics (MD) simulations in the presence and 
absence of 33RE in addition to co-crystallization of 33RE with the N-domain mutant having 
all S2 and S2’ residues mutated. Trajectory analyses highlighted the S2’ residues’ importance 
in formation of a favourable interface between the ACE subdomains and thus a closed, 
ligand-bound complex. This was supported by X-ray crystallography and provides a molecular 
basis for the inter-subsite synergism governing 33RE’s 1000-fold N-domain selectivity. 
 
Enzyme kinetics were also used to study the concentration-dependent competitive inhibition 
and time-dependent irreversible oxidative inactivation of ACE catalysed by the Cu-Gly-Gly-
His-lisinopril (CuGGHLis) metallodrug.  Although both domains displayed nanomolar affinity 
for metallodrug binding (N-domain Ki = 44.94±1.84nM and C-domain Ki = 15.57±1.30nM), 
rapid and complete CuGGHLis-mediated inactivation occurred exclusively in the N-domain 
upon incubation with ascorbate and H2O2 redox co-reactants (k2 = 59 710 M-1 min-1).  




revealed a decreased rate for hydrolysis of a non-domain selective substrate.  This suggests 
that although CuGGHLis binds with similar affinity to both domains, the metal-chelate is 
optimally orientated in the N- but not the C-domain to catalyze oxidation of residues involved 
in substrate hydrolysis. 
 
The C-domain, in contrast, showed increased susceptibility to oxidative inactivation by 
diffuse radicals.  This is of physiological significance as C-domain inactivation in normotensive 
individuals could result in accumulation of pro-inflammatory peptides.  Since the N-domain 
is more heavily glycosylated, the potential role of unique glycans in diffuse radical shielding 
was studied using glycoprotein MD simulations.  Unique C-domain solvent tunnels were 
identified that could increase diffuse radical access and, additionally, the mechanism 
whereby glycosylation contributes to ACE thermal stability was described for each site.  This 
has implications for future ACE crystallography studies and the design of ACE-modulating 
agents with potential anti-inflammatory activity. 
 
This study demonstrated the utility of combining in vitro and in silico approaches to reveal 
how subtle amino acid or glycosylation site differences between the highly homologous 
domains control dynamic behaviour.  It furthermore elucidated how two inhibitors with 
different mechanisms of action selectively target the N-domain active site by exploiting these 
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Abs  Absorbance  
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(Abz)-FRK-(Dnp)-P-OH  (Abz)-Phe-Arg-Lys-(Dnp)-Pro-OH  
Abz-Gly o-Aminobenzoic acid-glycine 
Abz-LFK(Dnp)-OH  Abz-Leu-Phe-Lys(Dnp)-OH  
Abz-SDK(Dnp)P-OH  Abz-Ser-Asp-Lys(Dnp)Pro-OH  
(Abz)-YRK-(Dnp)-P-OH  (Abz)-Tyr-Arg-Lys-(Dnp)-Pro-OH  
ACE Angiotensin converting enzyme 
ACE2  Angiotensin converting enzyme 2 
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Aβ Amyloid beta-peptide  
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GGHLis Gly-Gly-His-lisinopril  
GlcNAc N-acetylglucosamine 
GPU Graphics processing unit 
HBS HEPES Buffered Saline  
HCV Hepatitis C virus  
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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h-IAPP Human islet amyloid polypeptide  
HIV Human immunodeficiency virus  
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HREST-BP Hamiltonian Replica Exchange with solute tempering and biasing potential 
IC20 The amount of inhibitor required for 80% residual activity 
IC50 The amount of inhibitor required for 50% residual activity 
IFN-γ Interferon gamma 
IgG Immunoglobulin G 
IL-1 Interleukin 1 
IL-6 Interleukin 6 
K Kelvin 
k2 Second order rate constant 
kBp Kilobase pairs 






Ki Inhibition constant 
KKS Kallikrein-kinin system  
Km Michaelis constant 
LB Luria Bertani  
LH-RH Luteinizing hormone-releasing hormone 
Lis Lisinopril  
LRP-1 Low density lipoprotein receptor-related protein 1  
Man Mannose 
MAPK Mitogen-activated protein kinase 
MD Molecular dynamics 
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MMP Matrix metalloproteinase 
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NeuAc N-acetylneuraminic acid (predominant mammalian sialic acid) 
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NTA Nitrilotriacetic acid 
NVT Constant number of particles, volume and temperature 




PAGE Polyacrylamide gel electrophoresis 
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PD Parkinson’s disease  
PDB  Protein Data Bank (http://www.rcsb.org/pdb) 
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PKC Protein kinase C  
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PMA Phorbol 12-myristate 13-acetate  
PMEMD Particle Mesh Ewald molecular dynamics 
PMSF Phenylmethylsulphonyl fluoride 
PNGs Potential N-linked glycosylation site 
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RAAS Renin-angiotensin aldosterone system  
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Ri Intrinsic reactivity to oxidation  
RMSD Root mean square deviation 
RMSF Root mean square fluctuation 
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RT-PCR Reverse transcription-polymerase chain reaction 
sACE Somatic ACE 
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SP Substance P 
SrtA Sortase A 
T2DM Type 2 diabetes mellitus  
tACE Testis ACE 
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TGF-β1 Transforming growth factor β1 
Tm Melting temperature 
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1.1  Physiological regulation of fluid homeostasis 
Hypertension is a major risk factor for several disease states including stroke, cardiovascular 
disease and kidney disease and is considered one of the most important preventable causes 
of death (Danaei et al., 2009).  In 2010, 31.1% of the global adult population (1.39 billion 
individuals) were suffering from hypertension (Mills et al., 2016).  The burden of 
hypertension is especially high in middle- to low income countries and increased dramatically 
in the period between 2000 and 2010 from 599 million to 1.0 billion hypertensive individuals 
(Mills et al., 2016).  There is thus a great need for effective antihypertensive therapy. 
 
Antihypertensive drug development started more than sixty years ago with the first well-
tolerated antihypertensive, chlorothiazide, discovered in 1958 (Bolte et al., 1958).  Fluid and 
electrolyte homeostasis is regulated by the renin-angiotensin aldosterone system (RAAS) and 
the kallikrein-kinin system (KKS) (Acharya et al., 2003).  In the RAAS, the enzyme renin is 
produced by the kidneys and cleaves a liver-derived protein angiotensinogen (Figure 1.1).  
This results in release of the decapeptide angiotensin I (AngI) which is further processed into 
angiotensin II (AngII) through dicarboxypeptidase action of the angiotensin converting 
enzyme (ACE, EC 3.4.15.1).  Upon binding of AngII to the angiotensin receptor type I (AT1R) 
and stimulation of the adrenal gland, vasoconstriction, aldosterone release, vasopressin 
release and sodium retention ensues.  Although AngII binding to the angiotensin receptor 
type 2 (AT2R) has an opposing effect (Siragy, 2000), this receptor is only expressed during 
foetal development and declines after birth (Grady et al., 1991).  ACE further functions to 
increase blood pressure via the KKS by degrading the vasodilator bradykinin (BK).  This 









Figure 1.1: Regulation of blood pressure via the renin-angiotensin aldosterone system and kallikrein-
kinin system. 
 
1.2  Biochemistry of ACE 
Transcription of a single human Ace gene with tissue specific promotors results in expression 
of two distinct isoforms (Kessler et al., 2000).  While the testis ACE isoform (tACE) occurs 
exclusively in male germinal cells and is important for fertility (Hagaman et al., 1998), the 
somatic form (sACE) is expressed on the surface of endothelial, epithelial, neuroepithelial 
and immune cells and is thus widely distributed among tissues (Erdos, 1990).  Release of sACE 
from the membrane by a yet unidentified secretase yields a soluble form which has been 
detected in blood, urine, cerebrospinal fluid and seminal fluid (Ehlers et al., 2012).  A single 
polypeptide chain gives rise to this type I transmembrane protein, possessing a 20-amino 
acid transmembrane region and 30-amino acid C-terminal cytoplasmic tail.   
 
sACE is a zinc metalloprotease of the M2 gluzincin family and has two extracellular domains, 
the N- and C-domain, separated by a short linker region.  Each domain contains an HEMGH 
zinc-binding motif and is catalytically active (Wei, 1991).  In contrast, the tACE isoform 
consists of a single domain essentially identical to the C-domain of sACE, except for the 36-
residue serine- and threonine-rich N-terminal region present in tACE (Ehlers et al., 1989).  
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The high degree of homology between the sACE domains (60% overall sequence similarity 
and 89% active site identity) (Soubrier, 1988) suggests that they originated by an evolutionary 
gene duplication event and were conserved due to differences in their physiological function.  
 
sACE cleaves a remarkable range of substrates through both endo- and exopeptidase action.  
These include AngI, enkephalins, kinins, neurotensin, formyl-Met-Leu-Phe, substance P 
(Erdos, 1990), gonadotropin-releasing hormone, also known as luteinizing hormone-
releasing hormone (LH-RH) (Skidgel and Erdos, 1985), N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) 
(Rousseau et al., 1995) as well as the amyloid beta-peptide (Aβ) (Oba et al., 2005; Zou et al., 
2009).  The C-domain is primarily responsible for blood pressure regulation via AngI cleavage 
(Wei, 1991; Fuchs et al., 2008) whereas the peptides LH-RH, AcSDKP and Aβ are preferentially 
cleaved by the N-domain (Fuchs, 2004; Rousseau et al., 1995; Oba et al., 2005; Zou et al., 
2009; Jaspard et al., 1993).  Although both domains hydrolyse BK, the C-domain is 
approximately 4-fold more efficient (Jaspard et al., 1993). 
 
1.3  ACE glycosylation 
1.3.1 Sites of mammalian ACE glycosylation 
sACE is present as a type-I membrane glycoprotein with ten N-domain and seven C-domain 
potential N-linked glycosylation sites (PNGs) comprised of N-X-S/T (where X is any amino acid 
except proline).  Mass spectrometric analyses of single-domain truncated ACE expressed in 
mammalian CHO-K1 cells revealed that C-domain sites c1-3 (N72, N90 and N109) were fully 
occupied whereas sites c4-6 (N155, N337 and N586) were partially occupied and the C-
terminal site c7 (N620) unoccupied (Yu et al., 1997).  The N-domain sites n1-6 (N9, N25, N45, 
N82, N117, N131) and n8-9 (N416, N480) were found to be glycosylated with the C-terminal 
site n10 (N494) unoccupied and the glycosylation status of site n7 (N289) unknown (Anthony 
et al., 2010).  The N-domain crystal structure (PDB ID: 2C6F), however, shows density 
suggesting GlcNAc attachment to N289, thus providing experimental evidence for 
glycosylation at this site.  Based on mass spectrometric analysis of the truncated C-domain, 
a fucosylated sialylated biantennary complex type glycan structure was proposed (Figure 1.2) 
(Yu et al., 1997).  This was supported by earlier quantitative HPLC analysis on human kidney 
sACE and tACE expressed in CHO-K1 cells (Ehlers et al., 1992). 
 






Figure 1.2: Proposed structure of the glycan attached to ACE PNGs. 
Prepared using the GlycoBuilder Tool contained within the GlycoWorkbench v.2.1 suite (Ceroni et al., 
2008) and represented with standard Symbol Nomenclature for Glycans (SNFG) notation (Varki et al., 
2015). 
 
1.3.2 Influence of glycosylation on ACE folding and function 
Glycosylation is involved in glycoprotein folding, localization, stabilization, activity, receptor 
binding and dimerization (Mitra et al., 2006).  In ACE the glycan locations and functions are 
domain-specific, apart from N-domain sites n3, n4 and n6 having equivalent locations to C-
domain sites c1, c3 and c4.  The lack of non-glycosylated C-domain secretion into the medium 
has been reported, suggesting a role for glycosylation in protein expression and processing 
(Gordon et al., 2003).  Previously, it was shown that secretion of the amyloid precursor 
protein is enhanced by sialylation at its N-linked sites (Nakagawa et al., 2006).  Secretion of 
ACE, however, does not appear to rely on sialic acid protein interactions since glycosylation 
with Man5GlcNAc2 (CHO-K1 glycosylation mutant Lec3.2.8.1 or Trichoplusia ni (Tn5) 
expression) or Glc3Man7-9GlcNAc2 (CHO-K1 expression in presence of N-
butyldeoxynojirimycin (NBDNJ)) still yielded correct folding of N- and C-domain 
(Redelinghuys, 2006; Gordon et al., 2003; Yu et al., 1997; O'Neill et al., 2008).   
 
The contribution of glycosylation at specific sites towards protein folding was previously 
investigated by N>Q mutation of the truncated N- and C-domain PNGs.  It was concluded that 
correct N-domain folding and secretion occurs in the presence of glycosylation at C-terminal 
sites n7-9 or a combination of sites n1, n2 or n3 and n7, n8 or n9 (Anthony et al., 2010) (Figure 
1.3).  Glycosylation at two C-terminal (Ndom7,9 or Ndom8-9) or only N-terminal (Ndom1; 
Ndom3; Ndom1,3; Ndom2-3; Ndom1-3; Ndom1-4; Ndom1-5; Ndom1-6) sites resulted in 
protein misfolding and rapid intracellular degradation (Anthony et al., 2010; Redelinghuys, 
2006).  C-domain folding, on the other hand, could be achieved with glycosylation at sites c1; 
c1-2; c3; c1 and c3; c1-3; c2-3; or c1-4.  Site c1 alone slightly decreased the efficiency of 
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processing and solubilization whereas site c2 alone resulted in misfolding and rapid 
intracellular degradation (Gordon et al., 2003).   
Although glycosylation is important in folding and processing of the truncated domains, it 
does not appear to play a role in enzymatic function of mature protein.  N-domain catalytic 
efficiency between CHO-K1, CHO-K1 Lec3.2.8.1 or CHO-K1+NBDNJ expressed protein 
(Redelinghuys, 2006) and specific activity between glycosylation mutants and wild-type is 
comparable (Anthony et al., 2010).  Similarly, C-domain catalytic efficiency is not affected by 
treatment with NBDNJ, glycosylation site mutation (Gordon et al., 2003) nor removal of all 
but a single GlcNAc residue at each site (after endoglycosidase-H (Endo-H) treatment of CHO-
K1+NBDNJ expressed protein) (Yu et al., 1997). 
 
1.3.3 The role of glycosylation in thermal stability 
Apart from mediating folding, glycans can also function in stabilizing the underlying protein 
by directly interacting with certain surface residues (Mitra et al., 2006; Lee et al., 2015). This 
could increase the protein’s resistance to thermal degradation.  The N-domain melting 
temperature (Tm) is markedly higher than that of the C-domain and even allows purification 
of the single N-domain by selective thermal degradation of the C-domain (O'Neill et al., 2008; 
Voronov et al., 2002a).  Earlier reports suggested that the N-domain’s superior thermal 
stability is due to its N-terminal region’s high α-helicity, proline content and glycosylation 
(Voronov et al., 2003).  Site-directed mutagenesis of the N-X-S/T sites to Q-X-S/T, however, 
revealed that glycosylation at C-terminal regions is also involved.   
 
Thermal stability is conferred by complex-type sugars at N-domain sites n2 and n3 together 
with n7 or n9 with markedly increased thermal degradation upon loss of either site n2 or n3 
(O'Neill et al., 2008; Anthony et al., 2010) (Figure 1.3).  This stabilization might involve sialic 
acid interactions with the protein since the N-domain (in sACE form) Tm decreased by 6°C 
when expressed in Tn5 insect cells (lacking sialic acid residues) instead of CHO-K1 cells 
(O'Neill et al., 2008).  As opposed to loss of direct interactions it could, however, also be 
related to an increased solvent accessible surface area upon glycosylation with the smaller 
Man5GlcNAc2.  Since not only glycan-protein, but also glycan-glycan interactions occur, 
glycosylation could significantly decrease the exposed protein surface area.  Previously, 
Kryukova et al reported a contact area of 200–300Å between ACE and a sialylated 
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biantennary complex glycan (Kryukova et al., 2015).  Indeed, the C-domain Tm was decreased 
by only 2°C with CHO-K1+NBDNJ expression (Glc3Man7-9GlcNAc2) but by 6°C when expressed 
in Tn5 cells (Man5GlcNAc2), as seen for the N-domain.  Since removal of sites c5-6 or c2, c4, 
c5 and c6 decreased C-domain Tm by 6°C and 8°C, respectively, stabilization is largely 
conferred by sites c5 and c6 (O'Neill et al., 2008).  At present, however, the exact mechanism 
whereby glycosylation protects ACE against thermal denaturation and the basis for N-domain 



























Figure 1.3: Glycan contribution to ACE folding and thermal stability. 
C-domain numbering is given as standard tACE numbering (N.D.: Tm not determined; arrows signify 
the degree by which Tm was decreased; crosses indicate aberrant protein folding and resulting 
intracellular degradation). 
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1.4  ACE structural biology 
1.4.1 Structures of the N- and C-domain of ACE 
The degree of sACE glycosylation (30% carbohydrates by weight) presented a major hurdle 
for structural studies using X-ray crystallography since the flexibility of glycans is detrimental 
for crystal packing.  While enzymatic deglycosylation might yield purified protein amenable 
to crystallization, such an approach is costly and potential sample loss could be problematic 
for a technique which requires large protein quantities.  The first ACE structure was therefore 
solved using a site-directed mutagenesis approach to obtain a truncated C-domain protein 
with the minimum glycan requirement for correct folding and processing (Natesh et al., 
2003).  Subsequently, the truncated N-domain structure was also solved using this approach 
(Anthony et al., 2010).  The C-domain was glycosylated at sites c1 and c3 while the N-domain 
contained glycans at sites n3, n8 and n9. 
 
The overall topology is very similar between the two domains, in line with their high sequence 
similarity (Corradi et al., 2006).  Each ellipsoid ACE domain is largely composed of alpha 
helices which are separated by several flexible loops and six beta sheets (Figure 1.4).  The 
tertiary structure is further formed by three cysteine disulphide bridges.  The single unbound 
cysteine is located on a parallel beta sheet on the surface whereas two of the three cysteine 
disulphide bridges are proximal to the anti-parallel beta sheets.  The active site zinc is located 
within a large, occluded cleft which divides each domain into two subdomains and is covered 
by a lid-like structure comprised of the first three N-terminal helices.  Based on the lid’s high 
B-factors, it has been suggested that hinging in this region could mediate opening of the 
active site cleft to provide access to the large range of ACE substrates (Watermeyer et al., 
2006; Anthony et al., 2010).  Catalytic efficiency of especially the C-domain is dependent on 
the presence of chloride (Yates et al., 2014).  Some insight into the higher C- than N-domain 
chloride sensitivity was provided by the presence of two chloride ions in the C-domain and 










Figure 1.4: Structural alignment of the N- and C-domain of ACE. 
The N-domain (PDB ID: 3NXQ) and C-domain (PDB ID: 1O86) helices are given in green and cyan, 
respectively, with the N-terminal lid formed by helices 1-3 coloured dark pink.  The cysteine residues 
are shown as cyan sticks and the chloride ions as orange spheres.  The active site zinc ion within the 
deep cleft (dotted line) is shown as a grey sphere complexed to the ACE inhibitor, lisinopril (yellow 
ball-and-stick representation). 
 
1.4.2 Structure of the two-domain sACE 
Physiologically, however, sACE is comprised of both domains and their interactions have 
been shown to cooperatively affect not only its catalytic efficiency, but also inhibitor binding 
(Skirgello et al., 2005).  Furthermore, it has been proposed that upon inhibitor binding, 
intracellular signalling is activated via sACE dimerization to ultimately stimulate ACE 
expression (Kohlstedt et al., 2004; Kohlstedt et al., 2006).  To gain insight into the two 
domain’s relative orientations and the mechanism whereby these processes occur, the full-
length sACE structure is required.  Use of the mentioned PNGs N>Q mutagenesis approach 
for sACE, however, failed to produce correctly folded, minimally glycosylated full-length 
protein amenable to crystallization (Nkoe, 2014; Anthony, 2011).  Removal of glycosylation 
sites led to intracellular cleavage at the inter-domain linker and subsequent degradation of 
the individual domains.  Although three-dimensional electron microscopic reconstruction of 
NH2 
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negatively stained porcine sACE has been performed (Chen et al., 2010), fitting of the 
truncated domains into this low resolution (23Å) structure did not offer much atomic detail.  
At present, the precise orientation of the two domains in human sACE form and the location 
of inter-domain contacts is therefore not known (Corradi et al., 2006).  As such, the 
mechanisms of inter-domain substrate cooperativity and sACE homodimerization remain 
elusive.  Understanding the functional role of each domain’s glycosylation sites could greatly 
enhance the likelihood of successfully obtaining a correctly folded, minimally glycosylated 
sACE variant amenable to crystallization. 
 
1.5  First generation ACE Inhibitors 
Isolation of bradykinin potentiating peptides (BPPs) from Bothrops jararaca snake venom led 
to design of the first orally effective ACE inhibitor, captopril (Ondetti et al., 1977).  The first 
generation of clinically approved compounds were developed based on the structure of 
thermolysin and carboxypeptidase A, thought to be related to ACE (Ondetti et al., 1977; 
Patchett et al., 1980).  Captopril displayed low nanomolar potency and effectively lowered 
blood pressure by preventing the production of AngII and breakdown of BK.  It was therefore 
approved for clinical use in 1981 but later associated with the adverse side-effects of skin 
rash and loss of taste (Acharya et al., 2003).  This was attributed to the presence of a 
sulfhydryl zinc-binding group.  To circumvent this, subsequent ACE inhibitors were designed 
to rather contain ketone (keto-ACE and ketomethylene analogues), carboxylate (lisinopril, 
enalaprilat and ramiprilat) or phosphonate (fosinoprilat) metal-chelating moieties 
(Redelinghuys et al., 2005) (Figure 1.5). 
 
A further benefit of these inhibitors over captopril was that they interacted with both the 
prime and non-prime subsites flanking the scissile peptide bond (Acharya et al., 2003).  This 
enabled the design of drugs with increased specificity over other metalloproteases by 
incorporating weaker zinc-binding groups and optimizing interactions to the ACE subsites.  
The current clinically available ACE inhibitors are, however, unable to distinguish between 
the two domains of ACE and result in systemic bradykinin accumulation.  In a subset of 
patients this has been associated with persistent cough (5-20% of patients) and potentially 
life-threatening angioedema (0.1-0.2% of patients) (Bicket, 2002). 
 






Figure 1.5: Chemical structures of ACE inhibitors commonly used in the treatment of hypertension. 
The zinc binding groups are flanked by the P1, P1’ and P2’ moieties indicated by the orange, green and 
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1.6   Second generation C-domain selective inhibitors 
Following reports of these adverse side-effects it was therefore proposed that the next 
generation of ACE inhibitors should be designed to selectively inhibit the C-domain, leaving 
the N-domain free to hydrolyse BK (Acharya et al., 2003).  Keto-ACE and the 11-mer naturally 
occurring bradykinin potentiating peptide b (BPPb) respectively displayed approximately 40- 
and 260-fold selectivity for binding to the C-domain (Deddish et al., 1998; Cotton et al., 2002).  
Based on the observation that constrained, ACE inhibitors such as BPPs displayed more C-
selectivity, Georgiadis et al synthesized a series of pseudo proline-containing phosphinic 
peptide inhibitors (Georgiadis et al., 2003; Georgiadis et al., 2004).  The RXPA380 compound 
displayed low nanomolar affinity and an astounding 3300-fold selectivity for binding to the 
C-domain.  Shortly thereafter, a turning point came in the design of ACE inhibitors with the 
structural determination of tACE in complex with lisinopril (Natesh et al., 2003).  Important 
insights were gained into the factors responsible for potency of inhibition and, more 
importantly, unique residues that could be targeted in C-selective inhibitor design were 
identified.  This led to improvements in keto-ACE selectivity (Nchinda et al., 2006b; Sharma 
et al., 2012) and development of a C-selective tryptophan analogue of clinically used 
lisinopril, Lisinopril-Trp (Nchinda et al., 2006a).   
 
1.7   ACE inhibition and fibrosis 
Apart from decreasing blood pressure, the clinical use of non-selective ACE inhibitors has 
been associated with various antifibrotic effects.  The fibrinolytic system functions to 
promote wound healing via an inflammatory response which triggers recruitment and 
differentiation of fibroblasts with subsequent synthesis of extracellular matrix proteins 
(Wynn, 2008).  Conditions such as cardiovascular disease, insulin resistance, diabetes and 
obesity, however, can lead to prolonged inflammation and disruption of the normal tissue 
repair system (Ghosh and Vaughan, 2012).  This results in the hallmarks of fibrosis, namely 
increased synthesis of extracellular matrix proteins, progressive tissue scarring, decreased 
tissue elasticity and impaired organ function (Wynn, 2008).  An estimated 45% of human 
deaths are due to fibroproliferative disorders such as fibrosis (Bitterman and Henke, 1991) 
with lung fibrosis having a mean survival period of 2-4 years (du Bois, 2011).  A recent 
systematic review suggested that the incidence of idiopathic pulmonary fibrosis is on par with 
that of stomach, liver, testicular and cervical cancers (Hutchinson et al., 2015).  At present, 
there is no effective treatment for fibrosis. 
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1.8   Antifibrotic mechanism of ACE inhibition 
AngII is known to increase fibroblast proliferation, inflammation and transforming growth 
factor-β1 (TGF-β1) signalling (Wynn, 2008).  Inhibition of ACE could thus decrease fibrosis by 
limiting AngII production.  Infusion with the N-domain selective antifibrotic peptide AcSDKP, 
however, resulted in anti-inflammatory and antifibrotic effects equal to that of non-domain 
selective ACE inhibition (Rasoul et al., 2004).  Since co-administration of a monoclonal 
antibody against AcSDKP significantly reduced these effects of ACE inhibition, they are 
primarily mediated by AcSDKP (Peng et al., 2005).  Administration of this peptide either 
before or after fibrosis was shown to attenuate TGF-β1 signalling and AT1 receptor expression, 
thereby decreasing collagen deposition and myofibroblast differentiation (Xu et al., 2012).  
Since AcSDKP is ubiquitously expressed and selectively hydrolysed by the N-domain of ACE 
(Rousseau et al., 1995; Fuchs, 2004), selective N-domain inhibition holds promise for the 
treatment of fibrosis without affecting blood pressure. 
 
1.9   Second generation N-domain selective inhibitors 
Prior to solving the ACE structure, Dive et al screened a phosphinic peptide library and 
discovered a compound, named RXP407, which displayed 2083-fold selectivity for binding to 
the N-domain (Dive et al., 1999).  It is, however, unsuitable for therapeutic use due to its 
large size, low bioavailability and peptidic nature.  Peptidic inhibitors are generally 
considered poor drug candidates because of their low oral bioavailability, poor solubility and 
susceptibility to degradation by proteases (Redelinghuys et al., 2005).  Functional groups 
essential for N-selectivity therefore need to be identified to enable the design of clinically 
suitable N-domain inhibitors. 
 
RXP407 has N-terminal acetylated aspartate (P2), L-pseudophenylalanine (P1), L-
pseudoalanine (P1’) and C-terminal amidated alanine (P2’) moieties that respectively bind to 
the S2, S1, S1’ and S2’ subsites of the ACE active site (Figure 1.6).  Previous studies have shown 
a marked decrease in binding selectivity when the P2 and P2’ moieties were altered, 
suggesting key interactions with residues from these active site pockets (Dive et al., 1999). 
Mutation of the N-domain S2 residues Y369 and R381 to their corresponding C-domain 
counterparts (phenylalanine and glutamic acid, respectively) also led to markedly decreased 
inhibitor binding affinities (Kroger et al., 2009).  Considering this, a fragment based design 
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approach was recently employed to substitute the P2 acetylated aspartate of RXP407 by 
chemical entities predicted to interact similarly with these unique N-domain S2 residues 
(Douglas et al., 2014).  Molecular docking to the N-domain crystal structure suggested that 




Figure 1.6: Schechter-Berger diagram illustrating the S2 to S2’ enzyme subsites flanking the catalytic 
zinc-binding motif (HEMGH) binding to the P2 to P2’ moieties of N-domain inhibitors RXP407 and its 
analogue 33RE. 
The unique S2 and S2’ subsite residues are indicated in N-/C-domain nomenclature. 
 
Following synthesis and co-crystallization of 33RE with the N-domain, it was observed that 
the S1 to S2’ interactions were conserved (Douglas et al., 2014).  Replacement of the P2 
acetylated aspartate with an aminomethyl tetrazole moiety, however, led to loss of 
interaction with the unique R381 so that the only unique N-domain interaction of 33RE was 
to Y369.  Although replacement of the acid yielded a more drug-like molecule and simplified 
synthesis, kinetic characterization of 33RE is thus required to determine if this occurred at 
the expense of N-selectivity.  The mere presence of a P2 acetylated aspartate, however, does 
not guarantee N-selectivity as recently evidenced by the P2 aspartate analogue of 
sampatrilat’s lack of selectivity (Cozier et al., 2018).  The P1 to P2’ moieties of RXP407 and 
33RE therefore also play a role but, since their interactions are conserved between the 
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domains, the mechanism is poorly understood.  As such, no N-selective ACE inhibitors are 
clinically available at present. 
 
1.10  Irreversible inhibition of ACE 
In addition to the adverse side effects of persistent cough and angioedema, clinically 
available ACE inhibitors such as lisinopril, benazepril, moexipril and fosinopril also suffer from 
poor oral bioavailability (Brown and Vaughan, 1998).  The daily dosage required for effective 
hypertension treatment is generally high with that of captopril, lisinopril, benazepril, 
moexipril and fosinopril at 6.25-300 mg, 5-40 mg, 5-80 mg, 7.5-30 mg and 10-80 mg, 
respectively.  These inhibitors compete with substrates for binding to the active site of ACE 
and as such only offer transient, reversible inhibition.  Pseudo mechanism-based inactivators, 
on the other hand, have the potential to permanently deactivate the enzyme via covalent 
bond formation.  In an attempt to obtain ACE-inhibitory compounds with a longer duration 
of action, Choo et al designed two series of epoxyalkanoyl and α, β-unsaturated carbonyl 
analogues (Choo et al., 1998; Park Choo et al., 2000).  Some compounds irreversibly 
inactivated ACE, presumably by forming a Michael adduct with the zinc binding motif’s 
glutamate.  Their binding affinity, however, was significantly weaker than that of competitive 
ACE inhibitors with the most potent inactivator having an IC50 of 0.23mM. 
 
1.11  Irreversible target inactivation 
An alternative means of irreversible enzyme inactivation is through catalytic metallodrugs.  
These compounds characteristically have a target-recognition domain coupled via a flexible 
linker to a metal-binding domain (Cowan, 2008).  The target-recognition domain is usually a 
ligand which binds with moderate affinity to the target of interest.  Artificial nucleases are 
catalytic metallodrugs targeting DNA or RNA while artificial proteases target peptides or 
proteins.  The metal-binding domain consists of a chelator complexed to a transition metal 
which facilitates the conversion of dioxygen or hydrogen peroxide oxidants into reactive 
oxygen species (ROS) through Fenton-type chemistry (Figure 1.7).  The produced ROS 
subsequently results in cleavage of the target nucleic acid, peptide or protein and thus 
irreversible inactivation.  Coupling of these two domains ensures localized, as opposed to 
diffuse, ROS production and target cleavage at specific sites (Cowan, 2008).  Additionally, 
multiple turnover reactions occur since oxidized metal chelates are regenerated in the 
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presence of cellular reductants such as ascorbic acid or NADH (Gokhale and Cowan, 2005; 
Gokhale and Cowan, 2006; Joyner et al., 2012; Fidai et al., 2014).  Inherently, the likelihood 
of toxicity and side-effects is lower for catalytic metallodrugs since their regeneration upon 
target inactivation allows efficacy at sub-stoichiometric concentrations and thus lower or less 
frequent dosing.  This offers an advantage over irreversible suicide inhibitors which are 
consumed upon covalent modification of the target and thus required at saturating 
concentrations for efficacy.  Since the advent of drug resistance, there has been a great need 
to obtain pharmaceuticals with novel mechanisms of action.  Incorporation of transition 
metals not only offers a novel catalytic mechanism but also greatly enhances the chemical 





Figure 1.7: Irreversible target inactivation by metallodrug-catalysed Fenton-type chemistry. 
DNA, RNA, peptide or protein targets can be irreversibly inactivated through oxidative cleavage.  
Metallodrug dissociation from the inactivated target and regeneration by reduction in the presence of 
ascorbate enables efficacy at sub-stoichiometric drug concentrations.  Mn+: transition metal 
complexed to the metallodrug’s metal-binding domain. 
 
 
1.11.1 Artificial nucleases 
In 1966, a natural molecule named bleomycin was isolated from Streptomyces verticillus and 
found to be comprised of DNA-binding, metal-binding and carbohydrate domains (Umezawa 
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et al., 1966).  It was initially recognized for its antibiotic activity but subsequently approved 
for the treatment of Hodgkin’s lymphoma, squamous cell carcinoma and testicular, cervical 
and ovarian cancers (Yu and Cowan, 2017).  Metal-bound bleomycin is believed to promote 
cancer cell apoptosis by intercalating to DNA and inducing strand breaks via ROS generation 
(Galm et al., 2005).  Currently, bleomycin is the only catalytic metallodrug which has been 
approved for clinical treatment of a disease.  A major hurdle for the clinical application of 
catalytic metallodrugs has been their lack of substrate specificity in vivo (Yu and Cowan, 
2017).  Though numerous compounds developed in recent decades displayed high catalytic 
efficiency in vitro, their inability to differentiate between different cellular targets would 
result in decreased catalytic efficiency in vivo.  Furthermore, off-target catalytic inactivation 
can result in unwanted side-effects or toxicity.  The Fe2+-bleomycin complex, for example, is 
moderately selective for binding and cleavage around GC sequences in the DNA (Sugiyama 
et al., 1986).  Due to the common occurrence of these sequences, however, cancerous as 
well as normal cells are targeted and treatment is thus associated with side-effects.  This 
prompted inorganic chemists to rationally design catalytic metallodrugs with high chemical 
reactivity as well as target selectivity by optimizing the target-recognition and metal-binding 
domains employed.  An ideal compound should display low reactivity in the absence of target 
recognition, but rapid ROS generation upon binding to the target and optimal orientation of 
the metal-binding domain (Cowan, 2008).  By coupling different combinations of transition 
metals (Fe2+, Co2+, Ni2+ or Cu2+) and chelators (cyclam, cyclen, CB-TE2A, DOTA, DTPA, EDTA, 
NTA, TACN, tripeptide Gly-Gly-His or tetrapeptide Lys-Gly-His-Lys) to nucleic acid-targeting 
molecules, compounds with therapeutic potential for human immunodeficiency virus (HIV) 
(Jin and Cowan, 2006; Joyner and Cowan, 2011), hepatitis C virus (HCV) (Bradford and Cowan, 
2012) and cancer (Yu et al., 2015) have since been developed.   
 
1.11.2 Artificial proteases 
Artificial proteases were initially developed to address the limited number of selective 
protein-cleaving agents available for studying protein sequence, structure and function 
(Hoyer et al., 1990; Schepartz and Cuenoud, 1990).  Early research was focused on 
understanding the mechanism whereby streptavidin (Hoyer et al., 1990), calmodulin 
(Schepartz and Cuenoud, 1990; Cuenoud et al., 1992) and carbonic anhydrase (Gallagher et 
al., 1998) were cleaved since structural information and target-recognition domains were 
available for these proteins.  Although the therapeutic potential of artificial proteases was 
already realized in 1990 (Hoyer et al., 1990), the first metallodrug against a disease-related 
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protein was only discovered fourteen years later.  By synthesizing a library of target-
recognition domain candidates coupled to a Co3+-cyclen complex, Chae et al obtained one 
compound which catalysed rapid and selective cleavage of the peptide deformylase protein 
(Chae et al., 2005).  This is an attractive target in antibiotic drug design due to its role in 
prokaryotic protein translation (Chae et al., 2005).  More recently, catalytic metallodrugs 
have also been designed for the treatment of Staphylococcus aureus infection by targeting 
the Sortase A (SrtA) protein to potentially interrupt bacterial and host cell interaction (Fidai 
et al., 2014).  This Gram-positive bacterium is a major cause of hospital-acquired infections 
and has developed resistance against various standard antibiotics.  The designed Cu2+-Gly-
Gly-His (Cu2+-GGH) metallodrugs significantly reduced SrtA activity by selective sidechain 
oxidation of critical active site residues.  In this case, protein cleavage via protein backbone 
oxidation did not occur.   
 
Catalytic metallodrugs can also be designed to target peptides or proteins lacking active sites.  
Type 2 diabetes mellitus (T2DM), Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Transmissible spongiform encephalopathies and Huntington’s disease are thought to 
respectively arise from the presence of soluble oligomers of human islet amyloid polypeptide 
(h-IAPP), amyloid-β42 (Aβ42), α-synuclein, prion and polyglutamine amyloidogenic peptides or 
proteins (Haataja et al., 2008).  Co3+-cyclen metallodrugs specifically targeted to these 
peptides or proteins and efficiently catalysing their cleavage have shown great promise for 
the treatment of T2DM, AD and PD (Suh et al., 2007; Suh et al., 2008; Lee et al., 2008; Chei 
et al., 2011).  Apart from catalysing peptide bond cleavage, Co3+-cyclen metallodrugs can also 
drive oxidative decarboxylation of N-terminal aspartate-containing peptides (Kim et al., 
2005).  This has been demonstrated for the melanin-concentrating hormone and could have 
implications for the treatment of obesity (Kim et al., 2006).  Since AngII contains an N-
terminal aspartate and is associated with hypertension, Co3+-cyclen metallodrugs targeting 
AngI or AngII were also designed and two compounds subsequently identified to catalyze 
their oxidative decarboxylation (Kim et al., 2005).  At present, however, the implications for 
hypertension treatment are unclear since further studies are required to verify if the 
conversion of aspartate to pyruvate would prevent binding of AngI or AngII to ACE and AT1, 
respectively. 
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Anti-hypertensive catalytic metallodrugs have also been designed to target ACE.  The 
tetrapeptide Lys-Gly-His-Lys (KGHK) complexed to Cu2+ displayed competitive micromolar 
inhibition and irreversible catalytic inactivation of ACE at sub-stoichiometric concentrations 
in the presence of ascorbate (Gokhale and Cowan, 2005).  Since the endothelin converting 
enzyme (ECE), which regulates blood pressure via the endothelin system, was also 
inactivated by this complex, this can potentially be applied as a dual-action therapeutic 
(Gokhale and Cowan, 2006).  The clinical use of [KGHK-Cu]+, however, will likely result in side-
effects due to its DNA-cleavage activity (Jin and Cowan, 2005).  Since ECE contributes to 
bradykinin hydrolysis (Hoang and Turner, 1997), simultaneous inactivation of ACE and ECE is 
further expected to exacerbate the side-effects associated with its accumulation.  Although 
this approach appears promising for targeting ACE, optimization of the target-recognition 
domain would be required to circumvent these side-effects.  Tailoring it towards the C- or N-
domain could further enable the specific treatment of hypertension or fibrosis at sub-
stoichiometric concentrations by irreversible inactivation.  Catalytic metallodrugs possess so-
called double-filter selectivity where ROS is only produced if the target-recognition domain 
is bound and the metal-binding domain optimally orientated towards readily oxidizable 
amino acids in the protein (Figure 1.8).  This novel mechanism of action might be more 
sensitive to the slight variations between the ACE domains’ active site residues (90% identity) 




Figure 1.8: Double-filter selectivity displayed by the ideal catalytic metallodrug. 
The coupled target-recognition and metal-binding domains are carefully tailored during metallodrug 
design to ensure selective binding to the target protein and, even if off-target binding occurs, selective 
localized ROS production only at the desired site. 
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Their decreased effective dose further lessens the importance of high bioavailability for drug 
approval.   Altogether, this might increase the probability of obtaining a domain-selective 
inhibitor with pharmacokinetics suitable for clinical use.  Great strides have been made in 
this regard by coupling a range of chelates and transition metals to the lysine sidechain of 
the competitive inhibitor lisinopril (Joyner et al., 2012).  An overview of these metallodrugs 
will be given in Chapter 3.   
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1.12 Aims and objectives 
 
Despite availability of the truncated N- and C-domain crystal structures, factors governing 
selective inhibitor binding are uncertain.  Additionally, efforts at obtaining the full-length 
sACE structure are hampered by a limited understanding of its N-glycans’ function.  The 
current study therefore aimed to provide a detailed description of each glycan site’s 
functional role as well as insight into the molecular mechanisms whereby selective N-domain 
inhibition and catalytic inactivation occurs.   
 
The objectives were to: 
 
1. Identify the active site residues contributing to N-selective inhibition and elucidate 
their molecular mechanism using site-directed mutagenesis, enzyme kinetics, X-ray 
crystallography and molecular dynamics simulations, with a focus on the phosphinic 
ACE inhibitor 33RE 
 
2. Study the mechanism of N-selective, metallodrug-mediated catalytic inactivation 
using enzyme kinetics 
 
3. Investigate the contribution of each N- and C-domain glycan site towards protein 
















Elucidating the molecular basis of N-selective ACE inhibition 
2.1  Introduction 
The N-domain inhibition is intriguing since it prevents cleavage of AcSDKP and leads to its 
accumulation without affecting blood pressure (Junot et al., 2001) (see Chapter 1 section 1.8).  
Accumulation of AcSDKP has been linked to decreased deposition of collagen and proliferation 
of fibroblasts in the left ventricle, kidney and lungs (Yang et al., 2004; Xu et al., 2012; Peng et al., 
2003; Liao et al., 2010).  As such, it could have clinical importance in the treatment of fibrosis.  
The adverse effects currently associated with non-selective ACE inhibitors are unlikely to occur 
with N-selective inhibition since the C-domain would be free to hydrolyse BK (Bicket, 2002).   
 
To design new chemical entities for therapeutic intervention, the functional groups essential for 
N-selectivity should be identified.  Previous studies have shown a marked decrease in RXP407’s 
2083-fold N-selectivity when the P2 moiety was altered or the N-domain S2 residues (Y369 and 
R381) mutated to their corresponding C-domain counterparts (Phe and Glu, respectively) (Dive 
et al., 1999; Kroger et al., 2009).  Since these mutations did not completely abolish selectivity, 
unique S2’ subsite interactions are likely also involved (Kroger et al., 2009).  Contrary to RXP407 
where the P2 acetylated aspartate forms a salt bridge to R381 (PDB ID: 3NXQ), R381’s side-chain 
is swivelled away from the active site in the 33RE-N domain structure (PDB ID: 4BXK) (Figure 2.1) 
(Douglas et al., 2014).  Although the unique N-domain Y369 does interact with the P2 
aminomethyl tetrazole moiety of 33RE, it is thus unclear whether it would display the same 
degree of N-selectivity as the parent compound RXP407.
Chapter 2: Mechanism of N-selective inhibition 
23 
 
   
Figure 2.1: Structural alignment of the N- and C-domain illustrating direct binding of 33RE to unique S2 
residues but not distal, unique S2’ residues. 
C-domain (PDB ID: 1O8A) is given in cyan, N-domain (PDB ID: 4BXK) in green, Zn as a grey sphere and the 
phosphinic inhibitor 33RE (co-crystallized with the N-domain) in yellow.  Unique N-domain residues of the 
S2 and S2’ subsites are labelled, and their C-domain counterparts given in parentheses. 
 
The reason for the C-terminal or P2’ amide’s importance in selectivity is also unclear since the N-
domain RXP407/33RE co-crystal structures show that unique N-domain S2’ residues are distal 
from the inhibitor and thus the amide only interacts with S2’ residues conserved between the 
domains (Figure 2.1).  Single or double ACE mutants with unique S2’ residues mutated from N- 
to C-domain counterparts also did not result in significant changes in RXP407 inhibitor binding 
(Kroger et al., 2009).  Yet, it has been shown that replacing the P2’ amide of RXP407 with a 
carboxylate leads to a complete lack of selectivity (Dive et al., 1999). 
 
While mutagenesis studies can aid in identification of specific residues and their role in ligand 
binding, they provide limited insight into the mechanism of inhibition at an atomic level.  
Conversely, crystal structures can be useful in providing mechanistic insight but are limited by 
factors such as crystal packing and crystallization pH.  This artificial environment can potentially 
mask the effect that specific residue mutations have on binding, especially ones distal to the 
binding site.  These factors are particularly important to consider when studying dynamic 
proteins with hinge-bending motions.  
 
Based on homology modelling of ACE to its homologue ACE2 and normal mode analysis, it was 
previously suggested that the C-domain of ACE possesses a hinge mechanism for substrate 
binding (Watermeyer et al., 2006).  At present, all ACE N- and C-domain crystal structures are in 
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subdomains.  ACE2, however, has been crystallized in open (apo, PDB ID: 1R42) and closed 
(ligand-bound, PDB ID: 1R4L) conformations (Towler et al., 2004).  By aligning these structures 
to the N-domain of ACE it was observed that the unique N-domain S2’ residues reside in a region 
where structural changes occur upon transition to a closed conformation (Figure 2.2).  These 





Figure 2.2: Structural alignment of the N-domain-33RE structure to the open and closed conformations 
of the ACE2 homologue. 
N-domain (PDB ID: 4BXK) is given in green, ACE2 open conformation (PDB ID: 1R42) in grey and its closed 
conformation (PDB ID: 1R4L) in magenta.  The black arrow indicates a ~10Å shift in an active site helix’s 
position upon ligand binding to ACE2 and transition to the closed conformation.  The unique N-domain S2 
and S2’ subsite residues are labelled, Zn shown as a grey sphere and the phosphinic inhibitor 33RE (co-
crystallized with the N-domain) shown as yellow balls and sticks. 
 
In this study, it is therefore proposed that the two ACE domains have different open 
conformations and hinge-bending motions and that this might influence inhibitor binding.  This 
hypothesis is supported by three-dimensional electron microscopic reconstruction of negatively 
stained porcine sACE which revealed that the two domains’ active site clefts have distinct shapes 
(Chen et al., 2010).  While the N-domain internal void area was circular, the C-domain interior 










Chapter 2: Mechanism of N-selective inhibition 
25 
 
2.2  Aims and objectives 
The research described in this chapter aimed to investigate the contribution of all the unique N-
domain residues in the S2 and S2’ subsites towards N-selectivity using a combined in vitro/in silico 
approach.  Provided that the selectivity predicted via docking could be confirmed in vitro, the 
mechanism of N-selectivity would be studied using the more drug-like molecule 33RE.   
 
The objectives to achieve this aim were as follows: 
 
1. Identify the active site residues crucial for selectivity by: 
a. Obtaining active site mutants with unique N-domain residues converted to their C-
domain counterparts using site directed mutagenesis, cloning into an expression 
vector, mammalian cell transfection, heterologous protein expression and protein 
purification 
 
b. Evaluating the effect of mutation on inhibitor binding using an enzyme assay with 
quenched fluorogenic substrate to characterize inhibitor binding affinity 
 
2. Elucidate the mechanism whereby the identified residues govern selectivity by:  
a. Creating a mutant having all N-domain S2 and S2’ residues converted to their C-
domain counterparts in a minimally glycosylated form amenable to crystallization 
using site-directed mutagenesis, sub-cloning, mammalian cell transfection, 
heterologous protein expression and protein purification 
 
b. Utilizing X-ray crystallography to solve the structure of this active site mutant in 
open (apo) and closed (inhibitor-bound) conformations for comparison to the N-
domain active site cleft shape 
 
c. Assessing the effect of mutation on protein hinging using in silico mutagenesis and 
molecular dynamics simulations of apo and inhibitor-bound structures 
 
d. Monitoring the effect of ligand binding on wild-type or mutant protein structure in 
vitro using differential scanning fluorimetry 
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2.3  In vitro methodology  
2.3.1 Site-directed mutagenesis  
N- and C-domain ACE crystal structures (PDB IDs: 4BXK and 1O8A, respectively) were studied to 
identify the various unique residues thought to contribute to N-selectivity (Figure 2.1).  Despite 
the modest changes observed upon single or double mutation of unique S2’ residues (Kroger et 
al., 2009), the P2’ amide interaction of N-domain inhibitors is important for selective binding 
(Dive et al., 1999).  Since the N-domain residues differ in polarity and side-chain length from 
their C-domain counterparts, the S2’ subsite was progressively converted to C-domain (Table 
2.1) to study the possibility of a synergistic environmental role in 33RE binding.  The role of the 
S2 subsite in N-selective binding was assessed using the previously generated and purified S2 
mutants Y369F, R381E and YR/FE (Kroger et al., 2009). 
 
Table 2.1:  Active site mutants created via site-directed mutagenesis. 
Active site mutant N-domain residues C-domain residues Subsite 


























Y369F a Y369 F391 
S2 R381E 
a R381 E403 




















S2’ / S2 
a: mutants previously generated by Kröger et al (Kroger et al., 2009).  C-domain residues are given 
according to the standard tACE numbering (Ehlers et al., 1989). 
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The S2’ mutants SE/VD, SEDT/TSEV and SEDSTE/TSEVVD were created as part of this thesis.  The 
SE/VD mutant was chosen since single mutation of these S2’ residues had the greatest effect on 
RXP407 binding affinity (Kroger et al., 2009) and the inverse SEDT/TSEV mutant used to study 
the combined role of the remaining unique S2’ residues.  The possibility that synergism between 
all the unique residues could create a more favourable environment for P2’ amide binding was 
studied using the SEDSTE/TSEVVD mutant.  In addition, these mutations were combined with 
the non-prime mutations to investigate inter-subsite synergism between the unique residues 
outlined in (Figure 2.1).  The S2’/S2 mutant SEDSTE_YR/TSEVVD_FE was thus created. 
 
Sequences encoding soluble forms of the fully glycosylated wild-type human N- and C-domain 
ACE proteins were previously cloned into the pBlueScript vector (pBS SKII+, Stratagene).  The N-
domain construct starts with an N-terminal signal sequence and terminates after residue D629 
(Corradi et al., 2006) whereas the C-domain construct starts with the testis ACE signal sequence, 
lacks the 36 unique N-terminal O-glycosylated residues and transmembrane region and 
terminates after S625 (Yu et al., 1997).  N-domain numbering is according to the N-terminal 
domain of somatic ACE minus the signal sequence.  C-domain numbering in this chapter is 
according to the standard testis ACE minus the signal sequence.  Structurally, residues 13 
onwards of the N-domain and residues 40 onwards of the C-domain thus align (barring the N-
domain 5 residue insertion) to yield a difference of 22 amino acids in the numbering of 
equivalent N- and C-domain residues, as shown in Acharya et al (Acharya et al., 2003).  These 
constructs thus represent the individual catalytic domains of somatic ACE.   
 
Site directed mutagenesis was used to generate mutant N-domain constructs by converting the 
selected unique N-domain S2 and/or S2’ subsite residues to their corresponding C-domain 
counterparts, as previously described (Kroger et al., 2009).  This was performed in an iterative 
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2.3.1.1 Design of mutagenesis primers 
All site-directed mutagenesis primers used were 100% complementary and designed using the 
online WatCut tool (http://watcut.uwaterloo.ca/watcut/watcut/template.php).  The E262S, 
E431D, Y369F and R381E primers were previously designed and available (Kroger et al., 2009) 
whereas the S260T, D354E and V357S primers were synthesized by the Inqaba DNA Synthesis 
Unit (Inqaba Biotech Ltd.).  
 
Each primer contained two sets of mismatches to introduce the desired amino acid change along 
with a silent mutation (Table A1, Appendix A1).  This silent mutation created an additional 
restriction enzyme cleavage site to enable screening of resulting PCR amplicons for the codon 
change mutation.  The pBS SKII+ S357V and pBS SKII+ S357V, T358V (ST/VV) constructs 
previously generated by Dr R.G. Douglas (Kroger et al., 2009) were used as the initial PCR 
templates.  The mutagenesis strategy is outlined in Figures 2.3-4. 
 
 
     
 
Figure 2.3: Site-directed mutagenesis for generating pBS SkII+ SE/VD. 
The E431D mutation was introduced onto the pBS SkII+ S357V template.  The restriction enzyme sites for 
screening S357 and the newly introduced E431D are indicated in grey and green, respectively. 
 
 
The SEDT/TSEV mutant was generated by removing the S357V and E431D mutations from the 
pBS SkII+ SEDSTE/TSEVVD construct.  A V357S primer was designed and PCR performed to 
reverse S357V (Figure 2.5).  The E431D mutation was reversed to wild-type by sub-cloning of 
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   pBS SkII+ S357V, T358V (ST/VV) 
 






Figure 2.4: Sequential PCR strategy for generating pBS SkII+ SEDSTE/TSEVVD and pBS SkII+ 
SEDSTE_YR/TSEVVD_FE.   
Mutations were iteratively added onto an initial pBS SKII+ ST/VV template.  The newly introduced 




















































































































                 
                                                                           
                                                         
Figure 2.5: Strategy used to create the pcDNA 3.1+ SEDT/TSEV mutant.   
Site-directed mutagenesis and sub-cloning were used to reverse S357V and E431D in pBS Sk+ 
SEDSTE/TSEVVD.  The pBS SKII+ SEDSTE/TSEVVD construct was used as a template, a) the S357V mutation 
reversed by site-directed mutagenesis and b) the E431D mutation reversed by sub-cloning of pBS SkII+ 
SEDTE/TSEVD and pcDNA 3.1+ N-domain with EcoRI and BmgBI.  The introduced V357S site is indicated in 
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2.3.1.2 Site directed mutagenesis procedure 
A DpnI site-directed mutagenesis approach was followed to create mutant N-domain constructs.  
Final concentrations per PCR reaction were 0.3µM forward and reverse primers (Inqaba Biotech, 
Ltd.), 0.3µM dNTPs (Thermo Scientific dNTP Mix), a total mass of 100ng template DNA and one 
unit of KAPA HiFiTM high fidelity polymerase (KapaBiosystems Ltd., SA). Reactions for each 
mutagenesis run were carried out at 0mM and 2mM Mg2+ concentrations to determine the 
optimal conditions for primer specificity and polymerase activity using MgCl2 (KapaBiosystems 
Ltd., SA).  PCR reactions were performed in a Thermal cycler (Bio-Rad MyCyclerTM) with 
parameters as outlined in Table 2.2. 
 
Table 2.2:  PCR cycling parameters used for site-directed mutagenesis.  
Step Temperature (°C) Time Number of cycles 
Initial Denaturation 94 2 min 1 
Denaturation 98 20 secs  
Primer Annealing 85 30 secs 
Extension 68 2.5 min 
Final Extension 68 5 min 1 
Cooling 4 ∞ 
 
 
The resulting amplicons underwent agarose gel electrophoresis (protocols and recipes in 
Appendix A5) and visualization with Ethidium Bromide (EtBr) staining under ultraviolet (UV) 
light.  PCR products from mutagenesis runs showing the highest amplification and specificity 
were selected and digested at 37°C for 18 hours with methylation-specific restriction enzyme 
DpnI (Fermentas Life Sciences) to remove remaining template DNA.  Subsequently, 20µl of the 
digested amplicons were transformed into chemically competent DH5α Escherichia coli cells 
(protocols in Appendix A3).  Transformed cells were plated onto Luria agar plates with Ampicillin 
selection (100µg/ml (Sigma-Aldrich® Co.)) and incubated for 18 hours at 37°C (Appendix A2).  
Resistant colonies were picked and cultured overnight in Ampicillin-containing Luria Bertani (LB) 
medium from which the DNA was then crudely isolated using a STET prep (protocols and recipes 
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2.3.2 Confirmation of introduced mutations 
DNA isolated from cultured clones was digested with the appropriate screening enzymes as 
outlined in Table A1 (Appendix A1, (BfuI, BglII, BsmI, BstEII, CsiI and SspI from Fermentas Ltd., 
PvuII from New England Biolabs Inc.)).  The DNA fragments produced were resolved by agarose 
gel electrophoresis.  Positive incorporation of the desired mutations was identified by 
differences in the mutants’ DNA banding pattern compared to the template DNA due to 
simultaneous introduction of restriction enzyme sites.    
 
High quality plasmid DNA was isolated from colonies positive for the desired mutations using 
the GeneJETTM Plasmid Miniprep kit (Thermo Fisher Scientific Inc.).  The restriction enzyme 
digest results were subsequently confirmed and absence of spurious mutations verified by 
nucleotide sequencing.  Internal N-domain primers (Inqaba Biotech, Ltd.) and T3 and T7 vector 
primers (Promega Corp.) flanking the N-domain were used for sequencing of the entire N-
domain coding region (Gordon, 2011).  Samples were sent to the Stellenbosch University Central 
Analytical Facility for sequencing. 
 
2.3.3 Cloning of mutant constructs into a mammalian expression vector 
Positive mutant constructs were cloned from the pBS SkII+ bacterial sequencing vector into the 
pcDNA 3.1+ mammalian expression vector (InvitrogenTM) to enable transfection into mammalian 
cells and optimal expression, glycosylation and folding of the proteins.  The cloning strategy 
involved a double digest of 600ng mutant pBS SkII+ construct with one unit of EcoRI and a two-
fold excess of XbaI (both restriction enzymes from Fermentas Ltd.).  The wild-type N-domain 
pcDNA 3.1+ vector was similarly digested to allow compatible ends for cloning of the mutant N-
domain insert into the expression vector.  This approach was followed for the SE/VD, 
SEDSTE/TSEVVD and SEDSTE_YR/TSEVVD_FE mutants.  For the SEDT/TSEV mutant, 600ng of the 
pBS SkII+ SEDTE/TSEVD construct (produced by site-directed mutagenesis) was digested with 
one unit of BmgBI and a 2-fold excess of EcoRI.  This strategy allowed simultaneous removal of 
the E431D mutation and cloning into pcDNA 3.1+ to yield pcDNA 3.1+ SEDT/TSEV.  Following 
restriction enzyme digests, the DNA fragments were separated by agarose gel electrophoresis 
and visualized with EtBr staining under UV light.  Insert and vector bands corresponding to 
2000bp and 5389bp, respectively, (for all mutants except SEDT/TSEV which had 1291bp and 
6098bp, respectively) were excised and the GeneJETTM Gel Extraction kit (Thermo Fisher 
Scientific Inc.) used for DNA purification.  Ligation was performed by combining vector and insert 
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DNA at a 1:3 ratio in a reaction mix containing T4 DNA Ligase buffer and 5 units of T4 DNA Ligase 
(Fermentas Ltd.).  After incubation at room temperature for two hours, chemically competent 
DH5α cells were transformed with the ligation reaction, plated and grown for 18 hours under 
Ampicillin selection (protocols and recipes in Appendix A2-4).  Resistant clones were picked, 
grown in Ampicillin-containing LB medium and the DNA isolated as before using a STET prep 
(protocols and recipes in Appendix A2-A4).   
 
Successful cloning of the mutated inserts was confirmed by double digests with the cloning 
enzymes, EcoRI and XbaI, in addition to single digests with screening enzymes outlined in Table 
A1 (Appendix A1).  Agarose gel electrophoresis allowed identification of positive clones from 
which DNA was then bulk purified using the ZyppyTM Plasmid Midiprep kit (The Epigenetics 
Company).  
 
2.3.4 Generation of a minimally glycosylated SEDSTE_YR/TSEVVD_FE mutant 
The N-domain is routinely crystallized in a minimally glycosylated form where six of the nine 
PNGs have been mutated to glutamine residues.  The resulting construct only retains 
glycosylation at sites n3, n8 and n9 (Anthony et al., 2010).  To enable crystallization of the 
SEDSTE_YR/ TSEVVD_FE active site mutant, the asparagine residues at sites n1, n2, n4, n5, n6 
and n7 were converted to glutamine residues.   
 
Sites n1, n2, n4, n5 and n6 were situated upstream of the active site mutations.  They were thus 
removed by sequentially digesting 600ng of the fully glycosylated pcDNA 3.1+ 
SEDSTE_YR/TSEVVD_FE construct and an N-domain construct only containing site n3 (pcDNA 
3.1+ N-domain n3 (Redelinghuys, 2006)) with Bsu36I in 1x Tango buffer for 1 hour at 37°C and 
then EcoRI in 2x Tango buffer for 1 hour at 37°C.  The resulting bands were resolved on a 1% 
agarose gel and DNA purification, ligation, transformation and DNA isolation performed as 
described in section 2.3.3.  A double digest of EcoRI and XbaI was performed as before to screen 
for the presence of a 2000bp coding region and thus generation of the pcDNA 3.1+ SEDSTE_YR/ 
TSEVVD_FE n3789 construct.  Site n7 was removed via site directed mutagenesis using the 
primer previously designed by Dr P. Redelinghuys (Redelinghuys, 2006).  The PCR parameters 
used were as described in section 2.3.1.2.  Positive introduction of the desired mutation, and 
thus generation of the pcDNA 3.1+ SEDSTE_YR/ TSEVVD_FE n389 construct, was confirmed by 
restriction enzyme screening for the simultaneously introduced NdeI site.  Nucleotide 
Chapter 2: Mechanism of N-selective inhibition 
34 
 
sequencing was performed to confirm the presence of all active site mutations and N>Q 
mutation of sites n1, n2, n4, n5, n6 and n7. 
 
2.3.5 Protein expression  
The Chinese Hamster Ovary cell line (CHO-K1) was used for ACE protein expression.  Cells which 
were previously stably transfected with wild-type N- or C-domain (Kroger et al., 2009) were 
reconstituted into growth medium.  They were grown to confluency in T-175cm2 flasks (Nunc 
Ltd.) before replacing the growth medium with harvesting medium (constituents in Appendix 
A6).  Culture medium was harvested every 48 hours and the pooled harvests stored at -20°C 
until protein purification.  
  
To express the mutant proteins, untransfected cells were plated in 100mm2 plates (Nunc Ltd.) 
and incubated overnight at 37°C, 5% CO2 and 80% humidity in complete growth medium.  Three 
hours prior to transfection, fresh complete growth medium was applied.  At 40% confluency, 
the cells were transfected with mutant N-domain pcDNA 3.1+ constructs using the calcium 
phosphate Profection® Mammalian Transfection System (Promega Corp.).  A solution of 10µg 
DNA in CaCl2 was bubbled through a HEPES Buffered Saline (HBS) solution to form a fine DNA 
precipitate.  This was added to the cells in a dropwise manner with swirling to allow even 
distribution across the plate.  Following 4 hour’s incubation, a 2-minute glycerol shock (15% 
glycerol in 1X PBS, pH7.5) was performed to increase the transfection efficiency before removing 
the DNA solution.  Cells were incubated overnight at the aforementioned conditions in fresh 
complete growth medium until confluency was reached.   
 
After 24 hours, selection of positively transfected cells was commenced by replacing the growth 
medium with complete growth medium containing 0.9mg/ml of the mammalian antibiotic, G418 
disulphide salt (Sigma-Aldrich® Co.).  Resistant clones were picked into 48-well plates containing 
growth medium and kept under G418 selection until confluency was reached.  Growth medium 
was subsequently replaced with harvesting medium and the cells incubated for 48 hours.  After 
incubation, a fluorometric assay was performed to identify clones expressing high levels of ACE 
(see section 2.3.6).  The highest-expressing clone was selected for each mutant, grown to 
confluency in T-25cm2 flasks (Nunc Ltd.) and subsequently split into T-150cm2 flasks.  Upon 
reaching confluency, harvesting medium was applied to the T-150cm2 flasks and incubated for 
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48 hours to allow protein expression.  Medium was harvested, pooled and stored at -20ᵒC until 
protein purification. 
 
2.3.6 End-point ACE fluorogenic assay 
ACE activity was assessed during protein expression and purification using the non-domain 
selective fluorogenic substrate Z-phenylalanylhistidylleucine (Z-FHL) (Bachem Ltd.) (Schwager et 
al., 2006).  Two-hundred and twenty milligrams of Z-FHL substrate was dissolved in 2ml NaOH 
(0.28M) before addition of 2ml distilled water in a dropwise manner with vortexing. A 20mM 
stock solution was obtained by addition of a further 16ml distilled water and 1mM working 
solutions subsequently prepared in assay buffer (100mM K2HPO4/KH2PO4, pH 8.3, 300mM NaCl, 
10μM ZnSO4). 
 
Six microliters of harvested medium or 3µl of pure protein was added to 30µl of 1mM Z-FHL in 
triplicate wells of a 96-well plate.  The plate was incubated at 37°C on an orbital shaker for 15 
minutes to allow substrate hydrolysis by ACE.  This was followed by termination of the reaction 
with 177µl 0.28M NaOH and addition of 16µl O-phthaldialdehyde (20mg/ml (Sigma-Aldrich® 
Co.)) in methanol.  Incubation for 10 minutes at room temperature with shaking allowed 
derivatization of the HL sequestered by Z-FHL hydrolysis.  The reaction was stopped by addition 
of 30µl HCl (3M) and the fluorescence intensity detected at excitation and emission wavelengths 
of 360nm and 485nm, respectively, using a fluorescence spectrophotometer (Cary Eclipse Varian 
Inc.).  A standard curve was constructed using His-Leu (HL) standards (Sigma-Aldrich® Co.) 
prepared in assay buffer to relate fluorescence intensity to moles of HL, and thus enzyme activity 
(Appendix A7).   
 
2.3.7 Protein purification 
The purified Y369F, R381E and YR/FE proteins were a kind gift from Dr R. G. Douglas (Kroger et 
al., 2009).  ACE proteins harvested from CHO-K1 cells were purified using lisinopril-sepharose 
affinity chromatography, as previously described (Bull et al., 1985).  This involves binding of ACE 
in the medium to the potent inhibitor, lisinopril, coupled to sepharose beads.  To increase the 
affinity for lisinopril binding, a final concentration of 800mM NaCl was added to N-domain 
medium (Deddish et al., 1994).  The column was prepared and equilibrated by washing with 
wash buffer (20mM HEPES pH 7.5, 500mM NaCl) for 15 minutes.  Pooled harvested medium was 
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loaded onto the column and wash buffer applied for 12 hours to remove any remaining medium 
components from the column.  This was followed by dissociation of the protein with elution 
buffer (50mM Boric acid, pH 9.5).  Fractions were collected from the first point of elution as 
monitored by a UV detector (Settings: 5mV, 100m/h, A280nm).  Activity of each fraction was 
determined with the described Z-FHL assay (section 2.3.6) and the most active fractions pooled 
into SnakeSkin® dialysis tubing (Pierce Biotechnology Ltd.).  Pooled protein solutions were 
dialyzed for 24 hours at 4°C in dialysis solution 1 (5mM HEPES pH 7.5, 0.1mM PMSF in ethanol) 
after which they were transferred into dialysis solution 2 (50mM HEPES pH 7.5, 0.1mM PMSF in 
ethanol) for a further 24-hour period at 4°C. 
 
Purity of the resulting proteins was assessed by means of sodium-dodecyl-sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970).  A 10% acrylamide gel was used 
to separate proteins based on their molecular mass before staining the gel with Coomassie dye 
(Appendix A8) for visualization.  The concentration of pure protein was determined from the 
absorbance (extinction coefficient of 162 070 M-1 cm-1 for N-domain and 143 620 M-1 cm-1 for C-
domain; molecular mass of 72.36 kDa for N-domain and 77.82 kDa for C-domain) with the use 
of a NanoDrop® spectrophotometer. 
 
2.3.8 Preparation of substrate and inhibitor for kinetic assays 
The non-selective, quenched fluorogenic ACE substrate (Abz)-FRK-(Dnp)-P-OH was kindly 
donated by Dr A.K. Carmona (Universidad Federal de São Paulo, Brazil).  The peptide was 
dissolved in 100% DMSO and the concentration determined by measuring the absorbance at 
365nm and extinction coefficient of 17300 M-1 cm-1.  Subsequent dilutions were made in assay 
buffer (50mM HEPES, pH 6.8, 10µM ZnCl2, 200mM NaCl). 
 
The phosphinic inhibitor 33RE was synthesized by Dr R.K. Sharma (Department of Chemistry, 
University of Cape Town, South Africa).  Lyophilized 33RE was dissolved in distilled water to yield 
a stock concentration of 10mM. Subsequent dilutions were made in an assay buffer consisting 
of 50mM HEPES pH 6.8, 200mM NaCl and 10µM ZnCl2. 
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2.3.9 Preparation of an Abz standard curve 
The unquenched fluorescent group o-Aminobenzoic acid (Abz) coupled to glycine (Abz-Gly, 
Bachem Ltd.) was used to correlate the fluorescence intensity to the amount of Abz present.  A 
1mM stock of Abz-Gly was prepared in distilled water and serially diluted in assay buffer (50mM 
HEPES pH 6.8, 10µM ZnCl2 and 200mM NaCl).  Three hundred microliters of Abz-Gly at each 
concentration was added to triplicate wells of a 96-well plate and the fluorescence intensities 
read at excitation and emission wavelengths of 320nm and 420nm, respectively, using a 
fluorescence spectrophotometer (Cary Eclipse Varian Inc.).  The fluorescence intensity was 
plotted against picomoles of Abz-Gly and a standard curve obtained (Appendix A9) by linear 
regression analysis (GraphPad Prism® v6.01).  
 
2.3.10 Catalytic efficiency 
The amount of active protein was determined immediately after purification by calculating the 
specific activity from Z-FHL (Schwager et al., 2006) and Bradford (Bradford, 1976) assays.  
Binding and hydrolysis of the fluorogenic Abz-FRK(Dnp)P-OH substrate was determined as 
previously described in an assay buffer consisting of 50mM HEPES (pH 6.8), 200mM NaCl and 
10µM ZnCl2 (Carmona et al., 2006).  Briefly, a 50μM solution of Abz-FRK(Dnp)P-OH was prepared 
in assay buffer (50mM HEPES, pH 6.8, 10µM ZnCl2, 200mM NaCl) and variable volumes added in 
triplicate to a 96-well plate on ice.  A constant volume of enzyme was added to all wells and the 
final volume adjusted to 300μl with buffer to give a constant amount of enzyme with a range of 
substrate concentrations.  The hydrolysis of Abz-FRK(Dnp)P-OH from triplicate wells were 
continuously monitored at excitation and emission wavelengths of 320nm and 420nm, 
respectively, using a fluorescence spectrophotometer (Cary Eclipse, Varian Inc.).   
 
Since quenching of the released Abz fluorescence signal occurs at high Abz-FRK(Dnp)P-OH 
concentrations, a phenomenon known as the inner filter effect, initial velocities were adjusted 
by constructing a correction curve of Abz-Gly and (Abz)-YRK-(Dnp)-P-OH (Appendix A10) as 
previously described (Carmona et al., 2006; Liu et al., 1999).   
 
Initial reaction velocities were determined from the fluorescence intensity at each Abz-
FRK(Dnp)P-OH concentration using the Abz-Gly standard curve (Appendix A9), adjusted using 
the second order polynomial of the correction curve (Appendix A10) and plotted against 
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substrate concentration to obtain the Km and kcat kinetic parameters using the Michaelis-Menten 
model (GraphPad Prism® v 6.01).  Catalytic efficiency of the Y369F, R381E and YR/FE mutants 
were previously determined and described in Kröger et al (Kroger et al., 2009). 
 
2.3.11 Inhibition kinetics 
Inhibition assays were performed in triplicate wells of two independent experiments for wild-
type N-domain, C-domain and mutant proteins to determine the dissociation constant for 
binding of inhibitor to enzyme (Ki).  The Dixon method (Dixon, 1953) was used which involved 
measurement of initial reaction velocities at constant enzyme but two different substrate 
concentrations and a range of inhibitor concentrations.  Dixon plots were determined for wild-
type as well as mutant enzymes to study the effect of active site mutations on inhibitor binding 
and thus selectivity. 
 
An equal volume of enzyme (40nM) was incubated for 5 minutes with an appropriate 
concentration range of phosphinic inhibitor at ambient temperature.  Twenty microliters of the 
enzyme-inhibitor mix was aliquoted in triplicate to a 96-well plate followed by 280µl of (Abz)-
FRK(Dnp)P-OH substrate.  To construct a Dixon plot, two parallel assays with different substrate 
concentrations (4µM and 8µM) were performed for each enzyme.  Fluorescence due to 
liberation of the fluorescent Abz group from the quenching 2,4-dinitrophenyl (Dnp) group was 
detected continuously for 30 minutes at excitation and emission wavelengths of 320nm and 
420nm, respectively, using a fluorescence spectrophotometer (Cary Eclipse Varian Inc.).  Since 
detected fluorescence is directly proportional to the amount of Abz released, and thus reaction 
velocity, the inverse fluorescence was plotted as a function of inhibitor concentration at two 
different substrate concentrations to yield a Dixon plot (Appendix A12). 
 
2.4  In silico methodology 
2.4.1 Protein structure preparation 
Files containing the atomic coordinates and structure factors for the N-domain-33RE co-crystal 
structure were obtained from the protein data bank (PDB, www.rcsb.org; accession code 4BXK).  
Before using the deposited structure for modelling and molecular simulations the model’s fit to 
the electron density map was validated.  Phenix ReadySet was used to add hydrogens to the 
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protein and ligand prior to iteratively refining the structure in Phenix Refine with optimization 
for X-ray weight and stereochemistry (Adams et al., 2010).  Coot was used in conjunction with 
Phenix for visual inspection of electron density and adjustment of side chain rotamers/chi 
angles, if necessary (Emsley et al., 2010).  
 
Histidine tautomers and amide orientations (asparagine and glutamine) were visually inspected 
and altered to ensure optimal hydrogen bonding using the Schrödinger Suite’s Protein 
Preparation Wizard (Sastry et al., 2013).  Optimization was performed on protein chain A in the 
presence of crystallographic waters but the absence of protein chain B and crystallographic 
sugars.  The crystallographic waters were deleted after successful protein optimization.  
 
All subsequent simulations were performed using Biovia Discovery Studio v4.0 (Biovia, 2013).  
Valencies of the ligand structure were confirmed and the ionized phosphonate’s negative charge 
delocalized over the OAI, OAH and PBG atoms.  The 33RE P2’ carboxylate analogue was created 
by replacing the P2’ amide with a carboxylate having a partial double bond to each oxygen.  Even 
though protein chain A was more complete than B, it still had poor electron density for residues 
L129 - T133.  The missing loop of residues P130, Q131 and K132 was built using the random 
tweak algorithm in Biovia Discovery Studio (Shenkin et al., 1987).   All atoms except residues 
129-133 were held fixed in position while further optimizing the loop’s geometry through 1000 
steps of steepest descent minimization (rms gradient = 3) and conjugate gradient minimization 
(rms gradient = 0.01).  The protein and peptidomimetic ligand were protonated at pH 7.4 and 
typed with the CHARMm forcefield using the Momany-Rone partial charge method (Momany 
and Rone, 1992).  This forcefield allowed typing of the ligand tetrazole and peptidomimetic 
moieties.  To our knowledge, no parameters have yet been published for zinc coordination to 
phosphonate atoms.  To avoid estimation of these parameters but still maintain the catalytic 
zinc ion, distance restraints (force constant 50kcal/(mol.Å2)) were applied between the zinc (+2 
charge) and its coordinating atoms: the ligand phosphonate OAI and OAH, H361 NE2, H365 NE2 
and E389 OE1.  
 
The apo structure was prepared by deleting the ligand and only applying distance restraints 
between zinc and H361 NE2, H365 NE2 and E389 OE1. The mutant structures were all prepared 
from these two typed wild-type structures.  With each mutation or deletion of ligand, optimal 
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hydrogen bonding within a 5Å radius of the change was verified by visual inspection using the 
Schrödinger Suite’s Protein Preparation Wizard (Madhavi Sastry et al., 2013). 
   
2.4.2 Molecular dynamics 
Molecular dynamics simulations were performed on a total of six 33RE-bound, three 33RE P2’ 
carboxylate analogue-bound and six apo structures.   
 
i. Solvation and minimization: 
Fixed atom constraints were applied to all protein and ligand atoms before explicitly solvating 
the systems. The water molecules were added using the explicit periodic boundary TIP3P model 
(Jorgensen et al., 1983) with a truncated octahedron cell shape and a minimum distance of 10Å 
between protein atoms and the solvent boundary. This cell shape was the best fit for the 
globular ACE molecule and comparable to literature (Papakyriakou et al., 2007).   
 
Counterions to a concentration of 0.145M NaCl were added to neutralize the system and mimic 
physiological and in vitro assay conditions. The solvent box was subjected to one hundred steps 
of steepest descent minimization (RMS gradient = 3) and subsequently 2500 steps of conjugate 
gradient minimization (RMS gradient = 0.05).    Thereafter, the fixed atom constraints were 
released and the entire system minimized with 1500 steps of conjugate gradient minimization 
(RMS gradient 0.05) while harmonically constraining the protein backbone (force constant = 
10kcal/(mol.Å2)). Long-range electrostatics were calculated using the Particle Mesh Ewald 
method (Darden et al., 1993) with an interpolation order of 4 and spacing of 0.34 Å. 
 
ii. Heating: 
The minimized structures were heated for 2500 steps from the initial temperature of 50K to the 
target 300K by adjusting the velocity every 50 steps with a 2fs time step.  
 
iii. Equilibration:  
To ensure proper distribution of energy, the systems were equilibrated at the target 
temperature with constant pressure (1atm) for 55000 steps.  The Nosé-Hoover thermostat 
(Nosé, 1984; Hoover, 1985) was used for temperature control and the Langevin piston (Feller et 
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al., 1995) for pressure control with a piston mass of 1000 AMU and collision frequency of 25ps-
1.  Velocities were monitored and adjusted every 50 steps if necessary. The Leapfrog-Verlet 




Production runs of 12.55ns were carried out at physiological conditions in the NPT ensemble 
(1atm, 300K) with all restraints (except the Zn2+-binding distance restraints) having been 
released.  Snapshots of the trajectories were taken every 5ps for a total of 2510 frames per 
structure.  The non-bond list radius was set to 12Å with higher and lower cut-offs of 10Å and 8Å, 
respectively, for all simulations.  The SHAKE constraint, which fixes all bonds involving 
hydrogens, was applied to all runs except the explicit solvent box minimizations.  
 
2.4.3 Trajectory analysis 
Prior to analysis, the trajectory files were processed to remove all water molecules, sodium and 
chloride ions.  The sampling was increased to 10ps intervals to reduce computational cost and 
enable analysis of the fifteen structures.  Energy and temperature of the system were monitored 
during the equilibration and production stages to ensure stability and equilibrium.  Trajectory 
snapshots were analysed for backbone root mean square deviation (RMSD) against the first 
equilibrated frame with backbone fitting to remove the translational and rotational motions of 
the protein molecule over time.  The fitted conformations were subsequently analysed for 
amino acid root mean square fluctuation (RMSF), protein radius of gyration, ligand poses and 
per residue ligand interaction energy decomposition (within 5Å radius of ligand) using Biovia 
Discovery Studio v4.0 (Biovia, 2013).  
 
Ligand stability in the active site was visualized by dividing the 955 frames into 100 frame 
sections (equal to 1ns) to extract ten average conformations for each structure. The effect of 
mutation on active site size over time was evaluated by computing the volume of the central 
cavity for the 10 average conformations per structure using the online server CASTp (Binkowski 
et al., 2003). The 33RE-bound structures’ volumes were compared to their respective apo forms 
using a two-tailed, paired, parametric t-test with a 99% confidence level (GraphPad Prism® 
v6.01).  
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Protein backbone motions and subdomain hinging was studied by RMSD clustering, covariance 
and principal component analyses using Biovia Discovery Studio v4.0 (Biovia, 2013) and the 
Bio3D package in R (Grant et al., 2006).  Clusters of conformations were identified by calculating 
the RMSD with backbone fitting over all frames across the simulation using the hierarchical 
Unweighted Pair Group Method with Arithmetic mean (UPGMA). Correlated motions of 
backbone atoms were extracted and visualized on covariance heatmaps.  Diagonalization of the 
covariance matrix through principal component analysis (PCA) removed the high frequency 
protein motions and allowed visualization of long-range, low frequency backbone motions 
conserved throughout the simulations. The resulting eigenvectors and eigenvalues were 
visualized as porcupine plots using a python script written by Robert Schulz in VMD (Humphrey 
et al., 1996). Images were made with Biovia Discovery Studio v4.0 (Biovia, 2013), UCSF Chimera 
v1.10.1 (Pettersen et al., 2004), and VMD (Humphrey et al., 1996) software. VMD is developed 
with NIH support by the Theoretical and Computational Biophysics group at the Beckman 
Institute, University of Illinois at Urbana-Champaign.  
 
2.5  In vitro methodology 
2.5.1 Differential scanning fluorimetry 
Protein melting temperatures and thermal stabilization by 33RE were determined using the Life 
technologiesTM Protein Thermal Shift assay according to manufacturer’s instructions. Briefly, 
pure protein and 33RE were incubated in assay buffer (50mM HEPES pH6.8, 200mM NaCl and 
10µM ZnCl2) at final concentrations of 1.3μM and 0-85μM, respectively, for 10 minutes at 
ambient temperature.  The thermal shift fluorogenic dye was added to protein-inhibitor 
reactions in triplicate wells of 96-well RT-PCR plates on ice and the wells sealed with StarSeal® 
optically clear film.  Fluorescent signal due to protein thermal denaturation was monitored over 
a temperature range of 25-90°C at 0.5°C intervals using a BioRad® CFX-6 RT-PCR machine. Two 
independent experiments were performed for each protein.  Melting temperatures (Tm) were 
determined from the peak of the obtained first derivative results and averaged across the 
triplicate wells.  The degree of thermal stabilization (∆Tm) calculated as the difference in average 
Tm in the presence vs absence of 33RE was plotted against concentration and fitted to a one-site 
binding model (GraphPad Prism® v6.01). The maximum stabilization was calculated from these 
curves for each protein and that of the wild-type compared to the mutants’ using an unpaired, 
two-tailed parametric t-test with a 99% confidence level (GraphPad Prism® v6.01). 
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2.6  Results and discussion 
2.6.1 Generation of N-domain active site mutant constructs 
The N-domain construct starts with an N-terminal signal sequence and terminates after residue 
D629 (Corradi et al., 2006) whereas the C-domain construct starts with the testis ACE signal 
sequence, lacks the 36 unique N-terminal O-glycosylated residues and transmembrane region 
and terminates after S625 (Yu et al., 1997).  N-domain numbering is according to the N-terminal 
domain of sACE minus the signal sequence.  C-domain numbering in this chapter is according to 
tACE minus the signal sequence but including the 36 unique N-terminal residues.  The first amino 
acid present in the C-domain construct used here is thus numbered as 37.  Site-directed 
mutagenesis yielded positive amplification of all the desired constructs (Table A1) at magnesium 
concentrations of 0mM and 2mM, 100ng template DNA and primer annealing temperature of 
85ᵒC.  The restriction enzymes screens performed with the intermediate pBS SKII+ vectors are 
not shown but positive incorporation of the desired mutations was observed for all constructs.  
Nucleotide sequencing confirmed this result and showed no spurious introductions. 
 
The SEDT/TSEV mutant was generated from pBS SKII+ SEDSTE/TSEVVD by V357S site-directed 
mutagenesis and sub-cloning to replace E431D by wild-type.  Sequencing as well as digests of 
template and amplicon constructs with BstEII and EcoRI (data not shown) confirmed positive 
introduction of the V357S mutation and thus generation of pBS SkII+ SEDTE/TSEVD.  The E431D 
mutation present in pBS SkII+ SEDTE/TSEVD was reverted by replacing the C-terminal coding 
region with wild-type by means of an EcoRI/BmgBI digest.  The resulting pcDNA 3.1+ SEDT/TSEV 
was digested with all the restriction enzymes for which sites were introduced via PCR.  
Differences in banding patterns compared to wild-type confirmed the presence of all desired 
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Figure 2.6: Restriction enzyme screen for presence of all pcDNA 3.1+ SEDT/TSEV mutations.   
Vector map illustrates introduced screening sites in grey.  Right hand panels show electrophoresis results 
for the respective restriction digests (lane 1: O’GeneRulerTM DNA Ladder Mix (Fermentas), lanes 2, 4, 6, 8, 
10: pcDNA 3.1+ N-domain, lanes 3, 5, 7, 9, 11, 12: pcDNA 3.1+ SEDT/TSEV.  Lanes 2-3: CsiI, lanes4-5: SspI, 
lanes 6-7: PvuII, lanes 8-9: EcoRI/BstEII, lanes 10-11: BsmI and lane 12: EcoRI/XbaI). 
 
The prepared SE, SEDSTE and SEDSTE_YR coding regions were cloned into the mammalian 
expression vector by digesting the pBS SKII+ mutant and pcDNA 3.1+ N-domain constructs with 
EcoRI and XbaI (SE/VD shown as a representative example in Figure 2.7).  Subsequent ligation of 
the 2000bp mutant insert with the 5389bp pcDNA 3.1+ vector yielded 7389bp plasmids 
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Figure 2.7: Cloning of N-domain mutant SE/VD into mammalian pcDNA 3.1+ expression vector.  
a) Cloning strategy with restriction enzyme sites introduced during mutagenesis shown in grey.  The PvuII 
site at 1878bp was previously introduced with the S357V mutagenesis. b) Restriction enzyme digests (1% 
agarose gel) for cloning of the SE/VD insert into pcDNA 3.1+.  Lane 1: O’GeneRulerTM DNA Ladder Mix 
(Fermentas), lane 2: pcDNA 3.1+ N-domain digested with EcoRI & XbaI, lane 3: pBS SkII+ SE/VD digested 
with EcoRI & XbaI.  pcDNA 3.1+ vector and N-domain insert sizes correspond to 5389bp and 2000bp, 
respectively.  
 
All the resulting pcDNA 3.1+ constructs were screened with the restriction enzymes for which 
sites were introduced via PCR.  Differences in banding patterns compared to wild-type 
confirmed the presence of all desired mutations for the SE/VD (Figure 2.8), SEDSTE/TSEVVD 
(Figure 2.9) and SEDSTE_YR/TSEVVD_FE (Figure 2.10) constructs.  These results were verified by 




















































        
Figure 2.8: Restriction enzyme digests of the pcDNA 3.1+ SE/VD mutant. 
Screening enzyme sites introduced by mutagenesis are indicated in grey on the vector map.  
Electrophoresis gel illustrates the difference in banding pattern between mutant and wild-type constructs.  
Lane 1: O’GeneRulerTM DNA Ladder Mix, lanes 2 & 4: pcDNA 3.1+ N-domain, lanes 3 & 5: pcDNA 3.1+ 
SE/VD.  Lanes 2&3: BsmI digests, Lanes 4&5: PvuII digests. 
 
                  
Figure 2.9: Restriction enzyme digests of the pcDNA 3.1+ SEDSTE/TSEVVD mutant.  
Screening enzyme sites introduced by mutagenesis are indicated in grey on the vector map.  
Electrophoresis gel illustrates the difference in banding pattern between mutant and wild-type constructs.  
Lane 1: O’GeneRulerTM DNA Ladder Mix, lanes 2, 4, 6, 8: pcDNA 3.1+ N-domain, lanes 3, 5, 7, 9: pcDNA 
3.1+ SEDSTE/TSEVVD.  Lanes 2&3: CsiI digests, Lanes 4&5: SspI digests, Lanes 6&7: PvuII digests, Lanes 
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Figure 2.10: Restriction enzyme digests of the pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE mutant.   
Screening enzyme sites introduced by mutagenesis are indicated in grey on the vector map.  
Electrophoresis gel illustrates the difference in banding pattern between mutant and wild-type constructs.   
Lane 1: O’GeneRulerTM DNA Ladder Mix (Fermentas), lanes 2-3: pcDNA 3.1+ N-domain, lanes 4-5: pcDNA 
3.1+ SEDSTE_YR/ TSEVVD_FE.  Lanes 2 and 4: BglII digests, Lanes 3 and 5: BfuI digests. 
 
 
2.6.2 Generation of a minimally glycosylated SEDSTE_YR/TSEVVD_FE construct 
To enable crystallization of the mutant having all unique N-domain active site residues 
converted to C-domain, glycosylation sites n1, n2, n4, n5, n6 and n7 were removed.  A 
Bsu36I/EcoRI digest was used to ligate the C-terminal part of the pcDNA 3.1+ 
SEDSTE_YR/TSEVVD_FE construct (containing the active site mutations) to the N-terminal part 
of pcDNA 3.1+ N-domain n3 (having all glycosylation sites except n3 removed) (Figure 2.11). 
 
Since site 7 is located between the active site mutants E262S and S357V and no restriction sites 
were available in this region for selective removal of site n7, site-directed mutagenesis was 
employed.  PCR with the N289Q primer simultaneously introduced an NdeI site.  The difference 
in banding pattern observed upon NdeI digest of the resulting amplicon and template DNA 
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Figure 2.11: Sub-cloning used to construct pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n3789.   
a) Lane 1: O’GeneRulerTM DNA Ladder Mix, lanes 2 and 5: pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE, lanes 3 and 
4: pcDNA 3.1+ N-domain n3.  Lanes 2-3: Bsu36I digests, Lanes 4-5: EcoRI/Bsu36I digests. b) Coding region 
size confirmation following ligation.  Lane 1: O’GeneRulerTM DNA Ladder Mix, lane 2: pcDNA 3.1+ 







                            
 
Figure 2.12: Restriction enzyme screen of pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n389 for positive removal 
of glycosylation site 7.   
Lanes 1 and 3: O’GeneRulerTM DNA Ladder Mix, lane 2: pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n3789 (PCR 
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Sequencing showed the presence of all SEDSTE_YR/TSEVVD_FE active site mutations, 
glycosylation sites 3, 8 and 9 and the absence of glycosylation sites n1, n2, n4, n5, n6 and n7.  It, 
however, also led to the discovery of a spurious W40L mutation which resulted in the loss of a 
PvuII restriction site.  Further investigation through PvuII digests of all constructs used in creating 
pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n389 led to the discovery of the spurious W40L mutation in 
the original pcDNA 3.1+ N-domain n3 template (data not shown).  Since the N-domain n389 
construct routinely used for crystallization does not contain this mutation, pBS SKII+ N-domain 
n389 was used to replace the N-terminus of pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n389 (with 
W40L) using sequential Bsu36I and EcoRI digests, ligation and EcoRI/XbaI screens as previously 
described (data not shown).  Sequencing of the final construct showed the presence of W40, all 
eight active site mutations, glycan sites n3, n8 and n9 and N>Q mutations at the remaining 
glycan sites. 
 
2.6.3 Purification of the active site mutant for X-ray crystallography 
The pcDNA 3.1+ SEDSTE_YR/TSEVVD_FE n389 construct was stably transfected into CHO-K1 
cells, heterologously expressed and the protein purified via lisinopril-sepharose affinity 
chromatography.  Subsequent SDS-PAGE analysis showed a single band of ~70kDa for the N-
domain n389 (Anthony et al., 2010) and SEDSTE_YR n389 (Figure 2.13), indicating protein purity 
and a lower degree of glycosylation due to removal of sites 1, 2, 4, 5, 6 and 7.  The protein was 
concentrated to 3.8mg/ml, frozen at -20°C and sent to Prof K. R. Acharya at the University of 
Bath for crystallization in an apo form as well as complexed to 33RE.  An interpretation of the X-




Figure 2.13: Coomassie-stained SDS-PAGE gel (10%) of the purified minimally glycosylated proteins. 
 Lane 1: protein ladder (kDa), lanes 2, 3 and 4: fully glycosylated N-domain, minimally glycosylated N-
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2.6.4 Purification and kinetic characterization of the N-domain active site mutants 
The N-domain, C-domain, SE/VD, SEDT/TSEV, SEDSTE/TSEVVD, SEDSTE_YR/TSEVVD_FE and 
YR/FE mutant constructs (referred to by the mutated N-domain residues from this point 
onwards) were stably transfected into CHO-K1 cells, and proteins purified to homogeneity via 
lisinopril-coupled sepharose affinity chromatography following heterologous expression. Single 
bands were observed for each construct on SDS-PAGE corresponding to approximately 90kDa 
for N-domain/mutants and 70kDa for C-domain (Figure 2.14). 
  
 
                                                          
Figure 2.14: Coomassie-stained SDS-PAGE gels (10%) of purified fully glycosylated proteins.  
Lanes 1, 3 and 5: protein ladder (kDa); lanes 2, 4, 6, 7, 8 and 9: WT N-domain, SE, SEDT, SEDSTE, SEDSTE_YR 
and WT C-domain. 
 
The N-domain mutations introduced form part of the active site and as such could affect not 
only the binding of inhibitor but also substrate.  The inhibitor (33RE) competes with substrate 
for binding to the active site, thus it is crucial to determine the effect of the mutations on the 
substrate’s binding affinity as this could affect the observed inhibitor binding affinity.   
 
Although catalytic turnover (kcat) was altered upon mutation, the substrate Abz-FRK(Dnp)P-OH 
binding affinity (Km) was comparable between the mutant and wild-type N- and C-domains 
(Table 2.3).  Residual hydrolysis of this substrate could thus be used to accurately determine all 
the inhibitor binding constants. The overall catalytic efficiency (kcat/Km) was slightly higher for 
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Table 2.3: Catalytic efficiency of Abz-FRK(Dnp)P-OH hydrolysis by wild-type and mutant proteins.  









N-domain 6.09 0.299 0.049 
SE 10.76 0.010 0.001 
SEDT 3.55 1.513 0.426 
SEDSTE 7.33 1.050 0.143 
SEDSTE_YR 5.76 3.770 0.654 
C-domain 4.87 0.751 0.154 
 
 
2.6.5 Kinetic characterization of ACE inhibition by 33RE 
The affinity of 33RE and RXP407 binding to wild-type and N-domain mutant proteins were 
determined by means of kinetic assays using the non-domain-selective fluorogenic (Abz)-FRK-
(Dnp)-P substrate.  Dixon plots were constructed for wild-type as well as mutant enzymes to 
study the effect of active site mutations on inhibitor binding and thus selectivity.  A 
representative plot is given in the Appendix A12. 
 
Compound 33RE displayed low nanomolar inhibition of the N-domain (Ki=11.21 ± 0.74nM) and 
micromolar inhibition of the C-domain (Ki=11 278 ± 410nM), thus three orders of magnitude N-
selectivity, similar to RXP407 (Table 2.4).  To better represent the influence of mutation on 33RE 
selectivity, Ki values were compared on a logarithmic scale relative to the wild-type (Figure 2.15).  
Higher values indicate a decrease in inhibitor binding affinity upon mutation.   
 
The N-domain S2 mutants Y369F and R381E showed a drastic decrease in 33RE affinity (Ki=404.40 
± 17.30nM and Ki=86.97 ± 6.29 nM, respectively) with substitution of both these residues in the 
YR/FE mutant having an additive effect (Ki=2 794 ± 156nM).  Together with the weak side-chain 
density observed for R381 (PDB ID: 4BXK) this suggests that alternative R381 locations are 
possible.  The effect of these mutations on 33RE binding was similar to what was previously 
observed for RXP407 with the exception of YR/FE having a synergistic effect for RXP407 (Kroger 
et al., 2009).  Even though these S2 residues do not account for the full selectivity, they clearly 
play a major role (Figure 2.15).   
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The S2’ mutant SEDT displayed a modest 2-3-fold decrease in N-selectivity (Ki=29.21 ± 2.40nM) 
while the S2’ double mutant SE (Ki=481.2nM) and the complete S2’ mutant SEDSTE (Ki=237.22 ± 
13.60nM) dramatically decreased the selectivity by 43- and 21-fold, respectively (Table 2.4).  
Since these residues do not directly interact with 33RE, the prime mutants’ kinetic results could 
not be rationalized from the N-domain-33RE crystal structure.  Interestingly, the S2/S2’ double 
pocket mutant SEDSTE_YR, having all the aforementioned mutations combined, abolished all 
selectivity (Table 2.4).  The N-selective nature of ACE inhibition by 33RE thus appears to be 
governed by synergistic interactions with both the S2 and S2’ subsites since lack of either resulted 
in decreased selectivity.  It is inferred that the P1 and P1’ groups have no contribution towards 
selectivity though they might be required for potency (Dive et al., 1999). 
 
Table 2.4: Affinity of 33RE binding to the wild-type and mutant proteins.   
Inhibitor binding constants (Ki values) were determined from inhibition assays via Dixon plots and are 
represented as mean ± SD of two independent experiments, performed in triplicate. 
 RXP407 33RE 
Construct Ki (nM) Fold selectivity 
Ki 
(nM) Fold selectivity 
N-domain 21.03 ± 0.27 
2 896 
11.21 ± 0.735 
1 006 
C-domain 60 826 ± 9 175 11 278 ± 410 
Y369F 
n.d. 
404.4 ± 17.3 27.9 
R381E 86.97 ± 6.29 129.7 
YR 2 794 ± 156 4.04 
SE 481.2 † 23.4 † 
SEDT 29.21 ± 2.40 386.1 
SEDSTE 237.22 ± 13.60 47.5 
SEDSTE_YR 10 009 ± 157 1.13 
n.d.: not determined in the current study (see Kröger et al, 2009 (Kroger et al., 2009) for S2 mutants’ 








Figure 2.15: Logarithmic scale comparison of the relative inhibitor binding affinity of N-domain mutants 
to that of the wild-type domains.   
Relative binding affinities for RXP407 and 33RE are shown on the left and right, respectively. Positive 
values represent decreased affinity relative to wild-type N-domain, thus towards more C-domain-like Ki. 
Results are shown as mean ± SD from two independent assays performed in triplicate. 
 
 
2.6.6 Influence of mutation on 33RE tetrazole stability and interaction energy 
Structures of the various mutants prepared and kinetically analysed in vitro were also created in 
silico to simulate their dynamic behaviour in the presence and absence of ligand.  Prior to use of 
the wild-type N-domain crystal structure complexed to 33RE (PDB ID: 4BXK) in simulations, it 
was re-refined against its electron density.  This led to a change in initial and final values for Rfree 
of 0.1814 and 0.1784, respectively; RMS(bonds) of 0.020 and 0.006, respectively; and 
RMS(angles) of 1.322 and 0.916, respectively.  The resulting structure was prepared as described 
in the methods section for the wild-type N-domain, SE, SEDT, SEDSTE, SEDSTE_YR and YR 
mutants in apo, 33RE-bound and 33RE P2’ carboxylate analogue-bound forms. 
 
The wild-type and mutant structures were explicitly solvated and neutralized by adding 
approximately 17500 water molecules, 53 sodium and 47 chloride ions.  Each structure thus 
consisted of approximately 62700 atoms. Two thousand five hundred and ten trajectory frames 
were collected for all apo and ligand-bound proteins from 12550ps of production dynamics. The 
first 3000ps was discarded as part of equilibration since the structures relaxed and showed 
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further decreases in potential energy over this timeframe.  Trajectories were analysed for the 
remaining 9550ps, sampled at 2 frame intervals for a total of 955 conformations per structure. 
 
The residues’ root mean square deviation (RMSD) was calculated across these 955 frames with 
backbone fitting to the first frame (post-equilibration) to remove the rotational and translational 
motion.  All the structures were stable during this timeframe (Figure 2.16) and could be analysed 
further.  
 




Figure 2.16: Root mean square deviation (RMSD) over the 9550ps of simulation (last 955 conformations) 
after backbone fitting against the first equilibrated frame.  
Apo structures are shown in black with their corresponding 33RE-bound (a-f) or analogue-bound (g-i) 
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The secondary structure nomenclature to be used from this point onwards is according to the 
33RE co-crystal structure (PDB ID: 4BXK) assignments from the European Bioinformatics 




Figure 2.17: Secondary structure of the N-domain (PDB ID: 4BXK).  
Beta sheets are labelled as A, B or C, helices are labelled by number, the proposed hinges are indicated 
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In wild-type, binding of 33RE’s amide was seen to occur with the conserved K489, H491 and 
Y498 residues, similar to the interaction of most ACE inhibitors’ carboxylate in this subsite.  
Although the crystal structure showed binding to the conserved Q259 as well, the simulations 
only showed Q259 transiently binding to K489 and possibly indirectly assisting in its binding to 
33RE’s amide.   
 
Consistent with the 33RE co-crystal structure, the MD simulations failed to show any direct 
interactions to the unique N-domain S2’ residues or R381 in the S2 subsite.  Per-residue 
decomposition of interaction energies calculated for all frames and averaged over the 10ns 
simulation time showed that the majority of the binding affinity resulted from pi-stacking and 
Van der Waals interactions to H331, A332, S333, W335 and H491 (Figure 2.18).  Some 
contributions to binding affinity also arose from hydrogen bonding of the 33RE backbone to 
A334, the amino group to the unique S2 residue Y369, the phosphonate group to the conserved 
Y501 and the amide to the conserved K489 residue.  The positive interaction energy to the zinc-
binding E389 is likely as a result of electrostatic repulsion by the phosphonate.  Since the 
coordination of zinc to a phosphonate, two histidines and a glutamate has not been 
parameterized before, distance restraints were applied to maintain zinc-coordination 
throughout the simulation.  Without the use of custom partial charge values derived from 
quantum mechanical calculations the negative charge of the phosphonate was likely not shared 
by the positively charged zinc ion, resulting a higher negative charge and repulsion of E389.  
Although this precludes calculation of the net binding energy of the inhibitor, interaction 
energies between moieties other than the phosphonate could be calculated.  Taken together, 
the P2’ amide’s hydrogen bonding to conserved loop residues of subdomain 2 and the 
aminomethyl tetrazole binding to Y369 and stacking to beta sheets C of subdomain 1 
synergistically enabled the bridging of 33RE across the active site cleft (Figure 2.19).   
 
Mutation only slightly affected the energies of these interactions with SEDSTE_YR showing the 
weakest binding due to a 43-94% decrease in interaction energy (versus wild-type) to Y369, 
F435, K489, H491, T496, Y498, R500 and Y501 (Figure 2.18 b).  Considering the ten average ligand 
poses calculated over 1ns intervals each, however, it was found that while the tetrazole is very 
stable in the WT N-domain structure, its stability is decreased and orientation changed upon 
mutation (Figure 2.18 c-h).  This ultimately results in suboptimal bridging of 33RE across the 
mutant active site cleft (Figure 2.19 b). 




Figure 2.18: Interaction energies and ligand poses calculated over all frames of the 33RE-bound 
structures.  
Total interaction energy (green), Van der Waals component (grey) and electrostatic component (blue) 
represented as mean ± standard deviation for a) WT and b) SEDSTE_YR. Ligand poses of 10 average 





Figure 2.19: Bridging of 33RE across the active site cleft.  
Subdomain 1, subdomain 2 and the lid flanking the cleft are shown in green, blue and dark green, 
respectively.  Interacting residues are shown in grey sticks with 33RE in yellow for the average 
conformation from the last 1ns simulation of a) WT and b) SEDSTE_YR. 
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2.6.7 The effect of active site residue mutations on apo protein flexibility 
Since alterations in ligand stability can result from changes in protein flexibility, the amino acids’ 
root mean square fluctuation (RMSF) was calculated across the 955 frames and compared to 
wild-type.  Both the apo and bound forms were studied to ascertain whether mutation affected 
the dynamic nature of the protein prior to inhibitor binding or the stability of the resulting 
complex. 
 
Apo structure flexibility 
Firstly, looking at the apo forms it is noted that upon mutation some changes in backbone 
flexibility occur around the lid helices 3-5 (hinge 1), beta sheets A, hinge 2, hinge 3 and hinge 4 
(hinge nomenclature according to the proposed regions described from normal mode analysis 
by Watermeyer et al (Watermeyer et al., 2006)) (Figure 2.20).   
 
SE mutation decreased the flexibility of hinges 2 and 4 but increased hinge 3 flexibility over wild-
type with no great changes in the lid (Figure 2.20 a).  The hinge region 3 was unaffected in all 
other apo structures.  Mutation of SEDT decreased the lid, hinge 2 and hinge 4 flexibility, though 
to a lesser extent than in SE (Figure 2.20 b).  The combination of these in SEDSTE resulted in 
hinge 2 and 4 RMSF decreases similar to that of SE which could therefore be attributed mainly 
to these two residues (Figure 2.20 c).  In addition, the flexibility is increased for helix 10, the 450-
460 loop and the N-terminal, prime side of the lid’s helix 3.  Mutation of YR in the non-prime 
subsite did not decrease the hinge flexibility and showed along with increased RMSF of the N-
terminal, prime side of helix 3, decreased RMSF of the C-terminal, non-prime side of helix 3 
(Figure 2.20 e).  Mutation of all the aforementioned residues in SEDSTE_YR led to a similar effect 
on the lid’s helix 3 with additional decreased flexibility of hinges 2 and 4 (Figure 2.20 d).  Even 
though the resulting S2’ mutant complexes’ ligand interaction energies were comparable, 
changes in the apo protein dynamics upon mutation might thus have affected the initial affinity 
for inhibitor binding. 
 
Directions of motion affecting N-domain distal hinge and lid regions 
Further insight into the directions of motion and the mechanism whereby these active site 
mutations affect the distal hinge and lid regions was gained by using a combination of different 
MD analyses. Firstly, the most distinct conformations were identified from all-frame RMSD 
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clustering heatmaps, aligned and coloured according to RMSF (blue to red = low to high RMSF).  
Secondly, the relationship between the mutated residues and lid and hinge flexibility was 
studied by identifying correlated protein backbone motions from covariance heatmaps.  
Diagonalization of the covariance matrices by PCA allowed inspection of the long range, low 
frequency motions conserved throughout the simulation.  In all structures the first five principal 
components accounted for 50-60% of the overall motion (scree plots not shown).  The first 
principal component, which describes the majority of this, was compared across these 
complexes with the magnitude and direction of the eigenvalues visualized through porcupine 
plots. 
 
From these analyses the wild-type apo structure’s breathing appeared to be mediated by the 
tandem motion of hinges 2 and 4 located parallel to each-other and between the two 
subdomains (Figure 2.20 f).  This is accompanied by alternate lid movement through lateral shift 
of the lid’s helices 2-3 over the cleft and outward tipping of the opposite end’s helices 4-6 by 
twisting at the Y76 beta turn.  SE mutation greatly decreased the hinge 2 and 4 flexibility and 
increased the separation between the subdomains in the prime subsite.  The isolated nature of 
the two C-domain residues introduced into the N-domain on helix 18 (subdomain 1) and helix 
22 (subdomain 2) likely resulted in instability of the adjacent hinge 3 loop between the 
subdomains, and thus its increased RMSF.  Mutation of all the prime subsite residues was found 
to affect cleft closure by not only decreasing the hinge 2 and 4 flexibility but also altering the 
direction and magnitude of lid motion.  Instead of a cleft-closing lateral shift, the mutant’s helix 
3 N-terminus was seen to roll over helix 2 and increase active site exposure.   
 
Although the YR mutant displayed hinging similar to wild-type, R381E and the resulting salt-
bridge formation to R90 of helix 5 fixed this end of the lid in a more inward position and 
enhanced the lateral shift of the opposite end at the N-terminus of helix 3 for active site cleft 
closure.   
 
Lastly, the combined SEDSTE_YR mutant displayed increased prime subsite subdomain 
separation, decreased hinging, fixing of the lid at helices 4-6, enhanced flexibility of the N-
terminus of helix 3 in a rolling motion and thus ultimately a more open state (Figure 2.20 g).  
Altogether, this suggests that the unbound C-domain might be more rigid/exposed and have a 
greater energy barrier to overcome for effective active site closure than the N-domain. 





Figure 2.20: Apo structure flexibility.  
Backbone atom root mean square fluctuation (RMSF) is given for a) SE (yellow), b) SEDT (green), c) SEDSTE 
(teal), d) SEDSTE_YR (magenta) and e) YR (navy) in relation to wild-type (orange).  f) and g) Clusters of 
conformations coloured according to RMSF (low = blue, high = red, α = helix) for the lid region and 
porcupine plots of correlated Cα motions from the first principal component for WT and SEDSTE_YR, 
respectively. Quills indicate the direction and magnitude of motion.  Hinges 2 and 4 are given in red and 







Chapter 2: Mechanism of N-selective inhibition 
62 
 
2.6.8 The effect of active site mutations on protein hinging upon 33RE binding 
Wild-type 33RE-bound structure 
The trend in backbone RMSF of the simulated wild-type 33RE-bound structure compared well 
to that calculated from experimental Cα B-factors of PDB ID: 4BXK using equation (1) (where Bi 
is the main chain B-factor of the ith residue).  The absolute values were, however, slightly lower 







=      (1) 
 
Comparing the wild-type apo and 33RE-bound forms, an increase in backbone lid flexibility was 
noted in the presence of 33RE (Figure 2.21).  In the bound form the S2’ unique S357 formed a 
strong, stable hydrogen bond with the unique E431 that is maintained throughout the 
simulation.  Residues S357 and E431 are located opposite each-other on helix 18 of subdomain 
1 and helix 22 of subdomain 2, respectively, thereby forming a stable contact point at the 
interface of the two subdomains (Figure 2.21 f). The unique E262 (on loop between helices 12 
and 13) was observed to hydrogen bond to the unique D354 backbone at the tip of helix 18 while 
the D354 sidechain formed a salt bridge to R350 on the adjacent loop.  R350, however, also 
interacted with D140 on helix 8.  This helix thus moved inwards towards R350 but was repelled 
by the negative charge from D354, E262 and E431, resulting in its high RMSF and opening/closing 
of the active site.  The interaction of E262 with helix 18 and the presence of a favourable 
subdomain interface resulted in the movement of helices 12, 13 and the connecting loop 
towards the active site.  The interaction network between E262, D354, R350, S357 and E431 
(Figure 2.21 f) thus facilitated the correlated cleft-closing long-range motions of helix 18 (Figure 
2.22 a) and fixed the loops of hinge 2 in more bent conformations (vs apo), likely contributing to 
the high RMSF and movement of helix 15 towards the active site opening.   
 
In the non-prime subsite R381 located on hinge 3 slightly transitioned into the active site but did 
not bind the tetrazole.  This was likely the result of R381 backbone (and hinge 3 loop) 
stabilization through hydrogen bonding to the H388 sidechain.  Although a tetrazole can interact 
with arginine it would be sterically hindered in the S2 and likely weaker due to the tetrazole size 
and less optimal bond angle (Tominey et al., 2006) (compared to the Asp carboxylic acid in 
RXP407 where R381 is positioned in the active site).  Movement of the R381 sidechain facing 
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out of the active site caused charge repulsion of the conserved R90 residue of the lid’s helix 5 
(Figure 2.21 f).  This resulted in an upward tipping motion of the C-terminus of helix 3 and helices 
4-6 about a pivot point formed by an R380-E29 salt bridge (E29 is located in the middle of the 
lid on helix 2).  This, in turn, resulted in the downward tipping of the opposite end of the lid at 
the N-terminus of helix 3 towards the prime subsite.  This see-saw motion of the lid in the bound 
as opposed to lateral shift of the unbound further enhanced the active site cleft closure.  
Covariance analysis showed a clear positive correlation between residues of helix 15-20 and the 
N-terminus of helix 3 (subdomain 1) (Figure 2.22 a).  These residues are negatively correlated to 
helices 4-6 (lid R90), helix 8 (D140, subdomain 2) and helices 12-13 (E262, subdomain 2).  The 
unique S2 and S2’ active site residues of the N-domain thus acted synergistically to bring about a 
concerted active site closing motion through hinges 1, 2, 3 and 4.   
 
Mutant 33RE-bound structure 
In contrast to the situation of the apo forms, in the presence of 33RE the flexibility of hinges 2 
and 4 were not affected by mutation.  There was, however, a distinct decrease in flexibility of 
the helices 12-13 and their connecting loop (Figure 2.21) since none of the prime mutants 
possessed the E262 interaction with helix 18 to facilitate the inward motion of this region.  The 
negative correlation with helix 18 was thus also lost.   
 
SE mutation 
The SE mutation decreased the flexibility of the lid at helices 3-5, beta sheets A and helix 8 but 
increased the flexibility of hinge 3.  Upon mutation, the hydrophobic repulsion between S357V 
and E431D increased the distance between helices 18 and 22, thereby decreasing the repulsion 
of D140 (helix 8) by D354 and E431D.  The lack of S357 binding and shorter chain length of D431 
allowed direct hydrogen bonding of D431 to E262.  Binding of the D354 backbone by E262 thus 
did not occur and likely contributed to the separation of helix 18 from subdomain 2.  The D140-
R350 and D354-R350 bonds are thus more stable with a decrease in helix 8 backbone RMSF 
(Figure 2.21 a). Yet, the lack of binding between the prime residues on helices 18 and 22 (S357-
E431 in WT) and the isolated nature of these mutations decreased the helix 18 stability, thereby 
increasing the flexibility of Y369 and the hinge 3 loop harbouring R381.  Since Y369 binds the 
aminomethyl tetrazole moiety in wild-type, this increased flexibility likely led to decreased 
tetrazole stability (Figure 2.18 d).  RMSF of R380 was also increased which decreased the lid’s 
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E29-R380 pivot point stability and along with the SE subdomain contact point mutation made 
the lid’s see-sawing motion less likely so that the structure is overall more exposed and static. 
 
SEDT mutation 
The SEDT mutation increased the lid flexibility at the N-terminal prime side of helix 3 but 
decreased the flexibility of beta sheets A and helix 8 (Figure 2.21 b).  This mutation still allowed 
lid see-sawing motion since the SE is still present to form an interface between the subdomains.  
The T358V mutation, however, appeared to repel the D354E residue sidechain since valine is 
hydrophobic and the polar glutamic acid longer.  E354 therefore changed direction and bound 
to K427 on helix 22 opposite, thus forming a strong salt bridge to helix 18.  E354 also hydrogen 
bonded to E431 and therefore the S357-E431 interaction was lost, but helix 18-22 subdomain 
contact maintained.  This caused a slight shift in the position of helix 18 and the altered E354 
orientation allowed formation of a stable R350-D140 bond.  This, and the lack of repulsion by 
acidic prime residues, decreased the RMSF and long-range motions of helix 8.  The lid motion at 
the N-terminus of helix 3 was increased over WT since the slight helix 18 shift created more 
space for the lid to swing in.  The hinge 3 RMSF was unaffected by SEDT and therefore the E29-
R380 pivot was stable and R381 repulsion of R90 facilitated lid tipping.   
 
SEDSTE mutation 
In the case of SEDSTE it was found, similar to SE, that flexibility was decreased at the lid helices 
3-5, beta sheets A, helix 8 and the loops between helices 12 and 13 – no effect was seen on 
hinge 3, however (Figure 2.21 c).  The mutation of T358V and S357V created a hydrophobic patch 
along with L356 and V359.  This resulted in the D354E sidechain changing orientation towards 
K427 and formation of a stable salt bridge.  Yet, the increased side-chain length of D354E and 
K427 precluded close interaction between helices 18 and 22.  The decreased side-chain length 
of E431D also prevented the E354-D431 binding as seen for SEDT.  The lack of D354E-R350 
interaction and decreased negative charge of the prime subsite increased the D140-R350 
interaction’s stability with a resulting decrease in helix 8 flexibility and long-range motion 
towards the active site opening.  The six prime mutations together therefore exposed the active 
site to the exterior environment by increasing the subdomain separation between helices 18 
and 22 in this subsite.   
 
 




In the nonprime subsite YR mutation decreased the flexibility of hinge 2, the loop between 
helices 12 and 13, the active site helix 18, the lid’s C-terminal non-prime side of helix 3, and the 
region spanning helices 4-9 (Figure 2.21 e).  Important to note is the decreased flexibility of the 
60-95 region, but unaffected 1-60 lid region, which is only found for the YR and SEDSTE_YR 33RE-
bound forms.  Mutation of Y369F with hydrophobic repulsion of the tetrazole led to its 
movement towards H388 and disruption of the H388 hydrogen bonding with the hinge 3 
backbone.  In YR the R381E thus electrostatically interacted with the adjacent R380.  Repulsion 
of R90 thus did not occur and it instead bound the R381E backbone, decreasing the helix 4-6 
RMSF.  This stabilization of the non-prime subsite along with the favourable prime subsite 
interface enhanced the active site closure. 
 
SEDSTE_YR mutation 
The R90 repulsion observed in the YR mutation did not occur in SEDSTE_YR where R381E was 
located in the active site (Figure 2.21 g).  The added prime subsite mutations in the presence of 
33RE, however, increased the hinge 3 flexibility likely synergistically through increased helix 18 
- 22 separation, R381E electrostatic repulsion by the unstable, electronegative tetrazole and 
hydrophobic repulsion by Y369F.  Although the lid’s helix 3 displayed wild-type RMSF (Figure 
2.21 d) and positive correlation to helix 18 (Figure 2.22 b), the direction of motion was changed 
so that it rolled outwards over helix 2 instead of tipping towards the active site cleft as in wild-
type and YR.  Altogether, the increased helix 18 - 22 separation, lack of helix 13 E262-D354 (Ca) 















Figure 2.21: Backbone atom root mean square fluctuation (RMSF) of the 33RE-bound structures.  
a) SE (yellow), b) SEDT (green), c) SEDSTE (teal), d) SEDSTE_YR (magenta) and e) YR (navy) in relation to 
wild-type (orange). The lid and prime subsite interactions for the clustered WT and SEDSTE_YR are shown 
in f) and g), respectively with low to high RMSF coloured from blue to red, protein carbon atoms in green 
and 33RE in yellow (α = helix). 
 
 




Figure 2.22: Correlated motions in 33RE-bound structures.  
Heatmaps indicate positive (red), negative (blue) and no correlation (white) between Cα motions. 
Directions of these motions are shown on the corresponding porcupine plots of the first principal 
component for a) WT and b) SEDSTE_YR. Helices 13, 18 and 22 are given in yellow, hinges 2 and 4 in red 
and the approximate location by the boxes. 
 
 
2.6.9 Assessment of active site contraction upon 33RE-mediated protein hinging 
To ascertain whether the mutations’ effect on hinging and lid motion indirectly affected ligand 
binding affinity by influencing the transition from open, apo forms to more closed, ligand-bound 
forms, the average structure of each apo was aligned to its corresponding average bound form.  
As an indication of how the overall protein compactness varied over time, the radius of gyration 
and the central active site cavity volume was determined for 10 average structures calculated 
over 1ns intervals for each 10ns MD simulation.   
 
The wild-type N-domain was highly dynamic prior to ligand binding with its central cavity volume 
ranging between 11500 Å3 and 18500 Å3 (Figure 2.23a).  Although the protein was still dynamic 
upon binding of 33RE, its radius and cavity volume was decreased with the poorly aligned active 
Chapter 2: Mechanism of N-selective inhibition 
68 
 
site helices 18, 13 and 22 suggesting aid of their movements in ligand binding, subdomain 
interaction, cleft closure and stabilization of the complex.   
 
Mutation of the S2’ residues located at the subdomain interface abrogated this stabilization of 
the closed conformation with the isolated prime mutation SE causing cavity expansion upon 
33RE binding and a less dynamic active site (narrower volume range) (Figure 2.23 b).  The SEDT 
mutant, though also less dynamic, still displayed decreased volume and radius upon binding 
(Figure 2.23 c) while the SEDSTE, similar to SE, did not contract and showed increased 
subdomain separation upon binding.  The active site contraction was thus likely a result of helix 
18 motion towards helix 22, inter-subdomain contact through S357 and E431, and lid tipping.  
Since YR still possessed N-domain prime residues and the R381E mutation stabilized helices 4-6 
towards the active site, its radius and volume was greatly decreased upon binding, despite 
33RE’s repulsion by F369 (Figure 2.23 f).  Additional mutation of the prime residues, however, 
abrogated this contraction and the radius as well as volume was notably increased upon 33RE 
binding (Figure 2.23 e).   
 
A similar active site closing motion was previously proposed for the ACE2 homolog where the 
open and closed crystal structure forms were poorly aligned in this prime subsite region (Towler 
et al., 2004).  Lack of subdomain interaction and thus increased active site exposure upon 
mutation has implications for ligand binding affinity since it also increased the 33RE solvent 















Figure 2.23: Volume analysis of 33RE-bound structures.  
Radius of gyration over the last 955 frames, central cavity volume calculated over 1 ns sections (each 
represented by a dot with the mean as a line) and alignments of each overall average bound structure to 
its respective apo form are shown for a) WT (orange), b) SE (yellow), c) SEDT (green), d) SEDSTE (teal), e) 
SEDSTE_YR (magenta) and f) YR (navy) 33RE-bound structures in relation to their respective apo forms 
(black line/grey structure). Unique residues from the bound average structures are shown as sticks. 
Volumes of bound vs apo were compared with statistical significance set at a 99% confidence level (*P < 
0.01; n.s.: not significant). 
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2.6.10 Differences in hinging between amide and carboxylate P2’ analogues 
Looking at the 33RE P2’ carboxylate analogue it was noted that the wild-type structure was 
actually expanded more than in the apo structure upon binding (radius of gyration not shown) 
and no decrease in active site volume was detected (Figure 2.24).  The interaction energy to 
K489 and H491 was thus similar to that of the amide with the expansion of the prime subsite 
through a shift in helix 18 likely leading to contraction of the non-prime at the adjoining hinge 3 
and strengthening of the H331 and H388 interactions (Figure 2.24 a).   
 
Upon mutation of SEDSTE the RMSF was decreased overall (data not shown), the interaction 
energy to K489 and H491 increased, the active site less exposed (despite repulsion between 
prime subsite residues) and the protein more compact (Figure 2.24 b).  This suggests that the 
negatively charged inhibitor P2’ carboxylate is less favoured for binding to the electronegative 
N-domain prime subsite than the more neutral C-domain counterpart.  The non-prime subsite 
was therefore not contracted and H331 binding was similar to 33RE.  Since the P2’ carboxylate 
interaction is strong and the prime subsite effectively closed, the additional mutation of YR with 
resulting Y369F-tetrazole repulsion did not affect inhibitor stability as for 33RE.  In this case the 
R90 binding by R381E and thus increased stability of helices 4-6 also increased the interaction 
energy to H331.   
 
Selective active site closure and inhibition of the N-domain over the C-domain thus not only 
depends on the unique prime and non-prime residues but also the inhibitor’s amide.  This 
supports the hypothesis that the C-domain requires a stronger P2’ moiety, such as a carboxylate, 
for active site closure to occur by binding the loop between helices 12 and 13 and overcoming 
the energy barrier caused by repulsion at the subdomain interface.  Although these simulations 
were done on 33RE which has the tetrazole in P2, the binding affinity trend is similar to that 
presented for the RXP407 P2’ carboxylate analogue in vitro by Dive et al (Dive et al., 1999) in that 
the P2’ carboxylate increased the binding affinity to both domains, thereby abolishing selectivity. 
 
 




Figure 2.24: Interaction energies and volume analysis of the 33RE P2’ carboxylate analogue-bound 
structures.  
Total interaction energies (green), Van der Waals components (grey) and electrostatic components (blue) 
were calculated over all frames and represented as mean ± standard deviation for a) WT, b) SEDSTE, and 
c) SEDSTE_YR. Central cavity volume calculated over 1 ns sections (each represented by a dot) and 
alignments of each overall average bound structure to its respective apo form are shown for WT (orange), 
SEDSTE (teal) and SEDSTE_YR (magenta) 33RE analogue-bound structures in relation to their respective 
apo forms (grey structure). Unique residues and the 33RE analogue pose from the bound average 
structures are shown as sticks. 
 
2.6.11 In vitro assessment of change in active site solvent exposure upon 33RE binding 
To evaluate the effect of mutation on protein stability and 33RE-mediated active site closure in 
vitro, differential scanning fluorimetry was performed and the protein melting temperatures 
(Tm) determined across a range of 33RE concentrations.  This technique utilizes a dye binding to 
the hydrophobic protein core to allow detection of fluorescence signal upon protein unfolding 
with increasing temperature.  The first derivative of the resulting signal was used to construct a 
melting curve with the Tm derived from the midpoint of the peak as described by Niesen et al 
(Niesen et al., 2007) (Figure 2.25 a). 
 




            
Figure 2.25: Differential scanning fluorimetry results of wild-type N-domain titrated with 33RE.  
a) Melting curve from one representative assay showing an average gaussian fit over three wells at each 
33RE concentration, obtained from the first derivative of the fluorescence signal; b) kinetics of thermal 
stabilization upon 33RE titration of 1 μM protein in triplicate wells.  Tm0 indicates protein melting 
temperature in the absence of 33RE; ΔTm values were calculated from the rightward peak shift from Tm0 
on the derivative curves.  Tmmax was defined as the melting temperature at the 33RE concentration beyond 
which no further stabilization was observed (plateau on b)).  RFU = relative fluorescence units. 
 
The determined N-domain apo protein melting temperature (Tm0) of 69.5±0.6°C (Figure 2.26) 
compared well with the circular dichroism values of 70.5°C (Voronov et al., 2002a) and 72°C 
(O'Neill et al., 2008) for bovine and human N-domain, respectively, thus illustrating the reliability 
of this method in studying ACE thermal denaturation.  Binding of a ligand to the protein active 
site is generally thought to increase the free energy of unfolding and thus the protein Tm (Niesen 
et al., 2007).  Binding of 33RE to N-domain was found to shift the Tm0 from 69.5±0.6°C by a 
maximum of 11.1±0.8°C, resulting in a Tmmax of 80.6±0.2°C (Figure 2.26).  The YR mutant Tm0 
(68.8±0.1°C) resembled that of wild-type whereas the SEDSTE and SEDSTE_YR mutants displayed 
slightly lower stability (Tm0 of 66.3±1.1°C and 67.5±0.7°C, respectively). In addition, all mutants 
had significantly lower Tmmax values versus wild-type (78.7±0.2°C, 75.5±0.6°C and 73.3±0.4°C for 
SEDSTE, YR and SEDSTE_YR, respectively, with P<0.01).  With the YR mutant this likely resulted 
from a loss in Y369 hydrogen bonding enthalpy.  The decreased thermal stabilization of SEDSTE, 
however, suggests a decrease in the ligand binding entropy since these residues do not form any 
direct contacts with 33RE. 
 
These differences in melting temperatures and thermal stabilization by 33RE highlight the 
importance of the S2’ subsite residues and supports the notion that the identified unique 
Increasing [33RE] a) b) 
Chapter 2: Mechanism of N-selective inhibition 
73 
 
residues indirectly and synergistically influence 33RE’s behaviour by affecting the protein’s 




Figure 2.26: ACE thermal stability as determined by differential scanning fluorimetry.  
Minimum (Tm0) and maximum (Tmmax) melting temperatures are given as mean ± SD of two independent 
experiments in triplicate wells in the absence (grey bars) and presence (coloured bars) of 33RE, 
respectively. Statistical significance of mutant vs wild-type Tmmax was set at a 99% confidence level (*P < 
0.01). † YR vs SEDSTE_YR, P = 0.052. 
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2.6.12 In vitro investigation into the structural effects of mutation 
X-ray crystallography was used to evaluate the effect of active site mutation on the 33RE 
interactions in vitro.  The SEDSTE_YR-33RE structure was solved by Prof K.R. Acharya and Dr G.E. 
Cozier (Department of Biology and Biochemistry, University of Bath).  A resolution of 1.8Å was 
obtained for the two protein molecules in the asymmetric unit of the P1 space group.  
Previously, wild-type N-domain-33RE also diffracted in the P1 space group with two protein 
molecules in the asymmetric unit but the structure was solved at a slightly lower resolution of 
2.2Å (Douglas et al., 2014). 
 
Crystallization trials were also done in the absence of 33RE to obtain the apo structure, 
potentially in an ‘open’ conformation.  Unfortunately, none of the screened conditions allowed 
crystallization of the latter and the apo structure was not determined.  This is potentially due to 
the decrease in Tm that firstly results from mutation of the N-domain active site residues 
(discussed in section 2.6.11) and secondly from removal of the seven PNGs (Anthony et al., 2010) 
in creating the minimally glycosylated active site mutant.  The SEDSTE_YR n389 protein is 
thereby probably too unstable to form stable crystal contacts.  In the presence of 33RE, 
however, sufficient SEDSTE_YR n389 stabilization for successful crystallization is likely obtained 
through a ligand-induced increase in Tm (discussed in section 2.6.11), despite the effects of active 
site or PNGs mutation.  In future, a technique such as electron microscopy might be more 
suitable to visualize the apo structure of a fully glycosylated protein. 
 
Overall, the wild-type N-domain and mutant SEDSTE_YR 33RE structures were very similar and 
the two chains aligned with a mere 0.45Å RMSD.  As with wild-type, the mutant structure 
showed Zn coordination via the 33RE phosphonate group, binding of the P2’ amide to Q259, 
K489 and Y498 (forming the oxyanion hole) and no interaction with the unique, mutated S2’ 
residues (Figure 2.27a).  The Y369F and R381E orientations in the crystal structure were 
consistent with the simulated structures.  In contrast to the MD results, however, mutation did 
not alter the orientation of 33RE and the tetrazole position was only slightly shifted (Figure 
2.27b).  In addition to 33RE, three ethylene glycol molecules from the crystallization solution 
also bound to the mutant’s S2 subsite near the 33RE tetrazole (Figure 2.27a).  These ethylene 
glycol molecules likely masked the effects of mutation in this crystal structure by binding to the 
tetrazole and stabilizing its interactions to conserved residues in the absence of Y369 hydrogen 
bonding. 






Figure 2.27: Crystal structure of the SEDSTE_YR mutant complexed to 33RE.  
a) Interactions between 33RE (green sticks), ethylene glycol molecules from the crystallization solution 
(yellow sticks) and the mutant active site (grey sticks and pink ribbon). b) Alignment between 33re 
complexed to the wild-type (PDB ID: 4BXK, orange lines) and mutant (green lines) N-domain.  The zinc-
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The simulated separation that occurred between helices 18 and 22 upon mutation of the S2’ 
inter-subdomain contact point was also not observed in the crystal structure.  This could be due 
to the nature of the contacts formed between molecules within an asymmetric unit or between 
neighbouring asymmetric units.  Within a unit cell, numerous interactions are observed between 
the two molecules’ subdomain 2 surface residues (Figure 2.28).  Additionally, interactions are 
observed between unit cells via hinges 2 and 4 (molecule A) of one asymmetric unit and the lid 
residues (molecule A) of another (Figure 2.28).  Although these contacts enable crystallization 
of the protein they may have masked important consequences of active site mutation by 






Figure 2.28: Interactions between SEDSTE_YR-33RE molecules within an asymmetric unit or between 
neighbouring asymmetric units.  
Interactions between two molecules within the same asymmetric unit (pink) are shown on the right and 
interactions between molecules of neighbouring asymmetric units are shown in the upper middle (dark 
purple and pink Molecule A structures).  Interacting residues are shown as black sticks, 33RE as green 
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Mutation does, however, seem to result in protein flexibility changes in vitro.  The alpha carbon 
(Cα) B-factors were compared between the two mutant or wild-type molecules present per 
asymmetric unit.  The Cα B-factors of the two molecules in the wild-type unit cell are very similar 
(Figure 2.29a).  In the mutant structure, however, the Cα B-factors of molecule A are increased 
over wild-type and that of molecule B is greatly increased over the mutant’s molecule A (Figure 
2.29b).  This suggests that the mutant is less stable than wild-type in this ‘closed’ conformation.  
Flexibility is particularly increased at the lid and hinges 2 and 4, so much so that a part of 
molecule B’s lid is missing (Figure 2.30).  Given that the two structures were solved in the same 
space group and formed the same contacts between molecules, this effect on the B-factors is 
unlikely to be a crystal-packing artefact.  The MD results showed that the two subdomains’ 
separation is increased upon mutation of the unique S2’ residues.  Since this separation is 
reduced to wild-type in the presence of crystal contacts, the mutated residues on helices 18 and 




Figure 2.29: B-factor comparison of the wild-type N-domain-33RE and mutant SEDSTE_YR-33RE crystal 
structures.  
Alpha carbon B-factors of molecule A and molecule B are respectively given in grey and in colour for a) 








     
 
   
Figure 2.30: Structural view of wild-type N-domain-33RE and mutant SEDSTE_YR-33RE flexibility.  
The two molecules in the asymmetric unit were aligned for a) wild-type N-domain-33re (PDB ID: 4BXK) 
and b) mutant SEDSTE_YR-33re and coloured according to flexibility (high to low Cα B-factors from red to 
blue).  The region of the lid that is missing from molecule B in the mutant structure is encircled.  The active 
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2.6.13 Conclusions and implications for future drug design 
This study provides a clearer understanding of the mechanism whereby 33RE selectively inhibits 
the N-domain of ACE.  Kinetic characterization of inhibitor binding highlighted the importance 
of the unique S2 residues in selectivity, in line with previous studies on RXP407.  Interestingly, 
the unique S2’ residues distal to the 33RE binding site were shown to be equally important, 
particularly S357 and E431.  A complete loss of selectivity was seen upon combined mutation of 
both prime and non-prime subsites.   
 
Although the 33RE co-crystal structure of the SEDSTE_YR mutant suggested that mutation 
altered protein dynamics, molecular dynamics simulations were required to elucidate the 
mechanism whereby these unique N-domain S2 and S2’ residues synergistically govern 33RE’s 
1000-fold N-selectivity.  Here we propose that the S2 residues at hinge 3 and the hydrogen 
bonding network between S2’ residues facilitate active site closure upon 33RE binding through 




Figure 2.31: Proposed mechanism of N-domain selective inhibition by 33RE.   
N- and C-domain are given in green and blue, respectively, with the lid as cylinders, the hinges in red and 
33RE as grey sticks. 
 
Chapter 2: Mechanism of N-selective inhibition 
80 
 
In accordance with the in silico results, differential scanning fluorimetry of fully glycosylated 
proteins showed a decrease in protein thermal stability and ligand thermal stabilization upon S2’ 
subsite mutation, suggesting altered protein dynamics and/or increased solvent exposure.  The 
1000-fold selectivity of 33RE is thus dependent on the P2 tetrazole and P2’ amide interactions 
and is proposed to be effected through fundamental inter-domain differences in the dynamics 
of ACE.   
 
Previous attempts at incorporating the RXP407 P2 and P2’ moieties onto other ACE inhibitor 
backbones, however, did not yield the same order of N-selectivity.  While incorporating a P2 
aspartic acid onto the slightly C-selective ketoACE inhibitor backbone increased N-domain 
selectivity, the P2’ amide did not and instead decreased inhibitor potency (Sharma et al., 2012).  
This does not disprove our hypothesis, however, since the ketoACE analogues differed from 
RXP407 in their N-terminal protecting group, zinc binding, P1’ and/or P2’ moieties.  Use of a bulky 
N-terminal t-Boc instead of an acetyl protecting group may have decreased the potency by 
disrupting S2 interactions.  Another factor that could have affected the potency and N-selectivity 
is lack of the small, hydrophobic L-pseudoalanine in the P1’, a key feature of RXP407 (Dive et al., 
1999).   
 
All ketoACE analogues also possessed a carbonyl zinc binding group which would yield a strong 
zinc-binding geminal diol upon nucleophilic attack by a water molecule (Watermeyer et al., 
2008).  The use of strong zinc binding groups generally tends to yield less selective 
metalloprotease inhibitors (Dive et al., 2004).  Weaker-binding phosphinic peptide inhibitors 
might rely more on other moieties for binding affinity so that more favourable interactions by 
these in the N-domain environment can bring about selective inhibition.  For the highly C-
domain selective RXPA380 inhibitor the phosphonate likely also allowed for selection based on 
the P2 and P2’ moieties.  In this case the P2 phenylalanyl was seen to interact through Van der 
Waals and pi stacking with the Phe391 residue (C-domain counterpart of Y369) on subdomain 2 
while the P2’ tryptophan carboxylate formed hydrogen bonds to the loop between helices 12-
13 and hydrophobic interactions to the unique V379 and V380 residues (C-domain counterparts 
of T358 and S357 (Corradi et al., 2006)).  RXPA380 thus bridged the active site cleft with its 
binding synergistically governed by the unique C-domain residues of the S2 and S2’ subsites 
(Kroger et al., 2009). 
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Considering the RXP407, 33RE and RXPA380 results it thus appears that the right balance 
between prime/nonprime and subdomain 1/subdomain 2 binding is needed to attain three 
orders of domain-selectivity.  We hypothesize that addition of an appropriate combination of 
subdomain 1/subdomain 2-binding moieties onto current non-selective ACE inhibitors to 
achieve this balance might yield N-selective compounds.  Furthermore, the insight gained into 
the intrinsic differences in N- and C-domain dynamics could be exploited during future design of 
fibrosis drugs.  It also offers opportunities for the design of allosteric inhibitors for targeting 
distal binding sites like the lid C-terminus as recently reported for the ACE homolog neurolysin 
(Hines et al., 2014).  Alternatively, modification of non-selective, bioavailable ACE inhibitors for 
improved interactions with the distal unique N-domain prime subsite residues through moieties 
unfavorable for C-domain closure might lead to the development of clinically relevant N-domain 






Evaluating N-selective catalytic inactivation 
 
3.1  Introduction 
3.1.1 Design of catalytic metallodrugs to target ACE 
In recent years, the design of catalytic metallodrugs has received increased attention due to 
their potential for irreversible target enzyme inactivation at sub-saturating dosages.  Design of 
such compounds, however, could be more challenging since the drug’s target-recognition and 
metal-binding domains should be carefully tailored to obtain selective target inactivation 
through the production of metal-bound ROS with high catalytic efficiency under physiological 
conditions (Yu and Cowan, 2017).  This can be achieved by coupling a moiety selective for the 
target of interest via a linker to a metal chelate, optimally oriented towards target residues with 
high reactivity to oxidation (Cowan, 2008).  Once the metallodrug is bound to the target, the 
metal’s effective concentration is increased and ROS production is catalytically efficient in the 
presence of physiological redox co-reactants such as ascorbate and H2O2. 
 
Following development of the antihypertensive catalytic metallodrug [KGHK-Cu]+ (Gokhale and 
Cowan, 2005; Gokhale and Cowan, 2006), the Cowan group designed a series of compounds 
specifically targeted to ACE by coupling metal chelates to the lysine sidechain of the clinically 
used ACE inhibitor lisinopril (Joyner et al., 2012).  The lysine sidechain was thus used as a linker 
between the target recognition (lisinopril) and metal binding domains (transition metal chelate).  
Chelates varying in size, charge, reduction potential and coordination unsaturation were 








                        
               lisinopril   M-EDTA-lisinopril   M-GGH-lisinopril 
                                                 
                                                M-DOTA-lisinopril        M-NTA-lisinopril 
Figure 3.1: Lisinopril-derived metal chelate complexes designed by Joyner et al (Joyner et al., 2012). 
M = Fe3+, Co2+, Ni2+ or Cu2+. 
 
The ability of these metallodrugs to catalyze irreversible inactivation of sACE was investigated 
by monitoring hydrolysis of a non-domain selective substrate.  The Cu-Gly-Gly-His-lisinopril 
(CuGGHLis) metallodrug (Figure 3.2) was the most efficient catalyst in the presence of ascorbate 
and H2O2 and caused inactivation presumably through side-chain oxidation of amino acids 
involved in substrate binding and hydrolysis.  A time-dependent decrease in activity was 
observed at a sub-stoichiometric concentration of CuGGHLis.  This suggests that following 
inactivation, the metallodrug dissociated from the target molecule and the reduced metal state 
was regenerated to allow multiple turnover reactions.  Importantly, this metallodrug did not 
produce diffuse radicals (Joyner et al., 2012) (which might cause off-target inactivation) but 
rather metal-bound ROS, presumably an active Cu3+=O2- oxone intermediate (Cowan, 2008).  This 
GGH tripeptide is part of the amino terminal copper and nickel binding (ATCUN) motifs which 
play important roles in the transport of Cu2+ and Ni2+ in biological systems (Harford and Sarkar, 
1997; Lau and Sarkar, 1971) and are known to stabilize the Cu3+/2+ redox couple (McDonald et 
al., 1997). 





                        
Figure 3.2: Chemical structures a) the parent compound lisinopril, b) the GGHLis metal chelate and c) 
the CuGGHLis metallodrug.   
The two axial faces accessible for binding to target molecule are given as red lines. 
 
 
3.1.2 Chemistry of the CuGGH peptide 
At a pH > 6.7 where the histidyl imidazole nitrogen is deprotonated, Cu2+ induces deprotonation 
of the glycyl-glycyl peptide nitrogens (Lau et al., 1974).  Subsequently, quadridentate 
coordination of Cu2+ with the deprotonated peptide nitrogens, N-terminal amine and histidyl 
nitrogen results in a square planar complex consisting of two 5-membered and one 6-membered 
ring (Figure 3.2) (Camerman et al., 1976).  Such motifs provide the strongest peptide binding site 
for metal ions capable of deprotonating peptide nitrogens and the most stable complex if a 
histidyl residue is present in the third position (Sigel and Martin, 1982; Gonzalez et al., 2018).  
Although Zn2+ might also promote deprotonation of the peptide nitrogens, it has been shown to 
form binuclear complexes with GGH and its lower Lewis acidity and preference for the 
tetrahedral geometry makes it less likely to support the square planar quadridentate form at a 
pH < 9 (Agarwal and Perrin, 1977; Gonzalez et al., 2018).  Ligand exchange of CuGGHLis with Zn2+ 
present in the active site of ACE is thus not expected to occur.  Indeed, the absence of ligand 
exchange has been demonstrated experimentally for CuGGHLis in the presence of a molar 
equivalent of Zn2+ (Hocharoen et al., 2013). 
 
To be suitable for physiological use, the metallodrug needs to bind very tightly to the metal and 
the resulting complex must be stable to avoid loss of the active metallodrug and generation of 
off-target effects through depletion of essential metal ions by the free chelate.  Metallodrugs 
incorporating ATCUN peptides are unlikely to cause toxicity or side-effects since ATCUN motifs 
a) b) c) 




are naturally present in biological systems at the N-terminus of serum albumins (Harford and 
Sarkar, 1997).  Furthermore, GGH binds Cu2+ with a very high affinity (KD = 1.18 x 10-16 M for Cu2+) 
(Lau et al., 1974).  Upon administration, CuGGHLis would thus be resistant to Cu2+ extraction by 
other metal-sequestering agents and catalytic efficiency would be maintained. 
 
3.1.3 Domain-selectivity of lisinopril metal chelates 
Interestingly, by monitoring sACE activity in the presence of metallodrug and redox co-reactants 
with domain-selective substrates, Hocharoen et al found that CuGGHLis selectively catalysed 
irreversible inactivation of the N-domain although it reversibly inhibited both domains 
(Hocharoen et al., 2013).  It was proposed that the CuGGH moiety might be more optimally 
orientated in the N-domain than C-domain towards sidechain oxidation of critical amino acid 
residues but the exact mechanism of inactivation was not elucidated since the commercial sACE 
enzyme’s concentration was too low for mass spectrometry experiments.   
 
The recombinant human sACE used in their study was originally obtained from an NS0-derived 
murine myeloma cell line (R&D systems) (Hocharoen et al., 2013).  No decrease in sACE activity 
was reported in the presence of redox co-reactants but absence of CuGGHLis.  Previously, 
however, Chen et al observed that sACE expressed in cultured endothelial cells was completely 
inactivated within 4 hours by diffuse radicals generated by phorbol 12-myristate 13-acetate 
(PMA)-activated neutrophils (Chen et al., 1992; Chen and Catravas, 1993).  Oxidative inactivation 
of purified sACE was also described by Voronov et al and Michel et al and the C-domain was 
shown to be more susceptible than the N-domain to diffuse radicals (Voronov et al., 2002b; 
Voronov et al., 2003; Michel et al., 2001).  Since protein glycosylation varies greatly between 
host cell systems and susceptibility to oxidation by diffuse radicals is dependent on protein 
solvent accessibility, the disparities might have resulted from use of NS0-cell derived sACE (Li et 
al., 2017; Goh and Ng, 2017).  NS0 cell-expressed immunoglobulin G (IgG) has been shown to 
have a higher abundance of sialylated and high-mannose glycans than IgG found in human 
plasma while that expressed in CHO-K1 cells was more comparable to human (Goh and Ng, 
2017). 
 
Although the use of domain-selective ACE substrates allowed screening of the metallodrug 
series and identification of the most promising domain-selective inactivator, the absolute 
binding affinity and inactivation rate may have been influenced by two factors.  Firstly, the 




domain-selective ACE substrates Abz-LFK(Dnp)-OH and Abz-SDK(Dnp)P-OH used only display 
moderate domain-selectivities of approximately 75-fold C- and 50-fold N-selectivity, 
respectively (Rousseau et al., 1995; Bersanetti et al., 2004).  Furthermore, this results from 
differences in the rate of catalysis of each substrate by the two domains and not a difference in 
their binding affinity.  Since Abz-SDK(Dnp)P-OH binds equally to both domains but its catalysis is 
only 50-fold slower by the C-domain, complete inhibition would only be observed once 
CuGGHLis (in the absence of redox co-reactants), for example, has out-competed the substrate 
from both the N- and C-domain.  The individual domains’ inhibitor binding affinities might thus 
be underestimated when evaluating full-length sACE activity with these substrates.  Secondly, 
these underestimated inhibitor binding affinities might have caused an overestimation of the 
initial rate of time-dependent oxidative inactivation.  The inactivation experiments were 
performed in the presence of redox co-reactants and metallodrug at its IC20 (thus IC50 x 2/5) 
(Hocharoen et al., 2013).  CuGGHLis, for example, was present at 600nM or 60nM when 
monitoring N- or C-domain activity, respectively.  The observed initial rate of inactivation 
depends on the inhibitor and enzyme concentrations and thus cannot be directly compared 
between the two domains.   Since the second order rate constants which would account for 
these differences were not reported, the selectivity of CuGGHLis-mediated catalytic inactivation 
is uncertain at present.  Moreover, it is not clear whether the observed rapid decrease in Abz-
SDK(Dnp)P-OH activity is due to a combination of discreet N-domain oxidation and extensive C-
domain oxidation since the latter is completely saturated (based on Ki determined using Abz-













3.2  Aims and objectives 
The research described in this chapter aimed to critically evaluate the binding affinity and 
catalytic efficiency of CuGGHLis towards reversible inhibition and irreversible catalytic 
inactivation of the two ACE domains and to gain insight into the mechanism whereby this occurs.  
 
The objectives to achieve this aim were as follows: 
 
1. Characterize the affinity of lisinopril, GGHLis and CuGGHLis binding to N- and C-domain by: 
a. Obtaining truncated forms of the N- and C-domain proteins by affinity 
purification following transfection and heterologous protein expression in a 
CHO-K1 mammalian cell system 
 
b. Evaluating inhibitor binding affinity to each domain in isolation using a non-
domain selective fluorogenic substrate 
 
2. Evaluate the domain-selectivity of CuGGHLis-mediated oxidative inactivation by:  
a. Monitoring the decrease in N- or C-domain activity over time in the presence of 
metallodrug and redox co-reactants using a non-domain selective fluorogenic 
substrate and determining the initial rates and second order rate constants for 
inactivation 
 
3. Gain insight into the mechanism whereby oxidative inactivation occurs by:  
a. Characterizing the residual activity after inactivation by determining Michaelis-
Menten kinetic parameters for hydrolysis of a non-domain selective fluorogenic 
substrate 
 
b. Using SDS-PAGE to determine whether inactivation is as a result of amino acid 










3.3  Methodology  
Deionized MilliQ® distilled water with a resistivity of 18.2 MΩ.cm (at 25°C) was used in the 
preparation of all solutions throughout this chapter (except tissue culture media and buffers).  
Buffers (containing no detergent) were filter-sterilized, stored at 4°C and warmed to ambient 
temperature prior to use.   
 
3.3.1 Preparation of metallodrug 
3.3.1.1 Preparation of a CuCl2 solution 
To obtain a copper solution of known concentration for Gly-Gly-His-Lisinopril (GGHLis) titration, 
volumetric standardization was employed.  Copper chloride dihydrate (FlukaTM) was dissolved in 
deionized water before dropwise dilution with a titration buffer (20mM HEPES pH 7.5 and 
100mM NaCl) to a final concentration of 3mM CuCl2 while mixing.  The Cu2+ concentration of this 
solution was verified by titration into a solution of 4mM EDTA (Merck) prepared in the 
aforementioned titration buffer.  This was performed in the absence of zinc to prevent 
formation of a ZnEDTA complex. 
 
3.3.1.2 Titration of EDTA with Cu 
Titration buffer to a volume of 450µl was added to a quartz cuvette and the absorbance zeroed 
over a 190 - 800nm wavelength range using a Cary Varian 50 Conc UV-Vis spectrophotometer.  
Fifty microliters of the prepared 4mM EDTA was added to the cuvette while stirring and the 
absorbance read to establish a baseline.  While constantly stirring, copper was titrated into the 
EDTA solution in 10µl volume intervals and the absorbance read after a 15-minute room 
temperature incubation at each interval.  Formation of the CuEDTA complex was monitored as 
an increase in absorbance at a wavelength of 270nm with extinction coefficient of 3300M-1 cm-
1 as described by Dr J.C. Joyner (Joyner, 2012).  Copper addition proceeded until no further 
increase was observed at this wavelength.  The data was fitted to a segmental linear regression 
model using GraphPad Prism® v6.01.  The prepared stock solution’s Cu2+ concentration was 
subsequently determined from the molar equivalent of copper to EDTA at the inflection point 
on the curve.  
 
 




3.3.1.3 Titration of GGHLis with Cu 
Lyophilized GGHLis was a kind gift from Prof J.A. Cowan at Ohio State University.  It was dissolved 
in deionized distilled water to a stock concentration of 7.4mM and stored at -20°C.   
 
The CuGGHLis metallodrug was prepared by titration with the EDTA-standardized CuCl2 solution.  
This was performed in the absence of zinc to prevent formation of a ZnGGHLis complex.  
Titration buffer (20mM HEPES pH 7.5 and 100mM NaCl) to a volume of 450µl was added to a 
quartz cuvette and the absorbance zeroed over a 190 - 800nm wavelength range using a Cary 
Varian 50 Conc UV-Vis spectrophotometer.  Following equivolume dilution of the GGHLis 
chelator into the titration buffer, 50µl GGHLis was added to the cuvette while stirring.  The 
GGHLis concentration was confirmed by an absorbance peak at 257nm with extinction 
coefficient of 197M-1cm-1 due to presence of the lisinopril phenylalanine moiety. 
 
While constantly stirring, copper was titrated into the GGHLis solution in 10µl volume intervals 
and the absorbance read after a 15-minute room temperature incubation at each interval.  
Formation of the CuGGHLis complex was monitored as a shift in the 257nm peak and an increase 
in absorbance at a wavelength of 250nm with extinction coefficient of 4180 M-1 cm-1 as described 
by Dr J.C. Joyner (Joyner, 2012).  Detection of the d-d transition at 525nm (Lau et al., 1974) was 
less pronounced and thus not used for complex quantification.  Copper addition proceeded until 
no further increase was observed at 250nm.  Absorbance data was fitted to a segmental linear 
regression model using GraphPad Prism® v6.01 and the titration end-point determined from the 
inflection point. 
 
Two additional copper titrations were performed for GGHLis.  The second titration was 
performed up until the established endpoint to obtain a 1:1 molar ratio of metal to chelator.  
The metallodrug was aliquoted in 20μl volumes, stored at -20°C and used to characterize 
inhibitor binding.  The third titration was halted prior to the endpoint at a 1:1.1 metal to chelator 
molar ratio.  The metallodrug was aliquoted in 20μl volumes, stored at -20°C and used to 
characterize catalytic inactivation.  The slight excess of chelate ensured that no free copper ions 
were present and that only metallodrug-bound reactive oxygen species would be produced.  The 
lack of free copper ions with these two titrations was further confirmed by the absence of 
absorbance at 750 – 800nm. 




3.3.2 Protein expression and purification 
Chinese Hamster Ovary cells (CHO-K1) previously stably transfected with fully glycosylated N- or 
C-domain (Kroger et al., 2009) were reconstituted into growth medium.  They were grown to 
confluency in T-175cm2 flasks (Nunc Ltd.) before replacing the growth medium with harvesting 
medium (constituents in Appendix A6).  Culture medium was harvested every 48 hours and the 
pooled harvests stored at -20°C until protein purification.  Protein purification was performed 
as described in Chapter 2 with the exception that the dialysis solutions were prepared using 
deionized distilled water.  The dialyzed and concentrated proteins were stored at -20°C in 20µl 
aliquots to minimize freeze-thawing and possible protein oxidation or degradation during 
storage.  ACE activity was assessed during protein expression and purification using the non-
domain selective fluorogenic substrate Z-phenylalanylhistidylleucine (Z-FHL) (Sigma-Aldrich® 
Co.) as described in Chapter 2. 
  
3.3.3 Optimization of fluorogenic ACE assay 
Coordination of Cu2+ to the GGHLis chelator and formation of the square planar complex involves 
deprotonation of the backbone amides and histidine ionization (Camerman et al., 1976) (Figure 
3.2). A pH greater than 6.5 therefore should be maintained to prevent dissociation of the copper 
ion.  A time-dependent decrease in sACE activity upon incubation at 37°C was described by 
Hocharoen et al (Hocharoen et al., 2013).  This was circumvented by addition of the Brij-35 
detergent at a concentration of 0.05%.   
 
3.3.3.1 Optimization of detergent concentration 
The optimal Brij-35 concentration required for stability of the truncated N- and C-domain 
proteins was determined by incubation of the proteins at 4°C or 37°C across a range of detergent 
concentrations.  A 1% (w/v) Brij-35 (Merck) solution was prepared in deionized distilled water 
and stored at room temperature.  Dilutions of Brij-35 into an assay buffer consisting of 50mM 
HEPES pH 8.2, 300mM NaCl and 10µM ZnCl2 were freshly prepared from this stock solution each 
day. 
 
The non-selective ACE substrate Hippuryl-His-Leu (HHL) was prepared by dissolving 24.5mg HHL 
(Sigma-Aldrich® Co.) in 2.083ml NaOH (0.025M) with heating to 40°C and vortexing according to 
the protocol described by Schwager et al (Schwager et al., 2006).  Assay buffer consisting of 




50mM HEPES pH 8.2, 300mM NaCl and 10μM ZnCl2 was added dropwise to yield a 5.7mM stock 
solution.  Solutions of 2mM HHL, 7nM N-domain and 2nM C-domain were subsequently 
prepared in assay buffer containing Brij-35 ranging from 0.0004% to 0.5%.  The enzymes were 
incubated at 4°C or 37°C for four hours after which 20µl was aliquoted in triplicate wells of a 96-
well plate.  Twenty microliters of 2mM HHL was added to each well and the plate incubated at 
37°C for 15 minutes for substrate hydrolysis to occur.  This was followed by termination of the 
reaction with 177µl 0.28M NaOH and addition of 16µl O-phthaldialdehyde (20mg/ml (Sigma- 
Aldrich® Co.)) in methanol.  Incubation for 10 minutes at room temperature with shaking allowed 
derivatization of the HL sequestered by Z-FHL hydrolysis.  The reaction was stopped by addition 
of 30µl HCl (3M) and the fluorescence intensity detected at excitation and emission wavelengths 
of 360nm and 485nm, respectively, using a fluorescence spectrophotometer (Cary Eclipse Varian 
Inc.).  The assay protocol followed was analogous to that described by Schwager et al (Schwager 
et al., 2006).  Fluorescence intensity was plotted against detergent concentration and the Brij-
35 concentration yielding optimal stabilization determined.  Stability at this concentration was 
confirmed by incubating the enzymes (in assay buffer containing 0.0015% Brij-35) at 22°C or 
37°C for 100 minutes and assaying their activity at 20-minute intervals. 
 
3.3.4 Characterization of substrate hydrolysis: 
3.3.4.1 Construction of a standard curve 
A standard curve was constructed using His-Leu (HL) standards (Sigma-Aldrich® Co.) prepared in 
assay buffer (50mM HEPES pH 8.2, 300mM NaCl, 10µM ZnCl2 and 0.0015% Brij-35) to relate 
fluorescence intensity to moles of HL, and thus enzyme activity (Appendix A14).   
 
3.3.4.2 Kinetic characterization of HHL hydrolysis 
The amount of active protein was determined by calculating the specific activity from Z-FHL 
(Schwager et al., 2006) and Bradford (Bradford, 1976) assays as described in Chapter 2.   
 
Binding and hydrolysis of the non-domain selective HHL substrate was determined in an assay 
buffer consisting of 50mM HEPES pH 8.2, 300mM NaCl, 10µM ZnCl2 and 0.0015% Brij-35. Purified 
N- or C-domain was diluted in this assay buffer to 15nM or 4nM, respectively.  An HHL dilution 
series ranging from 0.04mM to 2.85mM was also prepared in assay buffer.  Enzyme and 
substrate were pre-warmed to 37°C for 5 minutes before 5µl enzyme and 28µl substrate was 




aliquoted to triplicate wells of a 96-well plate.  The plate was incubated for 15 minutes at 37°C 
on an orbital shaker to allow substrate hydrolysis and the rest of the procedure described in 
section 3.3.3.1 followed. 
 
The resulting velocity data was fitted to a non-linear Michaelis-Menten model using GraphPad 
Prism® v6.01.  The parameters describing HHL binding affinity (Km), turnover (kcat) and catalytic 
efficiency (kcat/Km) were subsequently determined for each domain from duplicate independent 
assays. 
 
3.3.5 Kinetic characterization of inhibitor binding affinity 
A 10mM stock solution of lisinopril (Sigma-Aldrich® Co.) was prepared in deionized distilled 
water, aliquoted and stored in the dark at room temperature.  Preparation of GGHLis and 
CuGGHLis was described in section 3.3.1.3.  A dilution series of each inhibitor was prepared in 
assay buffer consisting of 50mM HEPES pH 8.2, 300mM NaCl, 10µM ZnCl2 and 0.0015% Brij-35.  
The CuGGHLis used in this section was prepared at a 1:1 molar ratio of metal to chelator.  
Solutions of 15nM N-domain, 4nM C-domain and 2mM HHL were also prepared in assay buffer.  
Forty microliters of enzyme was incubated with 40µl of inhibitor at each concentration for 20 
minutes at 22°C and the substrate pre-warmed to 37°C.  Twenty microliters of the enzyme-
inhibitor mixture was aliquoted in triplicate wells of a 96-well plate before addition of 20µl HHL 
(2mM) to each well.  The plate was incubated for 15 minutes at 37°C on an orbital shaker to 
allow substrate hydrolysis and the rest of the procedure described in section 3.3.3.1 followed.   
 
Activity at each inhibitor concentration was calculated as a percentage relative to the 
uninhibited control and fitted to a sigmoidal dose-response curve using GraphPad Prism® v6.01.  
The inhibitor concentration at which 50% enzyme inhibition occurred (IC50) was determined and 
the inhibitor binding affinity (Ki) calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 
1973) (equation 2) where [S] = [HHL] = 1mM (final concentration) and Km determined for each 
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An alternative method of determining Ki values is via Dixon plots (as described in Chapter 2).  For 
CuGGHLis, however, not only the Ki but also the IC50 values were required for downstream 
experiments.  The Cheng-Prusoff equation allowed determination of both parameters from a 
single data set. 
 
3.3.6 Determination of the mode of inhibition 
To investigate whether CuGGHLis competed with substrate for binding to the active sites of the 
truncated single-domain proteins, inhibition was assessed using the Dixon method (Dixon, 
1953).  This involved measurement of enzyme activity at constant enzyme but two different 
substrate concentrations and a range of inhibitor concentrations.  The procedure described in 
section 3.3.5 was followed.  Duplicate samples were incubated with CuGGHLis (at a 1:1 molar 
ratio of metal to chelator) and each set assayed with either 20µl of 2mM HHL or 20µl of 1mM 
HHL per well.  The inverse fluorescence was plotted as a function of inhibitor concentration at 
two different substrate concentrations to yield a Dixon plot of which the shape revealed the 
mode of inhibition. 
 
3.3.7 Time-dependent oxidative inactivation 
3.3.7.1 Preparation of redox co-reactants 
The redox co-reactants ascorbate and H2O2 were made fresh each day immediately prior to use 
and kept on ice and in the dark.  The stock solution of stabilized H2O2 (30%) (Sigma-Aldrich® Co.) 
(stored at 4 degrees) was diluted to 40mM in an assay buffer consisting of 50mM HEPES pH 8.2, 
300mM NaCl, 10µM ZnCl2 and 0.0015% Brij-35.  One gram of L-ascorbic acid (Sigma-Aldrich® Co.) 
was dissolved in assay buffer to a concentration of 100mM and the pH adjusted to 8.2 using 
NaOH pellets.  The pH meter was calibrated each day using commercial standards (standard 
solutions of pH 4.00 and pH 10.00 Sigma-Aldrich® Co.).  Further dilution of ascorbate into assay 
buffer yielded a 40mM solution.  A solution containing both co-reactants at 40mM was also 
prepared. 
 
3.3.7.2 Time-course inactivation procedure  
Solutions of 15nM N-domain, 4nM C-domain and 2mM HHL were freshly prepared in assay 
buffer and the enzyme kept on ice.  The CuGGHLis metallodrug prepared at a 1:1.1 molar ratio 




of metal to chelator was used in this section.  It was diluted in assay buffer to a concentration of 
2xIC20 for each domain.  The IC20 values were calculated from the IC50 values obtained for N- and 
C-domain in section 3.3.5 as IC20 = IC50*2/5.  One thousand six hundred microliters enzyme and 
1600µl metallodrug or buffer were incubated for 20 minutes at 22°C in the absence of redox co-
reactants.  Prior to oxidative inactivation, each sample containing CuGGHLis retained 80% 
activity.  Two microliter aliquots of buffer, ascorbate, H2O2 or both co-reactants (each at 0.04M) 
were aliquoted to separate PCR tubes for a range of time-points for each sample and kept on 
ice.  Eighty microliters of the enzyme-inhibitor or enzyme-buffer reactions were aliquoted to 
each tube and incubated for 8 hours at 22°C to allow oxidative inactivation.  The final co-reactant 
concentrations were 1mM.  The use of PCR tubes ensured that no sample loss occurred due to 
evaporation over this prolonged time-period.  Timing of the inactivation reaction commenced 
upon first contact of the enzyme with co-reactant.  Samples were immediately assayed for 
activity at each timepoint using 2mM HHL as described in section 3.3.5.  Activity at each time-
point was expressed as a percentage relative to the control sample (enzyme containing no co-
reactant or metallodrug) as a function of time.  The data was fitted to a non-linear exponential 
decay model using GraphPad Prism® v6.01. 
 
3.3.7.3 Kinetic characterization of residual activity 
To gain insight into the mechanism of catalytic inactivation, the activity remaining was kinetically 
characterized.  The 100-minute inactivation timepoint was chosen to allow a degree of 
inactivation but still retain enough residual activity for detection with an HHL assay.  An HHL 
dilution series ranging from 0.04mM to 2.85mM was prepared in assay buffer.  Solutions of 
44nM N-domain or 19nM C-domain (prepared in assay buffer) were incubated for 20 minutes 
at 22°C with equivolume amounts of buffer or CuGGHLis at IC20.  These reactions were aliquoted 
to tubes containing buffer or co-reactants (at 40mM) and incubated for 100 minutes at 22°C to 
allow protein oxidation.  The final co-reactant concentrations were 1mM. The samples were put 
on ice and 5µl aliquots of each sample added to triplicate wells of a 96-well plate.  Twenty-eight 
microliters of HHL was added to each sample and the activity assayed across the range of 
substrate concentrations.  The data was fitted to the non-linear Michaelis-Menten model using 
GraphPad Prism® v6.01 for determination of the Km and kcat parameters. 
 




3.3.7.4 Assessment of artificial protease activity of CuGGHLis 
To determine whether any observed time-dependent decrease in activity was due to CuGGHLis-
mediated oxidative protein cleavage, the samples were analysed by SDS-PAGE.  A master 
dilution of 1.28µM N- or C-domain and CuGGHLis solutions of 2xIC20 were prepared in assay 
buffer and enzyme incubated with buffer/metallodrug for 20 minutes at 22°C.  The enzyme-
metallodrug or enzyme-buffer reactions were aliquoted to tubes containing buffer or co-
reactants (to a final concentration of 1mM) and incubated for 7 hours at 22°C to allow protein 
oxidation.  A 15mM stock solution of EDTA was prepared in 50mM HEPES pH 8.0.  The 
inactivation reactions were quenched at the 7-hour timepoint by the addition of EDTA to a final 
concentration of 1.5mM.  The samples were reduced, denatured and resolved using a 10% 
polyacrylamide gel with Colloidal Blue-Silver Coomassie staining (Appendix A15) to detect 
oxidative cleavage fragments.  A control sample which was not incubated for 7 hours and 
contained no co-reactants or metallodrug was included as a control.  Each sample contained 
500ng of protein. 
 




3.4   Results and discussion 
3.4.1 Standardization of a CuCl2 solution 
To obtain a copper solution of known concentration for titration of Gly-Gly-His-Lisinopril 
(GGHLis), volumetric standardization was employed.  An EDTA solution of known concentration 
was titrated with CuCl2 and formation of the CuEDTA complex spectrophotometrically 
monitored (Appendix A13 Figures A6 and A7). 
 
3.4.2 Preparation of the CuGGHLis metallodrug 
The CuGGHLis metallodrug was prepared by titration with the EDTA-standardized CuCl2 solution.  
The CuGGHLis titration end-point was determined (Appendix A13 Figures A8 and A9) before 
preparing the metallodrug to a 1:1 molar ratio of metal to chelate for binding affinity 
characterization (Appendix A13 Figure A10).  The third titration of GGHLis was halted prior to 
the endpoint at a 1:1.1 molar ratio of metal to chelate.  This ensured that no free copper ions 
would be present during the oxidative inactivation experiments.   
 
3.4.3 Protein purification  
The truncated N- and C-domain constructs were stably transfected into CHO-K1 cells and the 
proteins purified using affinity chromatography.  Two rounds of dialysis were performed in 
buffer prepared using deionized distilled water to ensure that no metal ions were present.  SDS-
PAGE and Coomassie staining revealed bands of ~90kDa for N-domain and ~70kDa for C-domain 
(Figure 3.7).  The difference in molecular weight between the domains is indicative of the greater 
extent of N-domain glycosylation (nine N-domain compared to six C-domain PNGs as described 













Figure 3.7: Coomassie-stained SDS-PAGE gel (10%) indicating protein size and purity.  
Lane 1: protein ladder (kDa), lane 2: N-domain and lane 3: C-domain. 
 
3.4.4 Optimization of a fluorogenic ACE assay 
The assay buffer used for the Z-FHL assay described in Chapter 2 consisted of 100mM K2HPO4 
/KH2PO4 pH 8.3, 300mM NaCl and 10µM ZnCl2.  Copper chloride used in preparation of the 
CuGGHLis metallodrug, however, precipitated in this buffer.  The titrations were therefore 
performed in a HEPES buffer.  To maintain consistency in the buffers used in this Chapter, the 
ACE activity assay was optimized for a HEPES buffer system.  The HEPES assay buffer used by 
Hocharoen et al consisted of 50mM HEPES pH 7.4, 300mM ZnCl2 and 10µM ZnCl2 (Hocharoen et 
al., 2013).  These conditions, however, resulted in instantaneous precipitation of the Z-FHL as 
well as HHL substrate.  Precipitation of the HHL substrate was prevented by increasing the pH 
to 8.2.  Since the Z-FHL substrate precipitated out at this pH after approximately one hour at 
room temperature, all enzyme assays from this point onwards were performed using the HHL 
substrate. 
 
It was previously described that sACE undergoes a time-dependent decrease in activity upon 
incubation at 37°C (Hocharoen et al., 2013).  This would pose a problem for the assessment of 
CuGGHLis-mediated catalytic inactivation over extended time-periods.  For sACE, this was 
circumvented by the addition of 0.05% Brij-35 detergent.  To confirm the truncated domains’ 
stability at 37°C, the proteins were incubated in an assay buffer containing 0.05% Brij-35 and 
their HHL activity assessed at 15- to 25-minute intervals.  Although the N-domain activity was 
largely unaffected even after two hours, the C-domain was not sufficiently stabilized by 0.05% 
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Figure 3.8: Enzyme stability at 37oC in the absence of inhibitor and co-reactants.   
N-domain and C-domain are indicated in green and blue, respectively, as % remaining activity relative to 
time zero in a buffer containing 0.05% Brij-35 using the HHL substrate. 
 
An in-depth investigation into the mechanism whereby Brij-35 stabilizes sACE has not been 
reported.  Each molecule of this non-ionic surfactant consists of a hydrophobic lauryl alcohol 
moiety and a hydrophilic moiety consisting of 23 units of ethylene oxide.  It is generally thought 
that protein aggregation is prevented and a protein’s hydrophobic sites protected from 
unfavorable interactions with water molecules by the lauryl alcohol moiety’s interaction with 
these sites, while the polyethylene oxide can increase its solubility (Otzen, 2011).   
 
A concentration of 0.05% Brij-35 is also generally recommended to maintain matrix 
metalloproteinase (MMP) activity.  Park et al, however, demonstrated that MMP-26 activity was 
dependent on the concentration of Brij-35 used (Park et al., 2010).  MMP-26 activation was 
observed at Brij-35 concentrations below the critical micelle concentration (CMC) whereas 
higher concentrations, such as 0.05%, counterintuitively resulted in non-competitive inhibition.  
The CMC is a property of each surfactant describing the point below which no micelles exist and 
above which all additional detergent molecules will form a micelle (Helenius et al., 1979). 
 
To evaluate whether the truncated domains of ACE display a similar concentration-dependence 
for Brij-35 stabilization, substrate and enzyme dilutions were prepared in assay buffer of varying 
Brij-35 detergent concentrations.  Duplicate enzyme samples across the dilution series were 
incubated for 4 hours at either 37oC or 4oC and assayed for HHL hydrolysis.  Activity of both 
domains was barely detectable after 4 hours at either temperature in the absence of detergent 
(Figure 3.9).  The N-domain was stable at both temperatures and showed maximum stabilization 
at 0.0015% Brij-35 which was equal to that observed at 0.05% Brij-35.  The maximum C-domain 




stabilization was also achieved at 0.0015% Brij-35 but the activity at 37oC, however, was 
approximately halved (vs. 4oC).  This emphasizes the inferior thermal stability of the C-domain 
which was described in Chapter 1 section 1.3.3.  Contrary to the N-domain, Brij-35 
concentrations greater than 0.0015% led to a decrease in C-domain activity.  The observed time-
dependent decrease in C-domain activity in the presence of 0.05% Brij-35 (Figure 3.8) likely 
occurred since it only provides a fraction of the maximum stabilization. 
 
The mechanisms whereby Brij-35 stabilizes the N-domain, C-domain and sACE thus appear to be 
distinct.  The optimal concentration of 0.0015% Brij-35 is below its reported CMC of 0.01% 
(Linke, 2009; Hait and Moulik, 2001).  It is therefore proposed that the truncated domains of 
ACE are protected against thermal denaturation and aggregation by binding of the monomer 
surfactant molecules’ lauryl alcohol moieties to their hydrophobic sites.  Based on the 
biophysical results obtained in Chapter 2, it was proposed that the C-domain active site cleft is 
more exposed to solvent.  It also has a lower N-glycan content than the N-domain (Chapter 1 
section 1.3.1).  Upon Brij-35 addition past the CMC, the large micelle structures likely interact 
with the more accessible C-domain but not the N-domain and decrease the stabilizing effect 















Figure 3.9: Enzyme stability after 4h incubation across a range of Brij-35 detergent concentrations.   
a) N-domain and b) C-domain were incubated at 4oC (grey) or 37oC (green and blue, respectively). FI: 
fluorescence intensity and CMC: critical micelle concentration. 
 
 
The N- and C-domain stability over time was confirmed by incubation in the presence of 0.0015% 
Brij-35 and assessment of all time-points’ HHL activity simultaneously using an inverse time-
course.  The experiment was performed in parallel at either 22°C or 37°C to determine whether 
a lower temperature would be more favourable for the less thermostable C-domain.  N-domain 
activity was sustained for 100 minutes in the presence of Brij-35 at either temperature (Figure 
3.10 a-b).  The C-domain displayed a slight time-dependent decrease in activity at 37°C even in 
the presence of the optimal Brij concentration (Figure 3.10 c-d).  Since the activity of both 
domains was maintained by 0.0015% Brij-35 at 22°C, all subsequent experiments were 








The fluorescent signal of N- and C-domain was amplified approximately 10- and 16-fold, 
respectively, by the addition of Brij-35 (Figure 3.10 a-d).  It thus appears that the surfactant 
monomers not only stabilize but also activate the truncated ACE domains. 
 
 
         
        
 
Figure 3.10: Enzyme stability as a function of time in the presence or absence of 0.0015% Brij-35.   
a) and b) N-domain or c) and d) C-domain were incubated at 22oC (a) and c)) or 37oC (b) and d)) in the 
presence (blue or green, respectively) or absence (grey) of Brij-35. FI: fluorescence intensity.  The time-
course was performed inversely to enable simultaneous assessment of all samples’ activity immediately 












3.4.5 Characterization of catalytic efficiency 
The affinity of the two domains for the Hippuryl-His-Leu (HHL) substrate and the efficiency 
whereby they catalyze its hydrolysis was determined from initial reaction velocities (where 
substrate hydrolysis was less than 10%) as a function of substrate concentration.  Fitting of the 
data to the non-linear Michaelis-Menten model revealed that substrate inhibition occurred at 
2.4mM HHL (Figure 3.11).  This was particularly pronounced for the C-domain.  Exclusion of this 
data point resulted in a good fit (according to the R2 fitting coefficients) of the initial velocities 






Figure 3.11: Michaelis-Menten kinetics for hydrolysis of HHL substrate.   
Velocities are given for a) N-domain and b) C-domain with substrate inhibition at higher concentrations 
indicated as red data points.  Michaelis-Menten parameters were determined using GraphPad Prism® 
v6.01 after exclusion of the last data point as shown on the right-hand panels.  Data represented as mean 
± SEM of triplicate wells. 
 
The parameters describing HHL binding affinity (Km), rate of hydrolysis (kcat) and overall catalytic 
efficiency (kcat/Km) could thus be determined for the N- and C-domain (Table 3.1).  The substrate 
binding affinity was non-domain selective whereas catalysis by the C-domain was slightly faster.  
Overall, the C-domain was approximately 4-fold more efficient than the N-domain at hydrolysing 
b) 
a) 




HHL.  The N-domain kcat compared well with that reported in literature under conditions of 
potassium phosphate buffer pH 8.3, 300mM NaCl and 10µM Zn (Woodman et al., 2006).  Under 
the conditions used here, however, the C-domain kcat was reduced and the binding affinity to 
both domains increased. 
 
Table 3.1: Catalytic efficiency of HHL hydrolysis by N- and C-domain.  
Data was analysed with the Michaelis-Menten model for determination of Km and kcat values (GraphPad 








N-domain 0.266±0.028 19.91±0.46 76.59±7.97 
C-domain 0.277±0.011 84.34±7.28 303.13±13.84 
 
 
3.4.6 Characterization of inhibitor binding 
Binding of lisinopril, GGH-lisinopril (GGHLis) and Cu-GGH-lisinopril (CuGGHLis) was characterized 
by determining the initial velocity of HHL hydrolysis across a range of inhibitor concentrations.  
The CuGGHLis used in this section was prepared at a 1:1 molar ratio of metal to chelator.  Since 
ACE is inhibited by CuSO4 (Friedland and Silverstein, 1976), no free Cu2+ should be present when 
characterizing the inhibitor’s binding affinity.  This was confirmed by the lack of absorbance at 
750-800nm (Appendix A13).   
 
For the assumptions of the Michaelis-Menten model to be valid, initial reaction velocities where 
less than 10% substrate hydrolysis has occurred should be used in kinetic analyses.  A low 
enzyme concentration of 7.5nM N-domain or 2nM C-domain was therefore chosen.  The slow 
rate of catalysis, however, necessitated a substrate concentration above Km (but below the 
substrate inhibition point) to ensure detectable fluorescent signal during the 15-minute assay in 
the presence of inhibitor.  An HHL concentration of 1mM was therefore chosen to characterize 
inhibitor binding.  Each inhibitor’s IC50 value was determined from a sigmoidal dose-response 
curve (Figure 3.12).   
 





Figure 3.12: Representative inhibition curve for determination of inhibitor concentrations at which 50% 
enzyme inhibition occurs (IC50 values).   
The N-domain was incubated with CuGGHLis and the percentage remaining activity fitted to a sigmoidal 
dose-response curve (represented as mean ± SEM of triplicate wells) to determine the IC50 value (arrow). 
 
The inhibitors’ binding constants (Ki values) were subsequently calculated using the Cheng-
Prusoff equation where Ki = IC50 / (1+[S]/Km) and [S] = [HHL] = 1mM (Table 3.2).  Kinetic 
characterization revealed low nanomolar inhibition of both domains by the three inhibitors 
tested.  Lisinopril binding occurred with sub-nanomolar affinity and approximately 10-fold C-
domain selectivity, presumably due to a strong amine interaction resulting from its more acidic 
prime subsite.  GGHLis displayed decreased binding affinity for both domains and lacked domain 
selectivity.  This likely resulted from an increase in inhibitor size and loss of the amine charge 
upon attachment of the GGH chelator.  Following chelation of GGHLis to Cu2+ and formation of 
the bulky square planar metal-binding domain, a further decrease in binding affinity was 
observed.  The slight C-domain selectivity suggests that the metallodrug is better 
accommodated by the larger C-domain prime subsite. 
 
Table 3.2: Affinity of inhibitor binding to the N- and C-domain.   
IC50 values were determined from sigmoidal dose-response curves and inhibitor binding constants (Ki 
values) calculated using the Cheng-Prusoff equation a.  Data represented as mean ± SEM of three 
independent experiments. 
 N-domain C-domain C-selectivity 
(KiNdom / KiCdom) Construct IC50 (nM) Ki (nM) IC50 (nM) Ki (nM) 
Lisinopril 4.09±0.16 0.86±0.03 0.40±0.02 0.09±0.004 9.6 
GGHLis 30.57±3.36 6.41±0.71 46.03±3.76 9.99±0.82 0.6 
CuGGHLis b 214.20±8.77 44.94±1.84 71.74±6.00 15.57±1.30 2.9 
a: Ki = IC50 / (1+[S]/Km) where [S] = [HHL] = 1mM  b: metallodrug prepared at 1:1 chelator to metal ratio 




The Ki values obtained for lisinopril corresponded well to those reported for the truncated 
domains of bovine ACE under similar conditions (Binevski et al., 2003).  GGHLis and CuGGHLis, 
however, displayed greater affinity to the truncated domains than reported by Hocharoen et al 
for full-length sACE using domain-selective substrates (Hocharoen et al., 2013).   
 
A higher concentration of inhibitor was likely required to observe complete inhibition of a 
particular domain in sACE form since the (Abz)-SDK(Dnp)P-OH and (Abz)-LFK(Dnp)P-OH 
substrates used were only 50- or 73-fold selective for the N- or C-domain, respectively (Rousseau 
et al., 1995; Bersanetti et al., 2004).  Since both domains have the same affinity for substrate 
binding, a fraction of the observed percentage remaining activity of (Abz)-SDK(Dnp)P-OH, for 
example, could originate from the C-domain.  This effect might have been exacerbated by the 
negative cooperativity that occurs upon inhibitor binding where binding of one molecule of 
inhibitor to sACE decreases the affinity of the second domain for inhibitor binding (Binevski et 
al., 2003).  Since these effects do not apply to the truncated domains, the IC50 and Ki values 
determined here likely provide a more accurate description of the inhibitors’ binding affinities. 
 
 
3.4.7 Determination of the mode of inhibition 
Due to the disparities in inhibitor binding affinity between full-length and truncated ACE, it was 
investigated whether CuGGHLis competed with substrate for binding to the truncated single-
domain proteins’ active sites, as reported by Hocharoen et al for sACE (Hocharoen et al., 2013).  
Inhibition was assessed over a range of inhibitor concentrations using the Dixon method (Dixon, 
1953).  As evidenced by the intersection of the Dixon plots in the upper left quadrant, CuGGHLis 













            
Figure 3.13: Dixon plots illustrating the mode of ACE inhibition by CuGGHLis.   
The activity (FI) of a) N-domain or b) C-domain was assessed over a range of CuGGHLis concentrations 
using 1mM HHL (green or blue, respectively) or 0.5mM HHL (grey).  Data represented as mean ± SEM of 
triplicate wells. FI: fluorescence intensity. 
 
 
3.4.8 Time-dependent oxidative inactivation 
The decrease in activity resulting from oxidative inactivation was monitored over 8 hours.  
Aliquots of samples containing protein in the absence or presence of CuGGHLis and/or redox co-
reactants (H2O2 or ascorbate or H2O2 and ascorbate) were incubated at 22°C and the activity 
assessed at 20-minute intervals using HHL assays.  The CuGGHLis used from this point onwards 
was prepared at a 1:1.1 molar ratio of metal to chelate and thus contained no free copper ions.  
The metallodrug was incubated with each domain at a concentration equal to its IC20 value (IC20 
= IC50 x 2/5) so that a time-dependent decrease in activity resulting from oxidative catalytic 
inactivation could be observed from the initial approximately 80% enzyme activity at time zero.  
The CuGGHLis IC20 values for N- and C-domain were equal to 85.68nM and 28.7nM, respectively.  
All samples within a time-course were prepared from the same protein, inhibitor and co-
reactant dilutions, incubated simultaneously and assayed in parallel to avoid introduction of 
technical variability.  Activity at each time-point was expressed as a percentage relative to the 
control sample (enzyme containing no co-reactant or metallodrug) as a function of time. 
 
Activity of the N- and C-domain samples containing no co-reactant or metallodrug was 
maintained for 8 hours (data not shown), thus confirming that 0.0015% Brij-35 successfully 
prevented thermal degradation at 22°C.   The N-domain displayed no inactivation in the absence 
of CuGGHLis and presence of ascorbate or H2O2 (Figure 3.14 a).  In the presence of both co-
b) a) 




reactants, however, an exponential decrease in activity to a plateau of 65% remaining activity 
was observed.  Since the co-reactants were present in an approximately 106-fold excess over 
enzyme, the inactivation reaction was not limited by their concentration.  Diffuse radicals thus 
did not completely inactivate the N-domain but only reduced its catalytic efficiency through 
oxidative modifications.  
 
The C-domain was slightly inactivated by diffuse radicals in the presence of H2O2 but markedly 
so in the presence of both co-reactants (Figure 3.14 c).  This diffuse-radical inactivation was 
faster than that of the N-domain (Figure 3.15) and ultimately led to a 57% loss of C-domain 
activity in the absence of CuGGHLis (Figure 3.14 c).  The levels of activity remaining after diffuse-
radical inactivation of the N- and C-domain (65% and 43%, respectively) were strikingly similar 
to those obtained by Michel et al (66% and 42%, respectively) after 4 hours’ incubation with a 
2,2’-azo-bis(2-amidino-propane) generator of hydroxyl radicals (1mM) (Michel et al., 2001).  This 
agreement with their study on the two domains’ oxidation in full-length sACE form suggests that 
the data presented here on the truncated domains is physiologically relevant.   
 
 
     
 
   
Figure 3.14: First-order exponential decay curves showing time-dependent catalytic inactivation.   
Remaining activity is given for N-domain (a-b) and C-domain (c-d) in the absence (a and c) or presence (b 
and d) of CuGGHLis at IC20.  Grey, orange, yellow and red curves correspond to samples containing no co-
reactant, 1mM H2O2, 1mM ascorbate or 1mM H2O2 + 1mM ascorbate, respectively.  Activity determined 
in triplicate wells at each time-point is represented as mean ± SD from two independent time-course 











Figure 3.15: Initial rates of N- and C-domain inactivation in the presence or absence of CuGGHLis and 
redox co-reactants.  
Yellow, orange and red correspond to samples containing ascorbate, H2O2 or ascorbate + H2O2.  Initial 
rates were calculated from the average first-order exponential decay curves obtained from two 
independent time-course experiments. 
 
Based on the observation that sACE was protected from oxidative inactivation by hydroxyl 
radical scavengers (dimethylthiourea or a combination of mannitol and methionine) or thiol-
reducing agents (dithiothreitol or mercaptoethanol), it was proposed that hydroxyl radicals were 
the active ROS species (Michel et al., 2001).  The thiol-reducing agents’ protection, however, did 
not offer much insight into the mechanism whereby diffuse radicals reduced ACE activity since 
the two active site cysteines are oxidized to a disulphide in the active enzyme (Sturrock et al., 
1996) and the single unbound cysteine resides on the protein surface.  The results were further 
confounded by the fact that dithiothreitol addition, in itself, caused significant inhibition of ACE 
activity (Michel et al., 2001).   
 
Although over-oxidation of the disulphide by H2O2 or singlet oxygen oxidants into thiosulphinate, 
thiosulphonate, disulphide trioxide or disulphone species might occur (Kim et al., 2015) (Figure 
3.16), it is unclear whether such modifications would induce conformational change and ACE 
inactivation.  Diffuse radicals might alternatively inactivate ACE through oxidation of the Zn-
coordinating histidine residues.  The greater susceptibility of the C-domain towards oxidation by 
diffuse radicals might be due to its more exposed active site (as discussed in Chapter 2) or its 










Figure 3.16: Mechanism of cysteine disulphide oxidation by oxidants such as hydrogen peroxide (H2O2) 
or singlet oxygen. 
Adapted from Kim et al (Kim et al., 2015). 
 
It has been proposed that in the presence of a metallodrug and O2, Fenton-type chemistry 
results in the formation and immediate reaction of metal-associated ROS at the site of 
production (Cowan, 2008).  The ATCUN motifs, such as GGH, stabilize the Cu3+/2+ redox couple 
(McDonald et al., 1997) and are believed to cause enzyme inactivation via formation of an active 
Cu3+=O2- oxone intermediate (Cowan, 2008).  In the presence of CuGGHLis and H2O2 alone, a 
slight degree of N-domain inactivation was observed (Figure 3.14 b).  Under these conditions, 
the Cu3+ state could be generated through a one-electron transfer reaction but since there is no 
efficient way of reducing the metal, redox cycling would not occur and the inactivation rate is 
very slow (Figure 3.15).   
 
In the presence of CuGGHLis and ascorbate, N-domain inactivation was noticeably increased 
(Figure 3.14 b).  Under these conditions, H2O2 would be formed from O2 and the Cu3+ state 
generated by one-electron transfer (Figure 3.17 b).  Following oxidation of the protein by the 
copper-associated ROS species, the Cu2+-GGHLis state would be regenerated through one-
electron transfer from ascorbate.  The rate of inactivation is therefore increased over that 
observed in the presence of CuGGHLis and H2O2 alone through redox cycling (Figure 3.15). In the 
presence of metallodrug and both co-reactants, the most pronounced rate of catalytic 
inactivation was observed with only 18% N-domain activity remaining after 125 minutes’ 




incubation (Figure 3.14 b).  Addition of H2O2 in the presence of ascorbate and O2 would result in 
a mechanistic shunt to drive formation of the Cu3+ state, protein oxidation and subsequently 
redox cycling through reduction of the oxidized metal centre (Figure 3.17 b).  This rapid copper-
mediated oxidation ultimately resulted in complete N-domain inactivation.  The initial 
inactivation rates determined from the exponential decay curves clearly illustrate that N-domain 
inactivation is enhanced over background (diffuse radicals in absence of inhibitor) in the 
presence of CuGGHLis (Figure 3.15). 
 
In contrast, addition of CuGGHLis did not affect the rate of C-domain inactivation and 27% 
residual activity was retained, even after 8 hours’ incubation with H2O2 and ascorbate (Figure 
3.14 d).  Previously, Joyner et al reported a similar plateau of approximately 30% remaining 
activity for the two-domain sACE after incubation with CuGGHLis (Joyner et al., 2012).  
Thereafter, Hocharoen et al reported that the C- as well as the N-domain experienced CuGGHLis-
mediated catalytic inactivation in the presence of both co-reactants, albeit at a reduced rate (18-
fold greater N-domain initial inactivation rate) (Hocharoen et al., 2013).  The results presented 
here, however, indicate that the C-domain only undergoes oxidation by diffuse radicals and that 
CuGGHLis-mediated oxidation occurs rapidly and exclusively in the N-domain.  This N-domain 
inactivation reaction is catalytically efficient as evidenced by the high second order rate constant 
(k2) in the presence of ascorbate and H2O2 (Table 3.3).  Since the N-domain was stable in 0.05% 
Brij-35 at 37°C, an oxidative inactivation time-course was also performed under these conditions 
to enable comparison with the second order rate constants determined by Joyner et al for full-
length sACE using a non-domain selective substrate (Joyner et al., 2012).  At this temperature, 
the N-domain inactivation trends were the same but the k2 values were increased (Appendix 
A16).  The k2 values determined under these conditions compared very well to those determined 
for the two-domain sACE, thereby providing further support for exclusive N-domain catalytic 
inactivation.  This would therefore provide a highly selective therapy for the treatment of fibrosis 
at sub-stoichiometric inhibitor concentrations.   
 
CuGGHLis is expected to be suitable for physiological use since previous studies showed that it 
induces production of metal-bound ROS as opposed to an abundance of diffusible ROS (Joyner 
et al., 2012).  The ROS species would therefore be located to the metallodrug’s immediate 
environment in the active site and selective target inactivation would occur.  This is further 
supported by the in vivo abundance of ATCUN motifs, such as GGH, used for copper and nickel 
transport (Lau et al., 1974). 
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    b)  
 
Figure 3.17: Mechanisms of radical generation in the presence of redox co-reactants.  
a) Diffuse radical generation in metallodrug absence and b) metallodrug-mediated generation of metal-
bound radicals in the active site. 
 
 
Table 3.3: Initial rates and second order catalytic inactivation rate constants (k2) determined at 22°C for 
N-domain in the presence or absence of CuGGHLis and redox co-reactants.   
Initial rates were calculated from the average first-order exponential decay curves obtained from two 
independent time-course experiments performed in triplicate and rate constants as k2 = (initial rate - 
background)/ [enzyme][CuGGHLis]. 
N-domain 
Initial rate (nM min-1) 
k2 for inactivation (M-1 min-1) 
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None 0.002 0.002 3 625 
Ascorbate 0.012 0.009 14 128 
H2O2 0.001 0.001 2 310 
Ascorbate + H2O2 0.049 0.038 59 710 




3.4.9 Kinetic characterization of residual activity 
To investigate the mechanism of inactivation and basis for the differences between N- and C-
domain, the residual activity was determined using a range of HHL concentrations after a 100-
minute incubation at 22°C, in the presence or absence of redox co-reactants and CuGGHLis.  The 
residual activity was subsequently characterized in terms of substrate binding affinity (Km), 
turnover number (kcat) and overall catalytic efficiency (kcat/Km).  The 100min timepoint was 
chosen to have detectable inactivation but still enough residual activity for fluorescence signal 
detection and Michaelis-Menten kinetic characterization.  All samples for both domains were 
prepared using the same inhibitor and co-reactant dilutions, incubated and assayed at the same 
time to avoid variability in substrate, inhibitor or co-reactant preparation between the samples 
or domains. All Michaelis-Menten curves were determined simultaneously for the 8 samples of 
each domain at the two time-points in triplicate wells of a 96-well plate. 
 
One hundred minutes’ incubation with co-reactants in the absence of metallodrug had no 
significant effect on the overall efficiency of N- or C-domain towards HHL hydrolysis (Figure 
3.18).  In the presence of CuGGHLis and ascorbate, however, a decrease in N-domain HHL 
binding affinity (increased Km) and a slight decrease in turnover number (kcat) was noticed (Figure 
3.18 a).  The N-domain catalytic parameters were not affected by H2O2 and CuGGHLis incubation 
but further addition of ascorbate led to a slight decrease in binding affinity and a significantly 
reduced turnover number.  The N-domain’s overall catalytic efficiency was thus significantly 
decreased after 100 minutes’ incubation under these conditions.  This suggests that CuGGHLis-
mediated N-domain oxidative inactivation occurs either via sidechain oxidation of amino acids 
directly involved in HHL catalysis or oxidative cleavage of the protein backbone to ultimately 
reduce the number of moles of intact N-domain available for HHL hydrolysis.  Oxidation of 
substrate-binding residues appears to play a less significant role.   
 
No significant changes in C-domain catalytic parameters were detected after 100 minutes’ 
incubation with co-reactants although the catalytic efficiency was slightly decreased in the 
presence of both co-reactants with or without CuGGHLis (Figure 3.18 b).  Overall, this suggests 
that although CuGGHLis binds with similar affinity to both domains, the metal-chelate is 
optimally orientated in the N- but not the C-domain to catalyze oxidation of residues involved 
in substrate hydrolysis. 
 







         
 
         
 
       
 
Figure 3.18: Characterization of residual activity of HHL hydrolysis after inactivation for 100 minutes. 
a) N-domain and b) C-domain.  Kinetic parameters (Km and kcat values) determined in the absence and 
presence of CuGGHLis at IC20 are given as blank and filled bars, respectively.  Black, yellow, orange and 
red bars correspond to samples containing no co-reactant, 1mM ascorbate, 1mM H2O2 or both (1mM 
ascorbate + 1mM H2O2), respectively.  Parameters determined in triplicate wells across a range of HHL 
concentrations for each sample are represented as mean ± SD from two independent inactivation 
experiments.  Analysed using an unpaired t-test (* P < 0.05); n.s: not significant. 
 
Based on the molecular docking experiments performed with CuGGHLis (Joyner et al., 2012) in 
the N- and C-domain, it appears that the metal may be near several readily oxidizable prime 
subsite residues (Figure 3.19).  The metal-binding domain was orientated differently in the two 
domains and this might have occurred due to differences in the chemical properties or sidechain 
a) b) 
- CuGGHLis + CuGGHLis - CuGGHLis + CuGGHLis 
- CuGGHLis + CuGGHLis - CuGGHLis + CuGGHLis 
- CuGGHLis + CuGGHLis - CuGGHLis + CuGGHLis 




lengths of unique S2’ residues (Figure 3.19 c-d).  Molecular docking experiments performed with 
HHL (Douglas, 2011) further suggest that these oxidizable residues are involved in the hydrolysis 
of HHL since they are proximal to the C-terminal His-Leu (Figure 3.19 b).  Flexibility in the 
CuGGHLis lysyl linker could allow the metal-chelate to transition slightly in the N-domain and 
cause oxidation of the critical oxyanion residues responsible for binding HHL’s C-terminal 
carboxylate (Figure 3.19 c).  In the C-domain, the metal-binding moiety is more distal from the 
oxyanion residues and therefore unlikely to affect HHL hydrolysis (Figure 3.19 d). 
 
  
       
             
 
Figure 3.19: Structures of CuGGHLis and HHL docked into the N-domain.   
Docking of HHL was performed by Dr R.G. Douglas (Douglas, 2011) and docking of CuGGHLis by Joyner et 
al (Joyner et al., 2012).  a) Oxidizable residues (blue lines) and unique residues in the N-domain prime 
subsite (green sticks); b) HHL (cyan) orientation in the N-domain, binding to the conserved oxyanion 
residues (orange sticks); c) CuGGHLis (yellow) orientation in the N-domain; and d) CuGGHLis (yellow) 








3.4.10 Assessment of artificial protease activity of CuGGHLis 
To determine whether protein inactivation results from sidechain oxidation or protein backbone 
oxidation culminating in protein cleavage, SDS-PAGE was used.  In this case protein was 
incubated for 7 hours at 22°C in the presence or absence of co-reactants and/or CuGGHLis to 
characterize the complete inactivation reaction.  A sample which was not incubated was 
included to control for any possible thermal degradation products.  No oxidative cleavage 
products were observed for either domain under any of the conditions tested (Figure 3.20). This 
suggests that sidechain oxidation is the main mechanism of irreversible ACE inactivation.  In a 
two-domain protein such as sACE, this mechanism of action is desired since oxidative cleavage 




                                 
Figure 3.20: SDS-PAGE of inactivated ACE stained with colloidal Blue-Silver Coomassie.   
a) N-domain or b) C-domain samples were incubated for zero minutes (lane 2) or 7 hours (lanes 3-10) in 
the presence or absence of CuGGHLis (at IC20) and redox co-reactants at 1mM.  Molecular weight markers 
(kDa) are given in lane 1. Lanes 2, 3 and 7: no co-reactant, lanes 4 and 8: ascorbate, lanes 5 and 9: H2O2, 
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a) b) 
- CuGGHLis + CuGGHLis - CuGGHLis + CuGGHLis 




3.5   Conclusion 
This study provides a careful analysis of the binding affinity of lisinopril, GGHLis and the 
CuGGHLis metallodrug by assessment of the two ACE domains in isolation with the same non-
domain selective substrate.  Upon incubation with a sub-stoichiometric amount of CuGGHLis in 
the presence of redox co-reactants rapid, complete and exclusive irreversible inactivation of the 
N-domain was observed.  This analogue of the clinically approved ACE inhibitor lisinopril thus 
appears to be very promising for the treatment of fibrosis. 
 
The basis for selectivity is likely a more optimal orientation of the CuGGH moiety to readily 
oxidizable residues in the N- than C- domain active site.  Residual activity characterization and 
protein cleavage analysis suggests that inactivation mainly results from sidechain oxidation of 
N-domain residues involved in substrate hydrolysis.  In future, the optimized conditions reported 
here could be used to explore the mechanism in more detail by utilizing X-ray crystallography 
and mass spectrometry to visualize the metal-chelate moiety’s binding site and identify the 





















Investigating the influence of N-glycans on ACE dynamics 
4.1  Introduction 
sACE is glycosylated at nine N-domain and six C-domain PNGs and the importance of these 
glycans in correct folding and processing of the enzyme has been shown experimentally (as 
discussed in Chapter 1 section 1.3.2).  The molecular mechanism whereby they mediate 
folding, however, is unclear and has hampered efforts at obtaining a minimally glycosylated 
sACE glycoform amenable to crystallization.  Elucidation of the sACE structure will offer 
insight into the mechanisms whereby negative cooperativity between the two domains and 
sACE dimerization occur upon inhibitor or substrate binding.  Experimentally, it has also been 
shown that these glycans are important for ACE thermal stability (as discussed in Chapter 1 
section 1.3.3).  It is hypothesized that interactions of glycans at specific sites assist in folding 
by stabilizing flexible regions of the underlying protein and that this might contribute to 
thermal stability of the mature protein.  Furthermore, it is proposed that the superior N-
domain thermal stability could be the result of a decreased solvent accessible active site or 
protein surface area due to its higher carbohydrate content. 
 
4.1.1 The role of glycosylation in oxidative inactivation 
Decreased exposure of the protein surface to solvent could not only improve thermal stability 
but also protect against amino acid oxidative modifications by limiting ROS access (Li et al., 
2017).  As described in Chapter 3, oxidative inactivation is the enzymatic activity loss 
observed upon oxidation of residues involved in substrate binding or hydrolysis.  Although 
the active sites are ~90% identical (Corradi et al., 2006), the C-domain is more susceptible 
than the N-domain to oxidative inactivation by diffuse radicals (Chapter 3 section 3.4.8) 
(Voronov et al., 2002a; Michel et al., 2001).  Interestingly, the location of C-domain sites 2, 5 
and 6 and N-domain sites 1, 2, 5, 7, 8 and 9 are unique to the respective domains (Figure 4.1).  
The 3D structure clearly shows that while the C-domain glycans (except site 6) are proximal 
to the N-terminal lid, the N-domain glycans are distributed around the molecule.  A network 
of glycan-glycan interactions surrounding the N-domain could thus form a glycan-shield to 
prevent access of ROS to the active site.  
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In contrast, the sparser C-domain glycosylation and inter-subdomain repulsion (described in 
Chapter 2) could result in increased exposure of key active site residues to ROS. 
 
a)           b) 
      
Figure 4.1: ACE crystal structures indicating PNGs. 
a) N-domain (PDB ID: 2C6F) and b) C-domain (PDB ID: 1O8A) with PNGs indicated by spheres.  
Numbering of conserved sites is given in red. The active site cleft is indicated by the dotted line and 
the catalytic zinc ion as a yellow sphere. 
 
Previously, Voronov et al reported that the C-domain (in sACE form) was greatly protected 
against water radiolysis-generated radicals by binding of the fluorescent hydrophobic dye 8-
anilino-1-naphthalenesulfonic acid (1,8-ANS) (Voronov et al., 2002b; Voronov et al., 2003).  
The N-domain, which inherently is more resistant to ROS, was only minimally protected by 
1,8-ANS.  Although a conserved hydrophobic binding site was suggested from a modelled C-
domain structure, the locations of these residues do not agree with the available 
crystallographic information.  The binding site and mechanism of protection by 1,8-ANS is 
therefore unknown.  Binding does appear to occur at a site distal from the active site since 
catalytic activity was unchanged.  Interestingly, 1,8-ANS also did not affect thermal stability, 
suggesting that it does not bind to flexible loop regions.  This molecule might function 
analogous to the unique N-domain glycan shield and protect C-domain residues involved in 
catalysis against ROS indirectly by facilitating active site cleft closure. 
 
4.1.2 Implication of oxidative ACE inactivation for inflammation 
Understanding the mechanism whereby 1,8-ANS offers protection against oxidation is of 
potential physiological relevance for the treatment of inflammation.  In 1992 and 1993 Chen 
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by phorbol 12-myristate 13-acetate (PMA)-activated neutrophils decreased ACE activity in 
cultured endothelial cells.  Neutrophil incubation with 10mg/ml PMA (neutrophil: endothelial 
cell ratio of 1.25:1) stimulated superoxide anion release and completely inactivated ACE 
within 4 hours.  In addition to ACE’s role in regulating blood pressure via AngI cleavage, it 
also functions to cleave and inactivate bradykinin (BK), substance-P (SP), formyl-Met-Leu-Phe 
(fMLF) (Erdos, 1990) and N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) (Rousseau et al., 1995).  In an 
inflammatory state ROS are produced by immune cells.  Given the aforementioned ability of 
ROS to oxidatively inactivate ACE, it thus follows that ACE function would be impaired at the 
site of inflammation. Consequently, not only AngI but also BK, SP, fMLF and AcSDKP levels 
would be elevated (Figure 4.2).  
 
Under basal conditions ACE is responsible for the majority of AngI cleavage and AngII 
production.  An alternative pathway of AngII production via the serine protease mast cell 
chymase has been reported (Reilly et al., 1982) but its contribution is minimal since chymase 
is stored in mast cell secretory granules as an inactive macromolecular complex.  In an 
inflammatory state, however, mast cell degranulation leads to chymase activation, 
production of AngII, pro-inflammatory cytokines and ultimately a significant increase in 
leukocyte adhesion to endothelial cells (Company et al., 2011).  Similarly, neutrophil 
cathepsin G also has the ability to cleave AngI into AngII (Reilly et al., 1982).  Although 
oxidative inactivation of ACE prevents cleavage of AngI, this therefore does not decrease 
AngII levels.  Increased AngII results in vasoconstriction, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) activation, production of superoxide anion, tumour 
necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6), interferon gamma (IFN-
γ), transforming growth factor beta 1 (TGF-β1) and increased vascular permeability via AT1R 
binding (de Gasparo et al., 2000).   Although AngII binding to the angiotensin receptor type 2 
(AT2R) has an opposing effect (Siragy, 2000), this receptor is only expressed during 
development (Grady et al., 1991).  ACE2 cleavage of AngII also results in increased production 
of Ang1-7 with subsequent NO production and vasodilation via the MAS receptor (Simoes e 
Silva et al., 2013).  NO is anti-inflammatory under basal conditions but becomes pro-
inflammatory when produced in high concentrations (Sharma et al., 2007).  The essentially 
irreversible reaction of NO with neutrophil-generated superoxide anion leads to 
peroxynitrite (ONOO-) formation (Beckman and Koppenol, 1996).  Interaction of proteins 
with this strong oxidant can result in tryptophan and cysteine oxidation, tyrosine nitration, 
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dityrosine formation and protein backbone oxidative cleavage (Ischiropoulos and al-Mehdi, 
1995). 
 
Vasodilation and NO production via the phospholipase C – protein kinase C – mitogen-
activated protein kinase (PLC-PKC-MAPK) pathway is also mediated by binding of the BK 
nonapeptide to its constitutively and ubiquitously expressed bradykinin receptor B2 (B2R) 
(Scharfstein et al., 2017).  Furthermore, BK binding to B2R leads to increased tissue 
plasminogen activator (t-PA) levels (Brown et al., 2000).  Binding of t-PA to the low density 
lipoprotein receptor-related protein 1 (LRP-1) and Annexin-A2 receptors, not only increases 
M1 macrophage motility (Lin and Hu, 2014) and survival (Lin et al., 2015) but also activates 
NF-κB, promoting M2 to M1 macrophage phenotypic change and inflammatory cytokine 
production (Lin and Hu, 2017).  The effect of increased t-PA might be off-set, however, by a 
chymase AngII-mediated increase in plasminogen activator inhibitor type 1 (PAI-1) 
expression (Fogari and Zoppi, 2006).  Nevertheless, increased PAI-1 is not beneficial since 
inactivation of t-PA along with TGF-β1 stimulation by AngII leads to tissue fibrosis via fibrin 
accumulation, migration and adhesion of inflammatory cells and fibroblasts (Ghosh and 
Vaughan, 2012). 
 
The bradykinin receptor B1 (B1R), on the other hand, is present at low levels in healthy tissues 
but rapidly induced upon tissue injury (Scharfstein et al., 2017).  Following BK cleavage by 
glycosylphosphatidylinositol-linked carboxypeptidase M (CPM), Des-Arg9-BK binds to B1R 
and increases neutrophil migration to the site of inflammation, leukocyte adhesion to 
endothelial cells (Figueroa et al., 2015), production of pro-inflammatory cytokines and 
hyperalgesia (Ahluwalia and Perretti, 1999).  BK also induces mast cell degranulation which, 
in addition to the aforementioned AngII-mediated pro-inflammatory effects, leads to 
increased vascular permeability and release of prostaglandin D2 (PGD2), leukotrienes, 
platelet-activating factor (PAF), SP, NO and histamine (Theoharides et al., 2012). 
 
Increased SP similarly induces vasodilation, mast cell degranulation, cytokine release, 
neutrophil recruitment and activation (Katsanos et al., 2008), angiogenesis (Kohara et al., 
2010) and t-PA production (Labinjoh et al., 2001).  Hyperalgesia in this case results from SP 
binding to the Neurokinin-1 receptor (NK-1), PLC-PKC signalling and ROS production (Linley 
et al., 2012). 
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The f-MLF peptide plays a role in inflammation by increasing neutrophil and macrophage 
recruitment upon binding to its formyl peptide receptor (FPR) or FPR-like 1 receptor on the 
surface of these cells (Schiffmann et al., 1975).  Increased adherence to endothelial cells, 
macrophage activation via PKC and protein tyrosine kinase (PTK) (Shrivastava, 2007) and 
subsequent pro-inflammatory cytokine, superoxide anion, H2O2 and NO production also 
result.   
 
In contrast to the pro-inflammatory effects of AngII, BK, SP and fMLF, increased AcSDKP levels 
upon oxidative ACE inactivation decreases inflammation and fibrosis.  AcSDKP reduces 
culture bone marrow stem cell maturation to mature macrophages, macrophage migration, 
TNF-α secretion and collagen deposition (Sharma et al., 2008).  This effect, however, might 
be overshadowed by the overwhelmingly pro-inflammatory events since it would still be 
selectively cleaved into inactive peptides by the less ROS-susceptible N-domain (Rousseau et 
al., 1995).  The ROS-susceptible C-domain has previously been shown to hydrolyse AngI, BK 
and SP more efficiently than the N-domain (Wei, 1991; Jaspard et al., 1993). 
 
Therefore, it is likely that swelling, angiogenesis, cell proliferation, cytokine production, 
neutrophil recruitment, macrophage activation and an increase in pain perception occurs by 
the collective action of AngII, BK, SP and fMLF.  Previously, a dose-dependent relationship 
was described between the degree of ACE inactivation and the number of immune cells, their 
activation and adherence to endothelial cells (Chen et al., 1992).  The pro-inflammatory 
effects of these peptides would thus initiate a continuous cycle of ROS production by immune 
cells and ACE inactivation, thereby promoting the progression of inflammation and 
development of fibrosis (Figure 4.2).     
 
Understanding the mechanism of C-domain protection by 1,8-ANS could facilitate design of 
an anti-inflammatory ‘ACE-protecting agent’ for co-administration with antioxidants and an 
N-selective ACE inhibitor in inflammatory disease.  Since binding supposedly occurs distal 
from the active site, no alteration in blood pressure or basal ACE expression is anticipated.  
Although the ROS-protected C-domain active site would be free to cleave AngI and produce 
AngII, in a normotensive state with basal ACE expression the cleavage of BK, SP and fMLF into 
inactive peptides and build-up of AcSDKP would overall have an anti-inflammatory outcome, 


















Figure 4.2:  Proposed cycle at the site of inflammation whereby ACE oxidative inactivation leads to fibrosis and progression of inflammation.  
Pro- and anti-inflammatory processes are indicated by red and green dotted lines, respectively. AngI, BK, SP and fMLF refer to ACE substrates that bind to their respective 
receptors (labelled grey). ACE: angiotensin converting enzyme; ACE2: angiotensin converting enzyme 2; AT1R: angiotensin receptor type I; AT2R: angiotensin receptor type II; 
B1R: bradykinin receptor B1; B2R: bradykinin receptor B2; NK1: neurokinin-1 receptor; FPR: formyl peptide receptor.
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4.2   Aims and objectives: 
This part of the study firstly aimed to determine the molecular mechanism whereby ACE N- 
and C-domain glycosylation confers thermal stability.  Secondly, the C-domain’s increased 
susceptibility to oxidative inactivation and protection by 1,8-ANS was investigated.  Insight 
gained by achieving these aims would in future assist sACE structure determination and 
design of novel ACE-modulating agents with potential anti-inflammatory activity. 
 
Molecular dynamics simulations on the fully glycosylated truncated N- and C-domains were 
employed to address the following objectives: 
 
1. Determine the mechanism for site-specific glycosylation in thermal stabilization by 
analysing protein flexibility, identifying glycan-protein interactions and evaluating 
the volume occupied per glycan. 
 
2. Investigate the molecular basis for the N-domain’s superior resistance to oxidative 
inactivation by identifying glycan-glycan interactions and analysing active site solvent 
access. 
 
3. Elucidate the mechanism whereby 1,8-ANS binding to the C-domain protects against 
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4.3  Methodology: 
4.3.1 Crystal structure selection 
Glycan attachment in eukaryotic cells occurs at a potential N-linked glycosylation site (PNGs) 
with sequence N-X-T/S (where X is any amino acid except proline) which remains solvent-
exposed after protein folding.  Biologically relevant glycosylation sites are therefore solvent 
exposed.  In addition to experimental evidence, in silico assessment of potential N-linked 
sites’ solvent accessibility can therefore guide the decision of which sites should be 
glycosylated.  High-resolution crystal structures of the N- and C-domain of ACE (in minimally 
glycosylated forms to facilitate crystallization) have previously been solved.  In the current 
study, however, these structures could not be used since N25Q mutation used in constructing 
the minimally glycosylated N-domain form (Anthony et al., 2010) caused reorientation and 
burying of the side-chain.  The lower resolution apo structures solved from fully glycosylated 
protein expressed in the presence of NBDNJ were therefore used instead (Corradi et al., 
2006; Natesh et al., 2003) (N-domain PDB ID:2C6F, 3.01Å resolution; C-domain PDB ID: 1O8A, 
2.00Å resolution).   The single C-domain molecule and molecule A of the N-domain 
asymmetric unit were chosen.  
 
4.3.2 Protein structure preparation 
The lacking C-domain N-terminal L37-V-T39 and C-terminal Y619-NWTPN-S625 residues (standard 
tACE numbering (Ehlers et al., 1989)) were built using Modeller (Sali and Blundell, 1993) in 
UCSF Chimera v1.10.1 (Pettersen et al., 2004) (Chimera is developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIGMS P41-GM103311)).  Since Modeller renumbered the residues during this 
process (for example L37-V38-T39 to L1-V2-T3), all references to C-domain from this point 
onwards are 36 less than the standard tACE residue numbering.  The glycan site numbering 
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Table 4.1: C-domain glycan numbering used in the glycosylated MD structures. 
  Standard tACE numbering Numbering used in this chapter 
N-terminal residue Leu 37 1 
Glycan site 
c1 N72 N36 
c2 N90 N54 
c3 N109 N73 
c4 N155 N119 
c5 N337 N301 
c6 N586 N550 
Standard tACE numbering is according to the testis ACE isoform which includes a unique 36-residue N-terminal 
region (absent in sACE).  The constructs used for X-ray crystallography lacked this region and thus the first N-
terminal amino acid was Leu37.  In this chapter, Modeller renumbered this construct to start at 1, thus numbering 
used is 36 less than standard tACE numbering. 
 
All subsequent N- and C-domain methodologies for protein preparation, simulation and 
analysis were analogous. Sugar, polyethylene glycol, N-carboxyalanine and acetate 
molecules were deleted prior to protein pre-processing with the Schrödinger Suite’s (version 
2014) Maestro Protein Preparation Wizard (Madhavi Sastry et al., 2013).  Bond orders were 
assigned, hydrogen atoms added for pH 7.0, disulphide bonds created and missing sidechains 
filled in with Prime.  The Interactive hydrogen bond optimizer was used to visually inspect 
and adjust the histidine, asparagine (except N-linked) and glutamine tautomers for optimal 
hydrogen bonding.  All crystallographic waters, except for the N-domain’s Zn-coordinated 
water, were deleted after successful protein optimization. 
 
4.3.3 Protein glycosylation and optimization 
The Glycoprotein Builder contained within the GLYCAM Web-tools suite (Woods Group 
(2005-2018) GLYCAM Web; Complex Carbohydrate Research Centre, University of Georgia, 
Athens, GA. (http://glycam.org)) was used to build and covalently link the 3D structure of a 
bisialylated fucosylated biantennary complex type glycan (Figure 4.3) (DNeup5Acα2-
3DGalpβ1-4DGlcpNAcβ1-2DManpα1-6[DNeup5Acα2-3DGalpβ1-4DGlcpNAcβ1-2DManpα1-
3]DManpβ1-4DGlcpNAcβ1-4[LFucpα1-6]DGlcpNAcβ1-OH) to N-linked ACE glycosylation 
sites.  This glycan structure was chosen since it was supported by previous mass 
spectrometric analysis of the truncated C-domain expressed in CHO-K1 cells (Yu et al., 1997) 
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and quantitative HPLC analysis on human kidney sACE and tACE expressed in CHO-K1 cells 





Figure 4.3: Stereochemical structure of the glycan attached to N- and C-domain PNGs.   
Glycosidic linkage types are indicated by Greek symbols and the monosaccharide names given in 
standard Symbol Nomenclature for Glycans (SNFG) colouring (Varki et al., 2015). 
 
The chloride, zinc and active site water were removed during the process of glycosylating the 
nine N-domain and six C-domain PNGs.  GLYCAM automatically performs 1000 steps of 
steepest descent minimization on the attached glycans while keeping the protein atoms 
restrained.  An error in the script (personal communication with GLYCAM developers), 
however, caused minimization of protein atoms in the absence of metal coordination.  The 
Zn-coordinating residues’ sidechain orientations in the resulting glycoprotein structure were 
thus altered and unsuitable for Zn binding.  After glycosylation the coordinates for H361/347, 
H365/351, E389/375 (N-domain/C-domain numbering), Cl and Zn were therefore manually 
replaced by those from the protein structures optimized for hydrogen bonding.  Additionally, 
a Zn-coordinating water molecule was built into both domains from its N-domain 
crystallographic coordinates. 
 
UCSF Chimera v1.10.1 (Pettersen et al., 2004) was used to detect steric glycan-glycan and 
glycan-protein clashes.  These were manually resolved by altering the Asn-GlcNAc glycosidic 
linkages’ phi (φ: O5-C1-ND2-CG), psi (ψ: C1-ND2-CG-CB) or chi (χ1: N-CA-CB-CG; χ2:CA-CB-CG-ND2) 
torsion angles, as previously described (Li et al., 2017; Wood et al., 2013).  Importantly, these 
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Asn-GlcNAc linkage angles were kept within allowed values (Petrescu et al., 2004) to ensure 
biologically relevant presentation of the sugar to the protein. 
To differentiate the N-linked asparagines, their residue names were changed to NLN in all 
relevant files.  Similarly, the metal site residues were renamed HIR, HIT, GLR, WAR and ZN1 
for H361/347, H365/351, E389/375 (N-domain/C-domain numbering), active site water and 
Zn, respectively. 
 
4.3.4 Preparation of coordinate and topology files 
All simulations were performed using AMBER 14 and AmberTools 15.  The glycosylated 
proteins’ coordinate and topology files were generated using the tLEaP module with AMBER 
ff14SB forcefield (Maier et al., 2015) for the protein and GLYCAM_06j-1 forcefield (Kirschner 
et al., 2008) for the glycan atoms.  Bond, angle and charge parameters for the Zn-site (residue 
library and forcefield parameter modification files) were obtained from Dr N.F. Brás 
(University of Porto) (Brás et al., 2014).  The custom residues of the metal site were 
differentiated from those present in the AMBER ff14SB forcefield by renaming them as 
follows: first His = HIR, second His = HIT, Glu = GLR, Zn-coordinating water = WAR.  The atom 
names were also changed accordingly (NK = HIR NE2; NN = HIT NE2; ON = GLR OE1; OK = WAR 
O; Z1 = ZN1).  Neutralization was achieved by addition of 33 and 26 Na+ ions to the N- and C-
domain, respectively.  The glycoproteins were subsequently explicitly solvated by immersion 
in a pre-equilibrated isometric truncated octahedron TIP3P water box (Price and Brooks, 
2004) with a 10Å barrier between the outer atoms and the box boundary (58504 TIP3P or 
30591 TIP3P to yield volumes of 2056181 Å3 and 1155503 Å3 for N- and C-domain, 
respectively).  The final neutralized and solvated systems consisted of 188042 N-domain and 
103072 C-domain atoms.  Glycan, disulphide and metal bonding information was manually 
added to the tLEaP input script.  The bonded model, previously reported by Brás et al (Brás 
et al., 2014), was initially employed to describe Zn-coordination. With the conditions used 
here, however, this resulted in Van der Waals overlap between the WAR OK and the GLR ON 
atoms during minimization.  A hybrid bonded/non-bonded model was therefore adopted 
where HIR, HIT and GLR were explicitly bound to ZN1, but WAR non-bonded and harmonically 
restrained.  This is similar to that used in the recently parameterized M1 ZAFF (Yang et al., 
2017b).  The lower- and upper-bound linear response regions were set to 0.056Å and 4.056Å, 
respectively, with an equilibrium bond length of 2.056Å and force constant of 66.54kcal/mol 
(Brás et al., 2014).  Cpptraj was used to centre the protein prior to simulation.   
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4.3.5 Glycoprotein molecular dynamics simulations 
The following procedure was followed using the sander module to allow equilibration of the 
systems’ energy, temperature and pressure: (a) 2500 steps steepest descent and 2500 steps 
conjugate gradient solvent minimization while imposing a 50.0kcal/mol restraint on the 
solute atoms; (b) 10000 steps steepest descent and 10000 steps conjugate gradient 
unrestrained minimization; (c) constant volume solvent heating from 10.0K to 300.0K in three 
stages over 600ps with the Langevin thermostat, while imposing a 50.0kcal/mol restraint on 
the solute atoms; (d) 200ps solvent equilibration at 300K and 1bar pressure using the 
Berendsen barostat with isotropic position scaling and a pressure relaxation time of 2.0ps, 
while imposing a 10.0kcal/mol restraint on the solute atoms; and (e) 200ps unrestrained 
system equilibration at 300K and 1bar pressure using the Berendsen barostat with isotropic 
position scaling and a pressure relaxation time of 2.0ps.  Finally, unrestrained production 
dynamics were performed using the Particle Mesh Ewald Molecular Dynamics (PMEMD) code 
with GPU-acceleration.  A total of 3000 trajectory frames taken at 10ps intervals and 
including all atoms were collected for each glycoprotein during 30ns of post-equilibration 
dynamics under physiological conditions (1bar, 300K). 
 
Long-range electrostatic interactions were calculated using the Particle Mesh Ewald method 
with a non-bond interaction cut-off distance of 10.0Å.  A 2fs timestep was used throughout 
with the SHAKE restraint applied during heating, equilibration and production dynamics.  The 
wall-clock time was used as seed for the pseudo-random number generator during dynamics 
simulations. 
 
4.3.6 Trajectory analysis procedure 
Unless otherwise noted, all analyses were performed using cpptraj in AmberTools15.  The 
systems’ energies, volume, density and pressure were monitored using the 
process_minout.perl and process_mdout.perl scripts of cpptraj.  Trajectory frames where 
these properties were equilibrated were subsequently analysed after stripping of TIP3P and 
Na+ atoms. Root mean square deviation (RMSD) of all non-hydrogen or protein backbone 
atoms was assessed and time-averaged structures created by mass-weighted fitting against 
the first equilibrated frame.  The root mean square fluctuation (RMSF) of backbone protein 
atoms was also assessed. 
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To ensure biological relevance of the obtained glycan conformations and evaluate sampling 
of conformational space, variations in α1-6, α2-3 and Asn-GlcNAc glycosidic linkage torsion 
angles were monitored over time.  The glycans’ behaviour was evaluated by extracting long-
range correlated motions of all non-hydrogen atoms using principle component analysis 
(PCA).  Direction and magnitude of motion was visualized as porcupine plots and pseudo-
trajectories of the first 3 modes with the Normal Mode Wizard in VMD v.1.9.3 (Humphrey et 
al., 1996).  Furthermore, VMD v.1.9.3 (Humphrey et al., 1996) was used to assess how these 
motions contribute to protein shielding by calculating glycan occupancy VolMaps.  After 
aligning the protein backbone CA atoms of all frames to the first equilibrated frame, 
occupancy VolMaps were computed for each glycan.  A three-dimensional grid encompassing 
the glycan heavy atoms was constructed with a voxel (grid-point) size of 1Å.  The atoms were 
treated as spheres based on atomic radii and assigned a status of ‘occupied’ if its atomic 
sphere overlapped with a voxel.  Fractional occupancy of each voxel was calculated by 
normalizing occupancy over all frames to 1, written to volume maps and visualized as 
isosurfaces.  To evaluate the dynamic range of glycan motion, the volume occupied per 
glycan was quantified using the Volutil package to convert fractional maps to binary volume 
maps.  Values of ‘0’ and ‘1’ were assigned to each unoccupied and occupied voxel, 
respectively.  Occupied volume was then quantified as the sum of all occupied voxels per 
glycan.  
 
To describe the probability of possible glycan-glycan interactions identified from occupancy 
VolMaps, radial distribution functions were calculated for each glycan pair.  The sugar 
residues involved in these contacts were subsequently identified by hydrogen bond analysis.  
Similarly, interactions between each glycan and the protein were identified and their 
frequency evaluated by hydrogen bond analysis over all frames.  Clustering of the glycan 
conformations was used to extract the most representative structure for visualization of 
these hydrogen bonds.  Five clusters were created for glycan heavy atoms of each domain 
using a hierarchical agglomerative approach with an epsilon of 15.0 and the average-linkage 
algorithm. 
 
Differences between the domains’ active site solvent accessibility were visualized by 
computing solvent tunnels using Caver Analyst v1.0 (Kozlikova et al., 2014).  Owing to 
limitations in computational resources, tunnel dynamics were only calculated over the last 
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100 frames (30th ns).  The active site Zn was set as the starting point for tunnel detection with 
a 0.9Å minimum probe radius, 3Å shell radius and 4Å shell depth. Glycan atoms were 
included and WAR, ZN1 and Cl- excluded from tunnel computation with all remaining settings 
kept to default.  Resulting tunnels were visualized in PyMOL v2.0.6 (Schrodinger, 2017) and 
VMD v.1.9.3 (Humphrey et al., 1996).   
 
The Caver Analyst calculation is useful for identifying gating residues but does not, however, 
consider the tunnels’ chemical properties.  The newly developed AQUA-DUCT (Magdziarz et 
al., 2017) tool was therefore used to quantify tunnel usage during the entire 30ns simulation 
of explicitly solvated N- and C-domain.  The full trajectory was screened for any TIP3P water 
molecule that entered or exited an object region via the scope region.  The object was 
defined as water molecules within a 3Å spherical zone around the centre of masses of the 
Zn-binding histidine, glutamate and water residues as well as a facing tyrosine (Y501 in N-
domain and Y487 in C-domain).  This was contained within the scope defined as the interior 
of a convex hull of Cα atoms.  The identified molecules were then traced throughout the 
trajectory, their paths calculated and inlets at the scope boundary identified.  Paths were 
trimmed to the protein surface using the Auto Barber procedure with a maximal cutting 
sphere radius of 4.0Å.  Inlets were clustered to identify tunnels using the Barber method with 
automatic detection of outliers (small clusters of 2 inlets).  Average paths were calculated 
and smoothed along with raw paths using a combined Distance Window and Max Step 
method (dwin_mss) with 5.0Å window and step sizes for convenient visualization in PyMOL 
v2.0.6 (Schrodinger, 2017). 
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4.4  Results and Discussion 
4.4.1 Protein glycosylation and optimization 
Amino acid numbering used in this chapter is explained in section 4.3.2 and Table 4.1.  
Following attachment of the 3D glycan structures to PNGs in GLYCAM, protein-glycan and 
glycan-glycan clashes were resolved by manually adjusting the torsion angles shown in Figure 
4.4.  The torsion angles of the final structures are given in Table 4.2 and corresponded well 
to literature values for this linkage (Petrescu et al., 2004).  Presentation of the core saccharide 




Figure 4.4: Torsion angles adjusted during clash resolution at linkage of PNGs asparagine to GlcNAc.  
Torsion angles were defined as: φ = O5-C1-Nδ-Cγ; ψ = C1-Nδ-Cγ-Cβ; χ1 = N-Cα-Cβ-Cγ; χ2 = Cα-Cβ-Cγ-Nδ. 
 
 
Table 4.2: PNGs glycosidic linkage torsion angles of the GLYCAM output and MD input structures.   
Initial and final refer to GLYCAM output and MD input, respectively, with final values given in 













N9 239.8 (228.5) 166.8 198.6 208.6 
N25 227.8 172.8 177.8 201.5 
N45 267.7 174.1 191.3 178.8 
N82 233.7 165.6 (187.0) 202.3 223.5 
N117 271.6 181.5 194.4 183.9 
N131 234.3 167.8 194.7 221.7 
N289 254.9 176.6 199.8 180.6 
N416 263.9 175.8 189.1 183.6 






N36 262.4 172.2 191.3 178.6 
N54 247.7 171.8 192.9 199.0 
N73 267.6 (230.0) 183.4 (192.0) 183.7 (200.0) 174.9 (153.0) 
N119 266.7 169.1 191.5 182.5 
N301 260.9 168.9 195.1 179.5 
N550 229.4 (187.0) 167.5 (190.0) 202.2 (221.0) 210.0 (166.0) 
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4.4.2 System equilibration during MD simulation 
Equilibration of the neutralized and solvated glycoprotein systems was evaluated after each 
stage of simulation using the process_minout.perl and process_mdout.perl scripts available 
in AmberTools 15.  Plots showing the variation in energy, temperature, pressure, volume and 
density for all stages are given in Appendix A17.  During the second equilibration stage 
(unrestrained) the energy, temperature, volume and density of both domains appeared 
stable (Appendix A17 Figures A14 and A17).  These final structures were therefore used as 
input to the production dynamics simulations.  The system parameters were monitored with 
the process_mdout.perl script throughout production to identify any system instabilities.  
This showed a slight increase in density and further decrease in potential energy and volume 
over the initial 2500ps of production (Appendix A17 Figures A15 and A18).  This likely resulted 
due to the switch from NVT (constant Number of particles, Volume and Temperature) to NPT 
(constant Number of particles, Pressure and Temperature) ensemble.  The initial 250 frames 
were therefore regarded as part of the equilibration stage and excluded from analysis.  A 
further 3000 trajectory frames were obtained from 30ns of production dynamics for analyses 
after equilibration in NPT conditions. 
 
The fluctuation in atomic positions versus the first equilibrated frame was described by the 
root mean square deviation (RMSD).  The protein backbone and all protein heavy atoms 
showed deviation of about 1Å in both domains, indicating that the protein was stable and no 
large-scale conformational changes occurred (Figure 4.5).  When considering all glycoprotein 
heavy atoms, however, the RMSD is increased to around 7Å in N-domain and 5Å in C-domain, 
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a)                     b) 
      
Figure 4.5: Root mean square deviation (RMSD) during MD simulation.  
RMSD calculated for a) N-domain and b) C-domain over all glycoprotein heavy atoms, all protein heavy 




Since the simulation setup used here differed from that used by Brás et al (Brás et al., 2014), 
the zinc site’s behaviour was evaluated by monitoring the distances and angles involved over 
simulation time.  The Zn bonds and angles to HIR, HIT, GLR and WAR were stable in both 
domains, indicating correct coordination in a tetrahedral geometry (Appendix A17 Figures 
A19-A22).  Additionally, the Zn-bound WAR hydrogens were tightly bound by N-domain E362 
and C-domain E348, in agreement with this residue’s role in activating the WAR for 
nucleophilic attack in substrate hydrolysis (Sturrock et al., 2004).   
 
When simulating the dynamic behaviour of ACE in its physiologically active form, one N-
domain and two C-domain chloride ions are required since they regulate enzyme activity 
(Yates et al., 2014).  To ensure that these chloride ions did not drift during the simulation, 
their stability was monitored as well.  The N-domain chloride in the second pocket (Cl(II)) and 
C-domain chloride in the first (Cl(I)) and second pockets (Cl(II)) were stable (Appendix A17 
Figures A23 and A24).   
 
4.4.3 Glycan conformational sampling 
Glycans have a larger range of motion than the backbone of a protein owing to the flexibility 
of their α1-6 glycosidic linkages and the N-linked asparagine rotamer.  An energy barrier 
exists which determines the ease of transition between conformational states and 
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population of each glycan conformation.  In glycoproteins, the sampled conformations are 
further affected by the presence of neighbouring protein and/or glycan atoms (Yang et al., 
2017a).  If the energy barrier between low energy states is high, transition between states 
might not be observed using traditional MD approaches.  Increased sampling of glycan 
conformational space was recently described for the HIV gp120/gp41 envelope trimer using 
enhanced sampling Hamiltonian Replica Exchange with solute tempering and biasing 
potential (HREST-BP) simulations (Yang et al., 2017a).  To assess glycan conformational 
sampling and biological relevance of the most populated conformations in the current MD 
simulations, the Asn-GlcNAc, Fucα(1-6)GlcNAc, Manα(1-6)Man and NeuAcα(2-3)Gal 
glycosidic torsion angles (Figure 4.6) were monitored over all frames. 
 
a)       b) 
              
 
c)          d) 
                 
 
Figure 4.6: Glycosidic linkage torsion angles monitored during simulation to assess sampling of 
glycan conformational space.  
Torsion angle definitions were (a) Asn-GlcNAc linkage: φ = O5-C1-Nδ-Cγ ; ψ = C1-Nδ-Cγ-Cβ ; χ1 = N-Cα-Cβ-
Cγ and χ2 = Cα-Cβ-Cγ-Nδ (b) Fucα(1-6)GlcNAc linkage and (c) Manα(1-6)Man linkage: φ = O5-C1-O6'-C6'; ψ 
= C1-O6'-C6'-C5' and ω = O6'-C6'-C5'-C4' (d) NeuAcα(2-3)Gal linkage: φ = C1-C2-O3'-C3' and ψ = C2-O3'-C3'-
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Overall, the glycosidic torsion angles were comparable between the N- and C-domain 
(Appendix A18 Tables A3 to A8).  The major Asn-GlcNAc linkage conformation had φ ranging 
between 220° and 270°, a narrow ψ distribution around 170°, a narrow distribution of χ1 
around 180° with some sampling of 280° to 300° and a wide distribution of χ2 ranging from 
60° to 300° (Appendix A18 Tables A3 and A6). These Asn-GlcNAc linkage torsion angles 
correspond to populations observed upon statistical analysis of protein-glycan linkages in 
experimental crystal structures (Petrescu et al., 2004).   
 
Similar statistical analyses have also been carried out on the glycosidic torsion angles in 
glycoproteins (Petrescu et al., 1999).  In the current MD simulations the Fucα(1-6)GlcNAc 
linkage was mostly populated with φ ~280° and ψ ~180° with some minor populations (23% 
for n1 and 37% for n3) of ψ around ~70° (Appendix A18 Tables A4 and A7).  The ω angle 
displayed conformational transition with a major population (69-99%) of ~50° and a minor 
population (1-31%) of ~300° to 350° observed for most PNGs.  This compares well with the 
angles of φ = 291.8±9.6°, ψ = 204.1±22.4° and ω = 66.1±14° reported for experimental 
structures (Petrescu et al., 1999).  The Manα(1-6)Man linkages showed a narrow distribution 
of φ ~60° with minor populations (1-5%) of φ ~160° at four N-domain PNGs (Appendix A18 
Tables A4 and A7).  The ψ angles ranged from ~107° to ~211° and conformational transitions 
were observed at one C-domain PNGs (ψ = 172° for 15% and ψ = 67° for 85%).  For the ω 
angles, a major population (93-99.97%) of ~50° with conformational transition towards a 
minor population (0.03-7%) of ~300° was observed at most PNGs.  An exception is N-domain 
N416 which had a major population (85%) of ω ~180° and a minor population (15%) of ω 
~60°.  This could be the result of favourable protein-glycan interactions and will be described 
in section 4.4.8.  The conformation around this linkage is in line with experimental structures 
where the major populations have φ = 65.4±9.0°, ψ = 109.1±13.7° or 182.6±5.1° and ω = 
66.4±10.2° or 185.0±11.2° (Petrescu et al., 1999).   
 
The reported torsion angles for the terminal NeuAcα(2-3)Gal linkage obtained from 14 crystal 
structures are φ = 68.7±13.6° and ψ = 234.9±15.5° (Petrescu et al., 1999).  Again, the current 
simulations correspond well with a major population (61-99.97%) of φ ~60° and a major 
population (85-100%) of ψ ~220° (Appendix A18 Tables A5 and A8).  Additionally, a second 
population of φ ~310° was observed to be populated in up to 39% of the trajectory frames.  
An exception is the α(2-3) linkage on the 1-6 arm of C-domain PNGs N54, N73 and N119 
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where no conformational transition was found, possibly indicative of strong sialic acid 
interactions as will be described in section 4.4.9.  The α(2-3) linkage on the 1-3 arm of N-
domain PNGs N416 is also an exception since it has a 63% population of φ = 314±11° and only 
a 37% population of φ = 54±16°.    
 
Further support for the biological relevance of the simulated glycan conformations was 
derived by comparison of the time-averaged structures to all ACE experimental crystal 
structures published to date (15 N-domain and 21 C-domain crystal structures).  No 
inferences could be made regarding glycans at N-domain N9, N82 and N131 and C-domain 
N119, N301 and N550 due to low resolution in these areas.  The N25 sidechain and core 
GlcNAc2 residues aligned well (~3.5Å RMSD for the first GlcNAc) between the average 
simulated N-domain conformation and two crystal structures (PDB IDs: 2C6F and 2C6N) of 
fully glycosylated N-domain.  Even stronger support was found for the simulated N45 and 
N416 glycan conformations where the respective GlcNAc2Man and GlcNAc2Man1-3Fuc 
structures were well-resolved and superimposed with over 10 crystal structures (the first 
GlcNAc of N45 aligned with a ~3.3Å RMSD to that of PDB IDs: 2C6F, 3NXQ, 4CA6, 4BXK, 5AMC, 
4BZS, 5AM8, 5AMB, 4UFA, 6EN5, 2XYD, 5AMA and 5AM9 while the first GlcNAc of N416 
aligned with a ~3.3Å RMSD to that of PDB IDs: 5AM9, 5AMB, 4UFB, 4CA6, 5AM8, 5AMC, 
4UFA, 3NXQ, 6EN5 and 2XYD).  Similarly, the simulated C-domain N36 and N73 
conformations were supported by alignment of N-linked asparagine sidechains and core 
GlcNAc, Fuc and Man residues in more than 10 C-domain crystal structures.  The time-
averaged GlcNAc of N36 aligned with a ~3.3Å RMSD to that of PDB IDs: 2XY9, 2IUL, 4C2O, 
2YDM, 4BZR, 4CA5, 4APH, 2IUX, 1O8A, 2IUL, 3BKK, 1UZF and 3BKL while the time-averaged 
core GlcNAc of N73 aligned with a ~3.4Å RMSD to that of PDB IDs: 2XY9, 4APJ, 2IUL, 3BKK, 
3L3N, 3KBL, 4C2Q, 4APH, 4BZR, 4CA5, 4C2P, 4C2R, 4C2N and 4C2O. 
 
Since the simulated glycosidic torsion angles agree with those observed in experimental 
unrelated crystal structures as well as ACE crystal structures, these dominant glycan 
conformations are likely of biological significance.  Conformations collected over this 30ns 
timeframe were therefore used for downstream analyses since they showed sampling of 
physiologically relevant glycan conformations and the RMSD, zinc and chloride ion 
interactions were stable over this period. 
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4.4.4 Glycan occupancy of cartesian volume 
The cartesian space occupied by each glycan is influenced by its glycosidic linkage flexibility 
and the resulting frequency of conformational transitions.  The VolMap plugin and Volutil 
package in VMD v.1.9.3 (Humphrey et al., 1996) were used to visualize and quantify the 
volume occupied by each glycan.  For simplicity, from this point onwards glycans at each site 
will be referred to by a prefix ‘n’ for N-domain or ‘c’ for C-domain and their respective 
position i.e. N-domain N9/n1, N25/n2, N45/n3, N82/n4, N117/n5, N131/n6, N289/n7, 
N416/n8 and N480/n9; C-domain N36/c1, N54/c2, N73/c3, N119/c4, N301/c5 and N550/c6.  
In line with the initial hypothesis, the N-domain is surrounded by glycans whereas the C-
domain subdomain 2 is more exposed (Figure 4.7).   
 
While N-domain n1 has a large range of motion, the volume occupied by n2, n3 and n7 
individually is decreased (Figure 4.8).  These three glycans form a glycan cluster on 
subdomain 1, possibly through glycan-glycan interactions.  Porcupine plot representation of 
the direction of dominant glycan motions obtained from PCA illustrated the lateral motion 
of n2 towards n3 and n7 (Figure 4.9).  Principal components 1, 2 and 3 respectively described 
28%, 16% and 11% (cumulative 55%) of the overall variation in the N-domain and 32%, 13% 
and 9% (cumulative 54%) of the overall variation in the C-domain.   
 
A second glycan cluster is formed on subdomain 2 between the stable n5, n9 and the highly 
dynamic n6 (Figure 4.7).  By coinciding at the active site cleft, these clusters could shield the 
protein from solvent as well as stabilize its closed conformation.  N-domain stabilization 
could also be afforded by the unique n8.  This glycan is seen to snugly glide over the protein 
surface (Figure 4.9) and since it had the lowest volume occupancy, it is likely very stable.  
Solvent exposure and protein stability can further be affected by the swinging of n4 at the 
lid’s N-terminus on subdomain 1 towards subdomain 2 observed in all three principal 










   
 
      
Figure 4.7: Cartesian volume occupied by N-glycans.   
Isosurfaces represent fractional occupancy volume (normalized to 1 over all frames) contoured at 
isovalues of 0.05 (opaque) and 0.005 (transparent).  Unique a) N-domain and b) C-domain glycans are 
shown in green and blue, respectively, with the equivalent conserved glycans given in yellow, brown 
and purple.  The catalytic Zn is given as a yellow sphere, N-linked asparagines as orange spheres, C-
terminal hinges as red loops and the N-terminal lid as red helices.  The active site cleft is indicated by 
a dotted line. 
 
Although regarded as conserved based on sequence alignment, the C-domain c3 counterpart 
of n4 has a decreased dynamic range and occupies a different region of space (Figures 4.7b 
and 4.8).  Glycan c3 appears to compensate for the lack of a C-domain n7 counterpart by 
changing direction and approaching the space occupied by this unique N-domain glycan.  In 
turn, the unique C-domain c6 transitions from the protein C-terminus towards the lid’s N-
terminus to perform the role of N-domain n4 (Figure 4.7).  However, while the net motion of 
n4 described by all three principal components was towards subdomain 2, c6 was more 
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The conserved glycan c1 has a lower dynamic range than its N-domain counterpart n3 and 
occupies a slightly different region (Figure 4.7).  This is likely due to glycan-glycan interactions 
upon formation of a glycan cluster on subdomain 1.  Although c3 occupies the space of n7, it 
does not contribute to cluster formation.  Instead, the C-domain cluster is formed by c1, c2 
and the unique c5 which occupies a space equivalent in location and volume to the unique 
N-domain n2.   
 
No cluster is formed on the C-domain subdomain 2 due to lack of n5 and n9 counterparts.  
This likely influenced the location, volume occupancy and direction of motion of the 
conserved c4 (Figure 4.7-9).  Additionally, there is no compensation for lack of a C-domain 




Figure 4.8: Volume occupied by each glycan’s heavy atoms calculated over all frames of MD 
simulation.   
Glycans are represented as green bars for N-domain and blue bars for C-domain with the 

















               
Figure 4.9: Porcupine plot representation of the dominant glycan motions. 
Principal components 1 (green), 2 (cyan) and 3 (magenta) respectively are shown for a) N-domain and 
b) C-domain with porcupine quills illustrating the direction and magnitude of glycan motion.  The N-
terminal lid is coloured red, N-linked asparagine residues given as orange spheres and the active site 
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4.4.5 Glycan-glycan interactions 
To validate the existence of the proposed glycan clusters and strength of the contacts, radial 
distribution functions were calculated between glycan pairs.  For the most prevalent 
interactions, hydrogen bond analysis was performed with a 3Å bond length cut-off to identify 
directly interacting sugars (this did not consider water-mediated bonds or interactions not 
involving hydrogen bonds).   
 
The minimal n1–n2 and n2–n3 distances between N-domain lid glycans ranged from ~15-50Å 
and interaction probability was low (Figure 4.10).  Although the minimal n2–n7 distance 
decreased to ~2-50Å, interaction probability remained low.  The minimal n3–n7 distance, 
however, ranged from ~2-40Å and probability of this interaction was increased.  The 
decreased probability of the aforementioned individual interactions might be attributed to 
competition between n1, n3 and n7 for n2 binding.  The subdomain 1 cluster is thus formed 
by a strong n3–n7 interaction, assisted by interactions of n2 with n7 and, to a lesser extent, 
n1 and n3.  Interaction between n5 and n9 at the N-domain subdomain 2 were highly 
probable although the minimal distance still extended to ~40Å, reflecting the dynamic nature 
of glycans.  Hydrogen bonds were frequently detected between the n5 sialic acid (0SA) or 
mannose (2MA) and n9 sialic acid (0SA) or fucose (0fA) residues (Table 4.3).  Despite its large 
range of motion, n6 is seen to interact with n5.  The subdomain 2 cluster is thus formed by a 
strong n5–n9 interaction, assisted by n6.  Since the probability of n5 interaction with n3 is 
rather low, the glycan clusters on each subdomain appear distinct.  They could, however, still 
function synergistically in shielding the N-domain active site cleft. 
 
 
Figure 4.10: Probability of N-domain glycan-glycan interaction (radial distribution function).   
Interacting glycan pairs are coloured according to the legend. 
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Table 4.3: N-domain glycan-glycan hydrogen bonds.   
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies indicated 
in parentheses and acceptor residue names italicized.   
Glycan Donor sugar - acceptor sugar 
(% frames) Donor Acceptor 
n5 n9 
0SA O4 - UYB O2N (27.7) 
0SA O9 - 0SA O4 (24.8) 
0SA O7 - 0fA O3 (11.1) 
2MA O4 - 0SA O4 (6.1) 
2MA O4 - 0SAO8 (5.5) 
n9 n5 
0fA O2 - 0SA O5N (71.9) 
0fA O3 - 0SA O7 (34.6) 
0SA O4 - 2MA O3 (9.3) 
0fA O3 - 0SA H7O (5.9) 
                                 0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc,  




Based on the volume occupancy, N-domain n3 and n2 are equivalent to C-domain c1 and c5, 
respectively (Figure 4.7).  Yet, the probability of n2–n3 interaction is markedly lower than 
that of c1–c5 (Figure 4.11).  This is likely because c5 and c1 are more proximal than n2 and 
n3.  Probability of c1–c5 interaction is further increased by decreasing the c1 dynamic range 
through interaction with c2.  Although the volume occupied by C-domain c3 was comparable 
to N-domain n7 (Figure 4.8), the probability of c1–c3 interaction is markedly lower than n3–
n7 (Figure 4.11).  Given that c3 is located on the lid’s N-terminus, it is likely unable to reach 
c1 on the lid’s C-terminus.  The C-domain subdomain 1 cluster is thus formed by strong 
interactions of c1 to c2 and c5 involving sialic acid (0SA), galactose (3LB), N-
acetylglucosamine (4YB), mannose (2MA and VMB) and fucose (0fA) residues (Table 4.4). 
 
 
Figure 4.11: Probability of C-domain glycan-glycan interaction (radial distribution function). 
Interacting glycan pairs are coloured according to the legend. 
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Table 4.4: C-domain glycan-glycan hydrogen bonds. 
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies indicated 
in parentheses and acceptor residue names italicized.   
Glycan  Donor sugar - acceptor sugar 
(% frames) Donor Acceptor 
c2 c1 0fA H4O - 0SA O1B (5.9) 0fA H3O - 0SA O1B (5.1) 
c1 c5 
VMB O4 - 3LB O6 (26.6) 
2MA O3 - 0SA O1A (26.3) 
2MA O4 - 0SA O1B (26.2) 
2MA O4 - 0SA O1A (17.2) 
4YB O6 - 3LB O2 (15.8) 
VMB O2 - 4YB O3 (12.9) 
2MA O3 - 0SA O1B (11.5) 
4YB O6 - 0SA O1B (10.6) 
2MA O3 - 3LB O6 (10.1) 
0SA O8 - 0SA O1B (9.8) 
0SA O9 - 0SA O1A (9.7) 
VMB O2 - 4YB O2N (7.5) 
4YB O6 - 4YB O6 (7.1) 
0SA O9 - 0SA O1B (6.9) 
0SA O7 - 0SA O1B (5.5) 
2MA O4 - 2MA O3 (5.2) 
c5 c1 
4YB O3 - 2MA O3 (15.3) 
3LB O6 - 2MA O4 (14.6) 
3LB O6 - VMB O2 (10.4) 
0SA O8 - 3LB O2 (9.5) 
0SA O8 - 0SA O8 (7.8) 
0SA O9 - 4YB O6 (6.9) 
3LB 06 - 4YB O6 (5.1) 
                                 0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc,  
                                 UYB =1st core GlcNAc, VMB = 1st Man linked to core GlcNAc 
 
 
4.4.6 Flexibility of the underlying protein 
Dynamic behaviour of the two domains was assessed by comparing the root mean square 
fluctuation (RMSF) of their backbone protein atoms.  Although the overall profile is very 
similar between N- and C-domain, some differences were noticed which could provide insight 
into their distinct thermal stabilities (Figure 4.12). 
 
Backbone flexibility of C-domain N-terminal residues 1-100 is markedly increased over N-
domain.  These residues are located at the lid’s N-terminus where differences in glycan 
occupancies were observed (Figure 4.13).  Increased C-domain backbone flexibility was also 
noticed towards the C-terminal sequence.  Interestingly, these residues located not only to 
subdomain 2 but also hinge region 3 and an active site helix harbouring the zinc-coordinating 
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glutamate (Figure 4.13).  Considering the location of unique glycans in relation to these 
regions of differential flexibility, glycosylation likely dampened the N-domain’s dynamics. 
 
 
            
 
Figure 4.12: Comparison of protein backbone flexibility between the domains.   
Root mean square fluctuation (RMSF) of N- and C-domain backbone atoms are given in green and blue, 
respectively, with lines indicating PNGs locations after structural alignment.  N-domain residue 
numbering is indicated on the x-axis and C-domain residue numbering as a blue ruler above the graph 
due to the presence of gaps in the sequence alignment. 
 
 
Two flap-like structures formed via cysteine disulphide bonds were observed on the surface 
of both domains.  The subdomain 1 flap comprises a loop adjacent to the antiparallel beta 
sheets found parallel to the active site zinc-binding motif (Figure 4.13).  Interestingly, the 
subdomain 2 flap harbours a conserved PNGs (N-domain n6, C-domain c4) and separates two 
helices lining the active site cleft.  Despite conserved glycosylation of this flap, flexibility of 
the adjacent helix 8 is increased in the N-domain.  




      
b) 
        
 
Figure 4.13: Location of residues with differential backbone flexibility.  
a) N-domain (in green) and b) C-domain (in cyan) structures are given with regions of increased or 
decreased RMSF over the opposite domain indicated in red or blue, respectively.  N-linked 
asparagines, catalytic Zn and Zn-binding residues are shown as orange spheres, a yellow sphere and 
yellow sticks, respectively.  The active site cleft is indicated by a dotted line and the surface flap 
structures by arrows. 
 
Differential flexibility of the C-terminal cleft-lining helix 8 is the result of unique protein as 
well as glycan-glycan interactions.  As described in Chapter 2, N-domain hinging to a closed 
state is mediated by contact between S357 of subdomain 1 and E431 of subdomain 2.  This 
is accompanied by transition from a D354-R350 to D140-R350 salt bridge and a resulting 
inward motion of helix 8 (Chapter 2).  Interaction of n6 with n5/n9 of the subdomain 2 glycan 
cluster, however, would cause a shift in the subdomain 2 flap towards the N-terminal cleft-
lining helix 7 (Figure 4.14).  This motion would translate to a shift of helix 8 and formation of 
an alternate D140 salt bridge to the subdomain 1 flap residue K321.  The large number of 
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hinging and strengthening of interactions over the active site cleft upon closure.  This 
mechanism is in line with the exceptionally high dynamic range detected for n6 (Figure 4.8). 
 
 
Figure 4.14: Representative N-domain structure illustrating inter-subdomain interactions proximal 
to n6.   
Glycan n5 is shown as dots and n6 as CPK spheres with standard Symbol Nomenclature for Glycans 
(SNFG) colouring (Varki et al., 2015).  N-linked asparagines are shown as orange spheres, interacting 
residues as grey sticks and dotted lines, N-terminal lid helices in green and the active site Zn as a yellow 
sphere.  Blue indicates the regions stabilized by N-domain glycans.  The cleft-lining helices and 
subdomain 2 flap is coloured magenta.  Residues at the S2’ subdomain interface are italicized.  Arrows 
indicate proposed motion upon interaction of n5 with n6. 
 
In the C-domain, lack of a favourable S2’ subdomain interface increases the stability of helix 
8 by decreasing the likelihood of hinging towards a closed S2’ conformation (as discussed in 
Chapter 2).  This is further enhanced by a stable hydrogen bond between H317 of the 
subdomain 1 flap and E126 of helix 8 (Figure 4.15).  Although H317 is conserved, the shorter 
N-domain counterpart D140 renders this interaction less likely than D140-R350 or D140-K321 
salt bridge formation.  In the absence of C-domain counterparts to n5 and n9, sideways 
motion of the subdomain 2 flap would also not occur, in line with the decreased dynamic 
























Figure 4.15: Representative C-domain structure illustrating inter-subdomain interactions proximal 
to c4.   
N-linked asparagine is shown as orange spheres, interacting residues as grey sticks, N-terminal lid 
helices in green and the active site Zn as a yellow sphere.  Blue indicates the equivalent regions to 
those stabilized by glycans in the N-domain.  The cleft-lining helices and subdomain 2 flap is coloured 
magenta.  For clarity, c4 atoms are omitted.  Residues at the S2’ subdomain interface are italicized. 
 
4.4.7 Glycan interactions with the N- and C-domain 
The mechanisms whereby glycans increased protein stability and the contribution of these 
towards thermal stability was investigated by analysing glycan-protein hydrogen bond 
frequencies.  Only hydrogen bonds which were present in more than 5% of the simulation 
were considered.  To visualize these hydrogen bonds, the most prevalent glycan 
conformations were extracted using clustering analysis.   
 
Apart from n1, n6 and n9, all N-domain glycans formed numerous hydrogen bonds to the 
protein (Appendix A19 Figures A25-A26 and Tables A9-A10).  Frequent hydrogen bonds were 
also observed between the C-domain and glycans c1, c3 and c6 (Appendix A19 Figures A27-
A28 and Tables A11-A12).  Although the occupancy volumes suggested that C-domain c5 
plays a similar role to N-domain n2, the protein interaction to c5 was markedly lower than 
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4.4.8 The role of glycosylation in N-domain thermal stability 
As discussed in Chapter 1 sections 1.3.2 and 1.3.3, glycans n2, n3, n7, n8 and n9 are involved 
in N-domain folding and thermal stability.  The n3 and n7 fucose, galactose and sialic acid 
residues were observed to hydrogen bond residues of N-domain subdomain 1, all of which 
are unique except E49 and R344 (Figure 4.16).  The strength of these interactions is 
exemplified by their presence in a large proportion of the simulation (Appendix A19 Figures 
A25-A26 and Tables A9-A10).  Apart from the glycan interactions formed to n3 in the 
subdomain 1 cluster, this glycan bridges over the tips of parallel helices 2 and 3, thus ensuring 
their concerted motion and stabilizing the lid’s C-terminus (Figure 4.16).  This, in turn, might 
indirectly stabilize the adjacent 317-352 cysteine disulphide-containing active site loop.  
Direct stabilization of this loop is achieved via n7 sialic acid and galactose hydrogen bonding 
to the conserved R344 and unique E315 and G316.  Furthermore, stretching of n7 over helix 
17 to bind R344 could stabilize the loop on which it resides (hinge region 2) as well as the 
adjacent active site loop harbouring Q259.  Stability in this region is important since Q259 
forms part of the oxyanion hole responsible for binding the substrate’s C-terminal 











Figure 4.16: Representative N-domain structure showing glycan-protein hydrogen bonding at n3 and 
n7.   
Glycans are shown as CPK spheres with standard Symbol Nomenclature for Glycans (SNFG) colouring 
(Varki et al., 2015), N-linked asparagines as orange spheres, interacting N-domain residues as grey 
sticks, N-terminal lid helices (helices 1-3) in green, regions proposed to be stabilized by glycan 
interactions in blue, active site Zn as a yellow sphere and the conserved oxyanion residue Q259 Cα as 
a black sphere.  All interacting residues except E49 and R344 are unique.  Helix 17 is labelled as α17. 
 
Active site loop stabilization is further augmented by the presence of n2.  Apart from n2’s 
role in formation of the subdomain 1 glycan cluster, it forms various stable hydrogen bonds 
to the protein (Appendix A19 Figures A25-A26).  The unique lid residues Q22 and Q30 
adjacent to n2 were bound in more than 10% of the simulation (Appendix A19 Tables A9-
A10).  Interestingly, very strong interactions were observed between the core N-
acetylglucosamine and the unique R340 located on the cysteine disulphide-containing active 
site loop (Figure 4.17).  Through a sweeping motion of the n2 1-3 arm, transient sialic acid 
interactions also occurred to the conserved Q371, R380 and unique C-terminal residues R541 
and Q545.  This motion might not only stabilize the lid but also assist in its closure at the N-
terminal cavity.  Since R380 resides on a loop described as hinge region 3 (Watermeyer et al., 
2006) parallel to the cysteine disulphide-containing active site loop, binding to n2 might 
affect hinging and confer stability to the adjacent Zn-coordinating helix 18.  Further N-domain 
C-terminal stabilization was achieved by very strong hydrogen bonds to the unique E518, 
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4.17).  Since n8 is located on hinge region 4 these interactions might not only affect thermal 




Figure 4.17: Representative N-domain structure illustrating glycan-protein hydrogen bonding at n2 
and n8.   
Glycans are shown as CPK spheres with standard Symbol Nomenclature for Glycans (SNFG) colouring 
(Varki et al., 2015), N-linked asparagines as orange spheres, interacting N-domain residues as grey 
sticks, N-terminal lid helices in green, regions proposed to be stabilized by glycan interactions in blue, 
active site Zn as a yellow sphere and the conserved oxyanion residue Q259 Cα as a black sphere.  All 
interacting residues except Q371 and R380 are unique. 
 
 
Analogous to n3, n4 stabilizes the lid’s N-terminus by forming a bridge between helices 2 and 
3 upon binding to the unique R89 (Figure 4.18).  It further contributes to C-terminal protein 
stabilization and closure of the N-terminal cavity by interacting with the unique N203.  Since 
n4 is located on hinge region 1, transient interaction to subdomain 2 might drive the lid’s 

























Figure 4.18: Representative N-domain structure illustrating glycan-protein hydrogen bonding at n4. 
Glycans are shown as CPK spheres with standard Symbol Nomenclature for Glycans (SNFG) colouring 
(Varki et al., 2015), N-linked asparagines as orange spheres, interacting N-domain residues as grey 
sticks, N-terminal lid helices in green, regions proposed to be stabilized by glycan interactions in blue, 
active site Zn as a yellow sphere and the conserved oxyanion residue Q259 Cα as a black sphere. 
 
Glycans n2, n3 and n7 thus synergistically stabilize the cysteine disulphide-containing active 
site loop while synergism between n2, n4 and n8 contributes to C-terminal stabilization.  
Furthermore, synergism between n2, n4, n7 and n8 has the potential to stabilize the entire 
protein by affecting hinging at regions 3, 1, 2 and 4, respectively. 
 
Although n9 rarely interacts with protein residues, it might contribute to protein stabilization 
through formation of the subdomain 2 glycan cluster.  The strong n5 – n9 glycan interactions 
restrict n5’s dynamic range and strengthen its binding to H483 and the N480 delta nitrogen 
(Figure 4.19).  Cluster formation likely also forms a barrier to prevent the N480-containing 
loop from exiting the protein.  This long loop extends from the surface into the active site 
where it terminates with Y498, an oxyanion hole-forming residue critical for binding the 











Figure 4.19: Representative N-domain structure illustrating glycan-glycan and glycan-protein 
hydrogen bonding at n5 and n9.   
Glycans are shown as CPK spheres with standard Symbol Nomenclature for Glycans (SNFG) colouring 
(Varki et al., 2015), N-linked asparagines as orange spheres, interacting N-domain residues as grey 
sticks, N-terminal lid helices in green, regions proposed to be stabilized by glycan interactions in blue, 
active site Zn as a yellow sphere and the conserved oxyanion residues Q259 Cα and Y498 Cα as black 
and pink spheres, respectively.  Only n5 and n9 glycan atoms are shown for clarity. 
 
Experimentally, it has been observed that the combined loss of n7, n8 and n9 leads to protein 
misfolding and that folding can be restored by reintroduction of either of these in the 
presence of one or more N-terminal glycans (Anthony et al., 2010).  Glycans n7, n8 and n9 
together, however, allow protein folding in the absence of N-terminal glycans.  The molecular 
dynamics simulations provided insight into the basis for this specific glycan requirement.  
During protein folding and processing, combined stabilization of the lid, active site loops, 
hinges as well as the protein C-terminus is crucial.  This can be achieved by hydrogen bonding 
to a single glycan at each of these regions.  Synergistic glycan interactions, however, are 
required to maintain the protein fold and prevent unravelling of critical substrate-binding 
loops at elevated temperatures.  It has been shown experimentally that n2, n3, n7, n8 and 
n9 synergistically govern thermal stability (Anthony et al., 2010).  This agrees with the in silico 
data presented here which revealed their role in stabilizing hinge regions 2-4, two crucial 
substrate-binding loops and a cysteine disulphide-containing active site loop proximal to the 
Zn binding site.  The latter appears to be the most labile since its stabilization necessitates 
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4.4.9 The role of glycosylation in C-domain thermal stability 
Analogous to what was observed at the N-domain n3, c1 stabilized the lid’s C-terminus by 
forming a bridge between helices 1 and 2 upon sialic acid interaction to E25, Q47, K48 and 
Q51 (Figure 4.20).  Although c5 and N-domain n2 appeared to occupy similar regions of space, 
c5 is strongly bound to c1 and only rarely contacts the protein at lid residues E28 and W31.  
Glycan c5 thus did not stabilize hinge region 3 and its more distal location from hinge region 
2 likely prevents stabilization of the loop harbouring oxyanion hole residue Q245.  Through 
formation of the subdomain 1 glycan cluster it could, however, stabilize the cysteine 




Figure 4.20: Representative C-domain structure illustrating glycan-protein hydrogen bonding at c1 
and c5.   
Glycan c1 is shown as CPK spheres and c5 as dots with standard Symbol Nomenclature for Glycans 
(SNFG) colouring (Varki et al., 2015).  N-linked asparagines are shown as orange spheres, interacting 
C-domain residues as grey sticks, N-terminal lid helices in green, active site Zn as a yellow sphere and 
the conserved oxyanion residue Q245 Cα as a black sphere.  Blue indicates the equivalent regions to 
those stabilized by glycans in the N-domain. 
 
Along with c1, c2 of the subdomain 1 cluster was also observed to hydrogen bond to helix 1 
and 2 lid residues (Figure 4.21).  These sialic acid interactions to E13, K58 and Q62 are, 
however, transient in nature and unlikely to offer much stability to the lid’s N-terminus 
(Appendix A19 Figures A27-A28 and Tables A11-A12).  Although c3 and N-domain n4 are both 
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domain n7 more than n4.  By forming a strong sialic acid interaction to N325, c3 stabilizes 
the cysteine disulphide-containing active site loop and appears to compensate for lack of a 
C-domain n7 equivalent (Figure 4.21).  However, interaction to D360 was only transient and 
hinge 3 stabilization thus inferior to that of n7.  In forming these interactions, c3 is also unable 




Figure 4.21: Representative C-domain structure illustrating glycan-protein hydrogen bonding at c2 
and c3.   
Glycans c1, c2 and c3 are shown as CPK spheres and c5 as dots with standard Symbol Nomenclature 
for Glycans (SNFG) colouring (Varki et al., 2015).  N-linked asparagines are shown as orange spheres, 
interacting C-domain residues as grey sticks, N-terminal lid helices in green, active site Zn as a yellow 
sphere and the conserved oxyanion residue Q245 Cα as a black sphere.  Blue indicates the equivalent 
regions to those stabilized by glycans in the N-domain. 
 
Occupancy volume analysis suggested that c6 could perform the same role as N-domain n4.  
Although this glycan formed very strong hydrogen bonds to the protein (Appendix A19 
Figures A27-A28 and Tables A11-A12), these were between the core N-acetylglucosamine 
and the proximal S192, D196 and M551 residues of subdomain 2 (Figure 4.22).  The lack of 
interactions between c6 and the lid’s N-terminus could be attributed to the C-terminal 
location of N550.  This likely contributes to the C-domain’s increased backbone flexibility of 
subdomain 2 and the lid’s N-terminus.  Furthermore, this likely renders the C-domain N-



















Figure 4.22: Representative C-domain structure illustrating glycan-protein hydrogen bonding at c6. 
Glycans are shown as CPK spheres with standard Symbol Nomenclature for Glycans (SNFG) colouring 
(Varki et al., 2015).  N-linked asparagines are shown as orange spheres, interacting C-domain residues 
as grey sticks, N-terminal lid helices in green, active site Zn as a yellow sphere and the conserved 
oxyanion residue Q245 Cα as a black sphere.  Blue indicates the equivalent regions to those stabilized 
by glycans in the N-domain. 
 
Experimentally, it has been observed that C-domain thermal stability is drastically decreased 
upon removal of c5 and c6 (O'Neill et al., 2008).  This decrease is slightly augmented upon 
additional removal of c2 and c4.  As seen for the N-domain, stabilization of the cysteine 
disulphide-containing active site loop thus appears most crucial for protein stability.  This in 
silico study is the first investigation into the basis for differential thermostability of the two 
ACE domains and, importantly, suggests that the N-domain is more resistant to thermal 
degradation than C-domain due to an increase in oxyanion hole, hinge, lid and subdomain 2 
stabilizing interactions.  Unique n2 and n4 N-domain interactions and cluster formation 
between n5, n6 and n9 likely increased the lid and subdomain 2 stability over C-domain.  
Unique N-domain interactions with n4, n7 and n2 further increased the stability of hinges 1-
3 while hinge 4 was equally flexible in both domains.   
 
N- and C-terminal protein stability, however, also depends upon the nature of their 
comprising residues.  In the N-domain, hydrogen bonds are observed between unique polar 
residues lining the active site cleft (Figure 4.23a).  By stretching across the cleft, these 
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counterparts, in contrast, are mostly hydrophobic with only one potential hydrogen bond 
detected (Figure 4.23b).  This likely contributes to the C-domain’s increased flexibility and 
ultimately could increase its active site exposure.  
 
Glycan forcefields have been validated by comparing the results of solvated glycans obtained 
from simulation to that obtained by experimental nuclear magnetic resonance. At present, 
there is no means to adequately validate the extent to which glycan-glycan or glycan-protein 
interactions predicted by the forcefield are populated in reality.  Since the simulated 
interactions of glycosylated N- and C-domain ACE presented here agree with melting 
temperature and protein expression experiments, it nevertheless provides a qualitative 
molecular basis for the experimentally observed involvement of N-linked glycosylation in ACE 






Figure 4.23: Contribution of unique N- and C-domain cleft-lining residues towards protein stability.  
a) N-domain and b) C-domain are given in green and cyan, respectively.  The region with lower N-
domain backbone flexibility is coloured blue in a) and red in b). The active site cleft is indicated by an 
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4.4.10 Implications for a minimally glycosylated sACE glycoform  
As discussed in Chapter 1 section 1.4.2, attempts at obtaining a minimally glycosylated sACE 
form have thus far failed due to misfolding or inter-domain linker cleavage of N>Q mutant 
sACE proteins.  The in silico data presented here offers insight into this phenomenon.  A sACE 
model was constructed from representative fully glycosylated N- and C-domain 
conformations.  The N-domain was orientated normal to the molecule’s long axis while the 
C-domain was inclined by ~60°, as suggested by low resolution electron microscopic 3D 
reconstruction of porcine sACE (Chen et al., 2010).  In accordance with their reconstruction, 
the domains were separated by 2.5nm. 
Glycans which could potentially shield and/or stabilize the linker were then identified to 
propose a minimally glycosylated sACE variant resistant to linker proteolysis. In this sACE 
model, the N-domain hinges 2 and 4 and its C-terminal helices are proximal to the C-domain 
N-terminal lid (Figure 4.24), reminiscent of the arrangement observed via X-ray 
crystallography between molecules of neighbouring N-domain asymmetric units (discussed 
in Chapter 2 section 2.6.12).  Instability at any of these regions could destabilize the inter-
domain linker and possibly increase its exposure by altering the relative domain orientation.  
The protein might then be susceptible to cleavage into single domains.  Glycan n4 and n8 can 
function to stabilize the N-domain C-terminal helices and hinge 4.  The adjacent hinge 2 can 
be stabilized by n7.  This would also ensure folding and thermal stability by binding to flap 1.  
Although fifteen minimally glycosylated N-domain (n3-n8-n9) crystal structures illustrate that 
equivalent stabilization of the lid, flap 1 and hinge 2-flanking helices can be obtained by 
binding of polyethylene glycol molecules, glycan n7 would nevertheless be required during 
protein expression.  The glycan cluster formed by n5 and n9 is proposed to be essential since 
n9 resides on a very long loop.  Lack of stabilization by this cluster might be transferred to 
the neighbouring helices (coloured light blue on Figure 4.24) and destabilize hinge 4 or the 
C-terminal helices (coloured black on Figure 4.24).  Experimentally, a 70% decrease in linker 
cleavage was observed upon introduction of n6, and thus glycan clustering, to an n2-n3-n8-
n9-c1-c3 sACE (Nkoe, 2014).  Based on the MD simulations, this decrease could be 
augmented by rather including n5 since its n9 interaction is stronger.   
 
On the C-domain, the glycan cluster formed by c1 and c5 is necessary to stabilize the lid’s C-
terminus.  Lid stability is further ensured by stabilizing the adjacent flap 1 via c3.  Analogous 
to n7, this is likely also required for correct folding in cell culture.  Furthermore, there is the 
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possibility of inter-domain glycan clustering via c1/c5–n7 and c3–n8 or inter-domain glycan 
to protein contacts.  It is therefore proposed that the minimal glycan requirement for a stable 
sACE protein for structure determination via X-ray crystallography is n4,5,7,8,9 c1,3,5 (53% 
of the wild-type carbohydrate content). 
 
 
      
Figure 4.24: Model of a proposed minimally glycosylated sACE variant.  
The N-terminal lid regions are shown in green, N-linked asparagines as orange spheres and the stalk 
as a black coil (after modelling it into an extended conformation).  The inter-domain linker was omitted 
since it packed onto the protein surface in the truncated N-domain structure.  The N-domain C-
terminal helices are coloured black, hinges 2 and 4 dark blue and the helices connecting n8 to the 
n5/n9 cluster light blue.  Glycan atoms of the proposed minimally glycosylated sACE are shown as 































Chapter 4: Influence of N-glycans on ACE dynamics 
159 
 
4.4.11 The role of glycosylation in regulating oxidative inactivation 
To investigate the molecular mechanism underlying the C-domain’s increased susceptibility 
to oxidative inactivation, Caver Analyst v1.0 (Kozlikova et al., 2014) was used.  All tunnels 
providing access to the active site Zn from bulk solvent were computed dynamically for the 
two domains over the last 100 trajectory frames (1ns).  Both domains displayed tunnels in 
the prime and non-prime subsites (Figure 4.25).  The C-domain, however, had a greater 
number of distinct tunnel clusters, particularly at the non-prime lid region.   
         
                     
                                            
                       
Figure 4.25:  Solvent access tunnels calculated using Caver Analyst v1.0 leading from the protein 
surface to the active site Zn. 
a) N-domain and b) C-domain tunnels depicted as spheres for the first analysed frame with glycan 
atoms in green and cyan, respectively, and the lid helices indicated by the dotted ellipse. c) N-domain 
and d) C-domain tunnels depicted as lines with all 100 frames superimposed.  Each colour represents 
a distinct cluster with the number of lines per cluster indicating the number of frames where it was 
accessible. The prime and non-prime subsites flanking Zn are indicated by dotted arcs. 
 
While the N-domain had one major access tunnel between the subdomain 1 and 2 flaps (cyan 
spheres in Figure 4.25a), additional tunnels formed in the C-domain at the S2’ subdomain 
interface (Figure 4.26).  When aligning the two domains it was observed that unique S2’ 
a) b) 
c) d) 





Chapter 4: Influence of N-glycans on ACE dynamics 
160 
 
residues of the N-domain overlapped with the C-domain tunnels.  These residues thus limit 
solvent access between the subdomains in the N-domain by interacting via hydrogen and 
ionic bonds (as detailed in section 4.4.6, Figure 4.14).  In the C-domain, replacement of these 
gating residues by smaller and/or hydrophobic counterparts allowed tunnel formation and 
thus increased solvent access.  Increased ROS influx via this subsite can lead to oxidation of 
the Zn-coordinating histidine residues as well as the substrate-binding oxyanion hole 
tyrosine.   
                          
 
Figure 4.26: Solvent access tunnels unique to the C-domain S2’ subsite. 
After alignment of the two domains, N-domain protein (grey cartoon and green sticks) was displayed 
with C-domain S2’ tunnels obtained from Caver Analyst (lines).  All labelled residues are unique to the 
N-domain (Q355 overlaps with the blue unique C-domain tunnel).  Substrate-binding oxyanion hole 
residues are shown as yellow sticks and Zn as an orange sphere. 
 
A greater number of distinct tunnel clusters were also observed in the C-domain non-prime 
subsite (Figure 4.25c-d).  This likely resulted from the C-domain’s increased lid flexibility and 
lack of c3 binding to subdomain 2.  In the N-domain, tunnel formation is restricted by 
decreased lid and subdomain 2 flexibility via the ionic zipper, subdomain 2 glycan clustering 
and protein hydrogen bonding to n4 and n8.  In bridging between the subdomains, n4 further 
provides a physical barrier to solvent access which is not duplicated by the more distal C-
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Although these calculations are useful to identify residues gating access to the active site, the 
tunnel-lining residues’ chemical properties are ignored and no information is provided 
regarding tunnel usage.  The AQUA-DUCT tool (Magdziarz et al., 2017) was therefore used to 
trace the influx of water molecules and quantify tunnel usage in the explicitly solvated 
proteins during 30ns simulation.  This agreed with the Caver Analyst results and showed 
water influx via the prime, non-prime and flap regions (Figure 4.27).   
 
                                                                                              
 
     
 
Figure 4.27: Quantitative analysis of water influx during 30ns MD simulation using AQUA-DUCT.  
a) N-domain and b) C-domain object and scope regions are given as orange and purple convex hulls 
encompassing the Cα atoms and the Zn-binding site, respectively.  Zn and Cl ions are given as orange 
and green spheres, respectively, and the lid region coloured lime green.  Clusters of inlets detected for 
water molecules during 30ns simulation are displayed as purple, tan, cyan and blue-grey spheres.  The 
averaged smoothed paths followed by these water molecules inside the scope are displayed as lines.  
Incoming, object and outgoing parts of paths are coloured red, green and blue, respectively.  The 
number of water molecules entering or exiting each tunnel are annotated with arrows.  Outliers do 
not below to any cluster of inlets.  The number of water molecules entering the object but never 
exiting the scope are indicated as well.   
 
The main site for entry and egress in both domains was the prime subsite with very little 
usage of the flap region tunnels (Appendix A20 Tables A13-A14).  This finding is interesting 
since the ACE crystal structures showed that access to the prime subsite is restricted to a 





a) b) flaps flaps 
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N-terminal pore (Sturrock et al., 2004).  Normal mode analyses also suggested that substrate 
entry occurs via the non-prime subsite through a shift in the N-terminal lid helices’ positions 
(Watermeyer et al., 2006; Anthony et al., 2010).  The in silico MD results presented here thus 
suggest for the first time that substrate/solvent entry or product/solvent release can occur 
through either subsite and that the prime subsite might be preferred.  In future, this could 
have implications for understanding the basis for domain-selective substrate binding since 
the prime subsite contains numerous unique residues which could gate substrate access.    
 
Water influx to the C-domain active site was increased by 4- to 5-fold at both the prime and 
non-prime inlets and a significantly greater number of these molecules got stuck (44 never 
left the scope region again) (Figure 4.27; Appendix A20 Tables A13-A14).  They did not reside 
in distinct pockets and instead roamed widely through the prime and especially the non-
prime subsites (Figure 4.28).  The space covered by the 10 molecules that got stuck in the N-
domain was noticeably narrower.  Although the unique N-domain prime subsite residues and 
glycan n4 do not completely prevent access to the active site, they thus do indeed decrease 
the influx, as suggested by the Caver Analyst results. 
 
 
            
 
Figure 4.28: Paths followed by water molecules that remain within the scope after entry during 30ns 
MD simulation (calculated with AQUA-DUCT).   
The object and scope regions for a) N-domain and b) C-domain are given as orange and purple convex 
hulls encompassing the Cα atoms and the Zn-binding site, respectively.  Zn and Cl ions are given as 
orange and green spheres, respectively, and the lid region coloured lime green.  Clusters of inlets 
detected for water molecules during 30ns simulation are displayed as purple, tan, cyan and blue-grey 
spheres.  The smoothed paths followed by water molecules that never exit the scope again are 
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There is a strong correlation between solvent accessibility and the intrinsic chemical 
reactivity of an amino acid to oxidative modification (Huang et al., 2015). To propose a 
mechanism whereby 1,8-ANS binding could protect against oxidative inactivation, the 
proximity of readily oxidizable active site residues to C-domain tunnels was visualized.  The 
Caver Analyst results were used for simplicity.  Values describing the intrinsic reactivity to 
oxidation (Ri) of each amino acid were taken from Huang et al (Huang et al., 2015) and 
mapped onto the C-domain structure.  In the prime subsite, tunnels between the subdomain 
1 and 2 flaps and the S2’ subdomain interface could contribute to oxidative inactivation of 
both domains via oxidation of the substrate-binding oxyanion hole tyrosine (Figure 4.26).  
The C-domain S2’ tunnels may further increase oxidative inactivation over N-domain by 
enhancing ROS influx to the readily oxidizable zinc-binding histidine residues (Figure 4.26 and 
4.29).  Oxidation of these key residues would result in a loss of Zn-coordination and thus, 
protein inactivation.   
 
Residues in the non-prime subsite were observed to have high reactivities to oxidation 
(Figure 4.29).  Enhanced ROS access via this subsite can also lead to oxidation of the zinc-
coordinating histidine residues.  In addition to this, however, the non-prime tunnels’ 
proximity to the Cl(II) pocket could result in Y188 and/or R486 oxidation and loss of this 
critical ACE-activating anion.  The high reactivity of these residues suggests that this subsite 
is the key differentiating factor in the domains’ susceptibility to oxidative inactivation.  
Unique glycans and amino acids endow the N-domain with superior resistance by stabilizing 
the protein and limiting ROS access. 
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Figure 4.29: Reactivity to oxidation of C-domain non-prime tunnel-lining residues. 
C-domain residues are coloured according to their intrinsic reactivity to oxidation (Ri (Huang et al., 
2015) where Ri (blue) < Ri (white) < Ri (red)) and displayed as a cartoon. The C-domain non-prime tunnels 
calculated by Caver Analyst are shown as lines, Zn as an orange sphere, Cl- as a green sphere in pocket 
II, Zn-coordinating residues as green sticks and Cl--binding residues as yellow sticks. 
 
Binding of 1,8-ANS to proteins greatly depends upon lysine or arginine salt bridge formation 
via its sulphonate.  This is reinforced by Van der Waals interactions with hydrophobic 
residues via its anilinonaphthalene (Gasymov and Glasgow, 2007).  To understand how 1,8-
ANS binding might prevent C-domain oxidative inactivation, the distribution of cationic and 
aromatic or hydrophobic residues over the protein surface was visualized.  Three arginine, 
two lysine, two tryptophan and one tyrosine residue were found at the C-domain lid’s N-
terminus, thus 1,8-ANS binding at this site appears likely (Figure 4.30).  It is proposed that 
1,8-ANS binding to one of these hydrophobic and cationic residues would protect the C-
domain against oxidation by stabilizing the lid and limiting solvent access, analogous to N-
domain n4.  Due to the flexibility of the C-domain lid residues, molecular docking of this 
molecule was not attempted.  In future, however, this hypothesis can be confirmed by C-
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Figure 4.30:  Cationic and hydrophobic C-domain residues proximal to the non-prime tunnels.  
Non-prime tunnels calculated by Caver Analyst are shown as blue lines, hydrophobic residues as grey 
and cationic residues as red sticks. Zn is shown as a yellow sphere.  Potential pairs of 1,8-ANS binding 
residues are encircled. 
 
4.5   Conclusions 
The research presented in this chapter illustrate the power of molecular dynamics 
simulations in elucidating the function of protein glycosylation.  For the first time, atomic-
level insight was obtained into the mechanism whereby glycosylation at specific sites 
contribute to N- and C-domain ACE folding.  These in silico results were in line with previous 
experimental work.  Additionally, it was found that the N-domain’s superior thermal stability 
and resistance to oxidative inactivation by diffuse radicals is the result of unique protein-
protein, glycan-protein and glycan-glycan interactions.  This study not only paves the way for 
determination of the full-length sACE structure but can also aid in the future design of ACE-









Concluding remarks and future directions 
 
This study demonstrates how a range of in vitro and in silico techniques can be integrated to 
gain insight into the mechanisms of differential ACE folding, thermal stability, inhibition and 
oxidative inactivation.  The molecular basis for N-domain selectivity of two compounds, 33RE 
and CuGGHLis, from different drug classes was described, with the former resulting in 
reversible inhibition and the latter irreversible oxidative catalytic inactivation of the N-
domain.  Additionally, the function of glycosylation at each of the nine N-domain and six C-
domain PNGs and the basis for the N-domain’s superior thermal stability and resistance to 
oxidative inactivation by diffuse radicals was elucidated.   
 
This research offered a better understanding of the ACE molecule as a whole and showed 
that, despite their high active site identity and sequence similarity, the two domains have 
distinct dynamic motions which could govern enzyme activity and inhibitor binding.  The 
abundance of unique residues at the subdomain interface and hinge regions and the unique 
locations of the PNGs suggests that, following evolutionary duplication of the Ace gene, these 
regions evolved independently in the two ACE domains.  This likely gave rise to their 
selectivity towards binding or hydrolysis of certain substrates and thus, distinct physiological 
functions. 
 
The findings of the current study have implications for the future structural elucidation of 
sACE as well as the design of ACE inhibitors, catalytic metallodrugs and modulating agents 
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5.1  Elucidating the molecular basis of N-selective ACE inhibition 
 
Implications for design of domain-selective competitive ACE inhibitors  
Using enzyme kinetics, differential scanning fluorimetry, X-ray crystallography and molecular 
dynamics simulations the molecular mechanism whereby the phosphinic inhibitor 33RE binds 
with a remarkable 1000-fold selectivity to the N-domain was elucidated.  A combination of 
in silico and in vitro techniques was required since this drug’s binding was mediated by the 
dynamic behaviour of the N-domain, governed by interactions between distal unique 
residues.  Although the 33RE co-crystal structure of SEDSTE_YR-n389 provided some hints 
that mutation of these unique residues altered the protein’s dynamics, the effect on 33RE 
binding could only be rationalized using MD simulations.  In future, the likelihood of obtaining 
new domain-selective ACE inhibitors with drug design could be improved by taking the 
unique dynamic nature of the two domains into account.  Usage of weaker zinc binding 
groups might also allow for increased selection based on interactions of the prime and non-
prime moieties with unique residues in these subsites.  Given the abundance of unique 
residues in the S2’ subsite, it is proposed that incorporation of a weak zinc binding group and 
small, polar P2’ moiety into available moderately N-selective ACE inhibitors might yield 
clinically-relevant compounds for the treatment of fibrosis.  
 
Design of domain-selective allosteric ACE inhibitors  
Domain-selective ACE inhibition might alternatively be achieved by exploiting the lid region’s 
dynamic behaviour.  Since hinging of the lid appears to govern inhibitor binding as well as 
substrate access and hydrolysis, allosteric inhibition of ACE could potentially be achieved by 
locking the lid in a particular conformation.  Recently, nanomolar potency allosteric inhibition 
of the metalloprotease neurolysin was demonstrated using this approach (Hines et al., 2014).  
Binding of a pyrazolidine derivative to the lid residues in the protein interior led to non-
competitive inhibition by presumably preventing a hinge-like motion following substrate 
binding.  Since ACE possesses a similar hinging motion and sequence conservation between 
the N- and C-domain is poorest at the lid region, allosteric inhibitor design against the lid 
appears promising for selective fibrosis and hypertension treatment, respectively.   
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Alignment of neurolysin co-crystallized with the allosteric inhibitor R2 (PDB ID: 4FXY) to the 
C-domain of ACE revealed that the 350-fold C-domain selective BPPb (PDB ID: 4APJ) and the 
230-fold C-domain selective FII peptide (PDB ID: 2XY9) were bound in the same vicinity as R2 
(Figure 5.1).  Interestingly, R2 was located next to the lid pivot point identified in Chapter 2 
of this thesis.  C-domain selective allosteric ACE inhibitors could thus be designed by using FII 
or the 11-mer BPPb peptide’s moieties in this subsite as a template and extending it into the 
space occupied by R2 to prevent lid tipping about the pivot point.  Incorporation of a strong 
negative charge such as fluorine could further be used to increase the potency of inhibition 
through displacement of the essential chloride in the second pocket, proximal to the lid.  This 
novel class of ACE inhibitors would not act by chelation of the essential zinc ion and thus 




Figure 5.1: Structural alignment of the C-domain and neurolysin complexed to an allosteric inhibitor.   
The three N-terminal lid helices are shown in tan for neurolysin (PDB ID: 4FXY) and navy for C-domain 
complexed to a) the phosphinic tripeptide FII (PDB ID: 2XY9) and b) the 11-mer peptide BPPb (PDB ID: 
4APJ).  The two bound FII molecules are given in cyan and blue sticks, the BPPb peptide in magenta 
and the neurolysin allosteric inhibitor R2 in yellow.  The Zn and Cl(II) ions are shown as grey and green 
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Interestingly, the lid region also displayed the greatest sequence diversity amongst species 
(Figure 5.2).  Recently, Hasan et al found that captopril led to the death of Anopheles gambiae 
and Aedes aegypti mosquito larvae by inhibition of their larvicidal ACE activity (Abu Hasan et 
al., 2017).  To combat insecticide resistance and control the spread of malaria, it was 
proposed that existing ACE inhibitors could be modified using rational drug design to 
selectively target mosquito ACE.   
 
Designing a compound exclusive for binding to the mosquito ACE might, however, prove 
challenging given the high sequence conservation of the active site amongst species.  Since 
various habitats and organisms would encounter an insecticide, insufficient selectivity could 
have dire environmental consequences.  Captopril and enalaprilat, for example, have been 
shown to prolong Caenorhabditis elegans roundworm and rodent life-span (Kumar et al., 
2016; Santos et al., 2009) while captopril, fosinoprilat and lisinopril decreased fertility of the 
Crassostrea gigas pacific oyster (Riviere et al., 2011).  The design of allosteric inhibitors 
against the poorly conserved lid region therefore appears more suitable for the development 
of insecticides against Anopheles gambiae and Aedes aegypti mosquito species.  In future, 
this can be achieved by rational drug design following homology modelling of ACE 
homologues from mosquito, fly, roundworm, rodent, oyster, crab and leech species to the 
















Figure 5.2: Protein sequence alignment between ACE homologues indicating regions of species 
diversity.   
Human ACE homologue sequences from the Drosophila melanogaster house fly, Anopheles gambiae 
mosquito, Carcinus maenas shore crab, and Crassostrea gigas pacific oyster were aligned to the 
human ACE N- and C-domain using DNAMan v 4.15 (Lynnon BioSoft. ©).  The poorly conserved N-
terminal lid region is indicated by the green box. 
 
5.2  Evaluating N-selective catalytic inactivation 
 
Identification of the sites of oxidative modifications 
The experimental conditions for studying oxidative inactivation of the truncated N- and C-
domain ACE proteins by the CuGGHLis metallodrug has been optimized in the current study.  
The observed concentration-dependent inhibition and time-dependent oxidative 
inactivation was not confounded by possible inter-domain cooperativity and allowed careful 
analysis of the inhibitory binding constants and inactivation rate constants.  In future, these 
conditions can be used to prepare inactivated ACE protein samples for mass spectrometric 
N-terminal lid region 
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analysis.  This would allow identification of the sites of oxidative amino acid modification and 
thus further investigations into the molecular basis for N-domain selective inactivation by 
CuGGHLis.  X-ray crystallography can additionally be used to determine the N- and C-domain 
co-crystal structures with CuGGHLis to visualize the metal-binding domain’s orientation to 
amino acids with high intrinsic reactivities to oxidation.   
 
Design of a C-domain selective catalytic metallodrug 
Previously, Hocharoen et al observed that upon incubation in the presence of ascorbate and 
H2O2 redox co-reactants, Cu-CB-TE2A-Lis catalysed oxidative inactivation of the N- and C-
domain to a similar extent (Hocharoen et al., 2013).  This metallodrug bound to both domains 
with equal affinity and thus also displayed non-selective reversible inhibition.  Previously, a 
lisinopril-tryptophan analogue was designed which was highly selective for inhibition of the 
C-domain of ACE (Nchinda et al., 2006a).  It is proposed that attachment of the CB-TE2A 
metal-binding domain to the lysyl sidechain of lisinopril-Trp and titration with Cu2+ might 
yield the first C-domain selective catalytic metallodrug for the treatment of hypertension.  
This compound might be more effective than lisinopril-Trp since it irreversibly inactivates the 
enzyme and attachment of the hydrophobic chelate could increase the bioavailability of 
lisinopril-Trp which, at 5.4%, is of potential concern for clinical application (Denti et al., 2014).  
Time-dependent oxidative inactivation by Cu-CB-TE2A-LisTrp and the mechanism of potential 
C-domain selectivity can be investigated using the experimental conditions optimized in this 
study, in addition to mass spectrometry and X-ray crystallography. 
 
5.3  Investigating the influence of N-glycans on ACE dynamics 
 
Experimental validation of the proposed glycan functions 
In future, the contribution of unique N-domain glycan and protein residues towards 
protection against thermal and oxidative inactivation can be validated using chimeric 
constructs.  Chimeric C-domain proteins have previously been generated by replacing N-
terminal (C1–163Ndom-ACE), active site (C164-416Ndom-ACE) or C-terminal (C417–579Ndom-ACE) 
sections by their N-domain counterparts (Woodman, 2003; Woodman et al., 2006).  Since 
these areas contained PNGs, this also led to the removal or addition of glycans to the C-
domain. 
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To experimentally validate the contribution of n8 and n9 towards thermal stability and 
protection against oxidative inactivation, C417–579Ndom-ACE can be studied.  This chimera 
retains the C-domain glycans, lid and cleft-lining residues but gains N-domain n8 and n9 
(Figure 5.3 a).  This would likely introduce a glycan cluster on subdomain 2 through 
interaction between n9 and the C-domain c4 to stabilize the active site oxyanion hole and 
protein C-terminus along with n8.  Thermal stability would likely be increased but inactivation 
unchanged since ROS access would still occur via the unique C-domain lid and S2’ tunnels. 
 
The C1–163Ndom-ACE construct, on the other hand, can be used to investigate the lid and cleft-
lining residues’ contribution.  Upon replacement of the lid and helix 7 residues with their N-
domain counterparts, this chimera lost c1, c2, c3 and c4 but gained N-domain n1, n2, n3, n4, 
n5 and n6 (Figure 5.3 b).  A subdomain 1 cluster would be retained via n2–n3–c5 and a 
subdomain 2 cluster introduced via n5–n6 interaction.  This, along with the addition of n2 
and n4 protein interactions, would increase the melting temperature by stabilizing the 
subdomain 1 flap, lid and subdomain 2.  Further stability would be gained by hydrogen 
bonding between the cleft-lining helices.  Apart from this lid stabilization, physical blockade 
by n4 would also decrease solvent and ROS access through the lid tunnels.  Solvent access 
via the unique C-domain S2’ tunnels, however, would be unchanged. 
   
The unique S2’ tunnels’ contribution to oxidative inactivation can be investigated using the 
fully glycosylated N-domain active site mutant SEDSTE/TSEVVD (Chapter 2).  This mutant 
would maintain N-domain thermal stability and decreased non-prime tunnel access via lid 
stabilization and n4 blockade. The loss of gating residues upon mutation of the subdomain 
interface, however, would lead to increased S2’ tunnel formation and an influx of solvent and 
ROS via this subsite. 
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Figure 5.3: Chimeric C-domain proteins for future experimental validation of glycan function.   
C-domain regions replaced by N-domain residues are shown in magenta, C-domain glycans in cyan and 
introduced N-domain glycans in green for the a) C417–579Ndom-ACE and b) C1–163Ndom-ACE chimeric 




Design of anti-inflammatory ACE-modulating agents 
Increased susceptibility of the C-domain to oxidative inactivation by diffuse radicals could 
lead to the progression or maintenance of inflammatory disease (as described in Chapter 4 
section 4.1.2).  Binding of the 1,8-ANS molecule has been shown to protect the C-domain 
against ROS and as such could potentially interrupt this inflammatory cycle.  Testicular 
inflammation due to bacterial or viral infection could potentially lead to decreased male 
fertility via oxidative inactivation of the testis ACE isoform, essentially identical to the C-
domain of sACE and known to be important for sperm motility (Hagaman et al., 1998).  
Although the 1,8-ANS binding site was predicted in the current study, it should be confirmed 
in future by co-crystallization with the C-domain.  Analogues of 1,8-ANS can then be designed 
using fragment-based drug design or scaffold hopping to obtain selectivity for binding to the 
C-domain of ACE.  This would further require in silico screening of the designed compounds 
against proteins known (from literature) to bind with high affinity to 1,8-ANS.  Once a 
selective compound has been obtained, its ability to protect the C-domain against oxidation 
by diffuse radicals should be verified in vitro using enzyme activity assays.  Further in vitro 
experiments can then be performed in cell culture to assess the lead compound’s potential 
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sACE structural elucidation 
This study allowed identification of the glycan sites with the largest contribution to N- and C-
domain folding and thermal stability.  This information can be used in future to guide the 
design of a minimally glycosylated sACE protein amenable to crystallization for elucidation of 
its structure.  The MD results suggested that a sACE n4,5,7,8,9 c1,3,5 glycoform might be 
devoid of linker proteolysis and suitable for X-ray crystallography and should thus be created 
using site-directed mutagenesis.   
 
If it is found, however, that the full glycan complement is required to prevent linker 
proteolysis, insight can be gained into the human sACE structure by solving the structure of 
Anopheles gambiae AnoACE9.  This protein is unique among the insect ACE proteins since it 
is similar to human sACE in that it consists of two catalytically active domains and possesses 
a hydrophobic C-terminus (Burnham et al., 2005).  It, however, could be more suitable for 
crystallization since it only contains six PNGs as opposed to the fifteen glycosylated PNGs of 
sACE.  Glycosylation is likely also less complex than in a mammalian system.  AnoACE9 shares 
38.6% sequence identity and 60.3% sequence similarity with human sACE.  Homology 
modelling of the truncated single-domain ACE structures onto the AnoACE9 structure could 
therefore be used to gain insight into the possible orientation between the two domains.  
These two proteins would likely share a similar overall fold as observed between the single 
domains of human ACE and Drosophila melanogaster AnCE (Harrison and Acharya, 2014) 
(45% sequence identity and 60% sequence similarity to human C-domain ACE). 
 
Elucidation of this structure would have great implications for understanding inter-domain 
cooperativity, homodimerization, intracellular signalling and, ultimately, the function of sACE 







A1 Primers used to create active site mutations 
 
Table A1: Details of primers for site-directed mutagenesis. 
Screening enzyme recognition sequences are underlined, base-pair changes in lowercase and codon 













N-domain S357V CGATGGACCAGCTggtCACAGTGCACCATGAGATGG 78.3 PvuII 





S357V T358V CGATGGACCAGCTcGTCgtAGTGCACCATGAGATGG 81.1 PvuII removed 
S357V 
T358V D354E 






















































A2 Medium for bacterial growth 
 
Luria Bertani (LB) Medium: 
Medium for bacterial growth was prepared by addition of 2.5g tryptone, 1.25g yeast extract, 
2.5g NaCl and distilled water to a final volume of 250ml.  Medium was autoclaved at 120°C for 
20 minutes. 
 
Luria Agar (LA) Plates: 
Agar plates for growth of bacterial colonies was prepared by addition of 3.75g agar to 250ml 
sterilized LB medium.  LB-agar was subsequently autoclaved at 120°C (20 minutes) and ampicillin 
added to a final concentration of 100μg/ml once the solution had cooled to room temperature.  
Plates were poured and stored at 4°C. 
 
A3 Preparation and transformation of chemically competent cells 
 
Chemically competent bacterial cells: 
One hundred microliters of DH5α bacterial cells (from frozen glycerol stock) were inoculated 
into 5ml LB medium and incubated overnight at 37°C while shaking.  The overnight culture was 
used to inoculate 50ml LB medium which was incubated at 37°C while shaking.  The optical 
density was monitored periodically and the cells removed from the incubator once the log phase 
of growth was reached (culture optical density of 0.4 – 0.6 at a wavelength of 600nm).  The cells 
were pelleted from culture medium by centrifugation for 10 minutes at a speed of 5000rpm and 
temperature of 4°C.  The pellet was kept on ice for 25 minutes while resuspending the cells in 
10ml of 100mM MgCl2.  This was followed by centrifugation at a speed of 5000rpm and 
temperature of 4°C for 10 minutes.  After discarding the supernatant, the cells were 
resuspended on ice in 2ml of a CaCl2 solution consisting of 100mM CaCl2 and 15% glycerol.  The 
resulting competent cells were aliquoted into sterile Eppendorf tubes in 100μl volumes and 





Chemically competent DH5α cells were thawed on ice before incubation for twenty minutes 
on ice with 10μl of plasmid DNA.  This was followed by a five-minute incubation at 42°C, 
incubation on ice for one minute, addition of 450μl LB medium and incubation at 37°C for 
one hour.  One hundred microliters of the resulting transformed cells was spread onto Luria 
agar plates containing ampicillin and incubated overnight at 37°C.  
 
A4 Plasmid DNA Isolation 
 
Minilysate prep (STET Prep): 
A modified version of the minilysate prep by Ausubel et al was used to crudely isolate plasmid 
DNA following cloning or mutagenesis (Ausubel et al., 1989).  Briefly, ampicillin-resistant 
colonies were inoculated into 5ml LB medium (containing ampicillin) and incubated overnight 
at 37°C while shaking.  One millilitre of culture medium was transferred to a sterile Eppendorf 
tube and centrifuged for two minutes at a speed of 11500rpm.  After discarding the 
supernatant, the pellet was resuspended in 250μl of lysozyme-containing STET buffer (recipe 
below), briefly vortexed, boiled for one minute and centrifuged for eight minutes at a speed 
of 11500rpm.  The pellet containing cell debris was discarded and plasmid DNA precipitated 
by addition of 250μl isopropanol.  After centrifugation for eight minutes at a speed of 




The buffer used for the abovementioned boiling minilysate prep was prepared by addition of 
8g sucrose, 5g Triton X-100, 10ml EDTA (0.5M, pH8.0), 5ml Tris (1M, pH 8.0) and distilled 
water to a final volume of 100ml. 
 
A5 Agarose gel electrophoresis 
 
A 10X stock of TBE buffer for use in agarose gel electrophoresis was prepared by addition of 
53.9g Tris, 27.5g Boric acid, 3.7g EDTA and distilled water to a final volume of 500ml after 
adjustment of the pH to 8.0.  A working solution of 1X TBE buffer containing ethidium 




EtBr (at 10mg/ml) per litre.  A 1% agarose gel was prepared by addition of 0.5g agarose to 
50ml of 1X TBE containing EtBr.  DNA samples were electrophoresed using 1X TBE buffer 
containing EtBr as running buffer at a voltage of 80V. 
 
A6 Mammalian cell culture 
 
Tissue culture media were prepared in a fume hood, filter-sterilized and stored at 4°C. 
 
Growth medium 
CHO-K1 cell growth medium was prepared by addition of 430ml Dulbecco’s Modified Eagle 
Medium (Gibco®, Invitrogen), 430ml F-12 Ham’s nutrient mixture (Gibco®, Invitrogen), 100ml 
10%FCS (foetal calf serum inactivated at 56°C for 30min, Sigma-Aldrich® Co.) and 20ml HEPES 
(1M, pH 7.5). 
 
Harvesting medium 
Medium used for CHO-K1 cell protein expression consisted of 475ml Dulbecco’s Modified 
Eagle Medium (Gibco®, Invitrogen), 475ml F-12 Ham’s nutrient mixture (Gibco®, Invitrogen), 
20ml 10% FCS (foetal calf serum inactivated at 56°C for 30min, Sigma-Aldrich® Co.), 20ml 
HEPES (1M, pH 7.5) and 10ml Pen-Strep (penicillin-streptomycin, Lonza Research Solutions). 
 
Wash solution 
CHO-K1 cells were washed during culture using a phosphate buffered saline solution 
prepared by addition of 8.0g NaCl, 0.20g KCl, 1.78g Na2HPO4, 1.36g KH2PO4 and distilled water 








A7 His-Leu standard curve in phosphate assay buffer 
 
 
Figure A1: Standard curve of the linear correlation between moles of His-Leu and fluorescence 
determined in phosphate assay buffer pH 8.3. 
Represented as mean ± SEM of triplicate readings (Analysed with GraphPad Prism® v 6.01). 
 
 
A8 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
 
Proteins were separated according to molecular weight using sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis (SDS-PAGE).  Sample buffer consisted of 0.0625M Tris-
HCl (pH 6.8), 2% SDS, 10% Glycerol, 5% Mercaptoethanol and 0.001% Bromophenol Blue.  
Five microliters of sample buffer was added per protein sample.  The protein was denatured 
by boiling for 5 minutes.   
 
A 10% running gel was prepared by addition of 3.3ml running gel buffer (consisting of 1.125M 
Tris-HCl (pH 8.8) and 0.3% SDS), 4.07ml distilled water, 2.5ml acrylamide (at 40%), 100µl of 
ammonium persulphate (AMPS at 0.1%) and 15μl N,N,N’,N’-tetramethylethylenediamine 
(TEMED).  A 3% stacking gel was prepared by addition of 3.33ml stacking gel buffer (consisting 
of 0.375M Tris-HCl (pH 6.8) and 0.3% SDS), 5.2ml distilled water, 1.1ml acrylamide, 300µl of 
AMPS (at 0.1%) and 20μl TEMED.  The gel was cast, samples loaded and electrophoresis 
performed in a buffer consisting of 0.025M Tris-HCl (pH 8.3), 0.192M glycine and 0.1% SDS 





A Coomassie solution consisting of 0.25% Coomassie Brilliant Blue, 50% methanol and 10% 
acetic acid was used to stain the gel for one hour while shaking.  It was subsequently de-
stained by incubation in a solution of 25% ethanol and 10% acetic acid for two hours while 
shaking. 
 
A9 Abz-Gly standard curve 
 
 
Figure A2: Standard curve of linear correlation between moles of Abz-Gly and fluorescence. 
Represented as mean ± SEM of triplicate readings (Analysed with GraphPad Prism® v 6.01). 
 
 
A10 Abz-Gly correction curve 
 
 
Figure A3:  Inner filter effect correction curve. 
Correction values represent the ratio of Abz fluorescence at increasing substrate concentration 
relative to that in the absence of substrate.  The data was fit to a second order polynomial and is 










Figure A4: Representative Michaelis-Menten graph illustrating Abz-FRK(Dnp)P Km determination. 
N-domain a) Initial uncorrected data and b) data corrected for the inner filter effect are represented 



















A12 Example of a Dixon plot used in characterizing inhibitor binding affinity 
 
 
Figure A5: Representative Dixon plot of N-domain titrated with 33RE, illustrating Ki determination. 
The inverse of initial reaction velocity is represented as 1/FI, where FI = fluorescence intensity.  
Extrapolation of linear trendlines from different substrate concentrations gives a point of intersection 
(indicated by the red arrow) representing –Ki on the x-axis, thus Ki = 11.94nM. Data represented as 






A13 Titrations of EDTA and GGHLis with Cu2+  
 
Standardization of a CuCl2 solution 
To obtain a copper solution of known concentration for titration of Gly-Gly-His-Lisinopril 
(GGHLis), volumetric standardization was employed.  An EDTA solution of known 
concentration was titrated with CuCl2 and the formation of the CuEDTA complex monitored 
spectrophotometrically.  Upon addition of Cu2+, an increase in absorbance was detected at a 
wavelength of 270nm (Figure A6).  After 65µl of CuCl2 was added (pink line on Figure A6), a 
slight shift in the baseline was observed and further titration yielded no additional increase 
in the 270nm peak.  This indicated that all EDTA molecules were complexed to copper.   
 
 
Figure A6: Titration of an EDTA solution with CuCl2.  
Absorbance (Abs) of buffer only is given in black and EDTA only in blue.  Absorbance after sequential 
addition of 10µl volumes of CuCl2 is given in purple to red.  Titration was performed in buffer consisting 
of 20mM HEPES pH 7.5 and 100mM NaCl.  An increase in absorbance at 270nm indicates formation of 
the CuEDTA complex. 
 
The absorbance data from this complete titration was subsequently fitted to a segmental 
linear regression model relative to the molar ratio of metal to chelator.  The titration end-




the actual Cu2+ concentration in the prepared CuCl2 stock solution was slightly greater than 
the intended 3mM. 
 
 
Figure A7: Establishing the titration end-point for the CuEDTA complex.  
Complex formation was monitored as an increase in absorbance at 270nm.  The data was fitted to a 
segmental linear regression model using GraphPad Prism® v6.01.  The titration end-point was 




Preparation of the CuGGHLis metallodrug 
The CuGGHLis metallodrug was prepared by titration with the EDTA-standardized CuCl2 
solution.  Firstly, the absorbance peak detected at 257nm (Figure A8) was used to confirm 
the GGHLis concentration using an extinction coefficient of 197M-1cm-1, due to the presence 
of the lisinopril phenylalanine moiety.  Subsequent addition of CuCl2 into the GGHLis solution 
led to a shift in the 257nm peak and an increase in absorbance at a wavelength of 250nm 
(Figure A8).  The d-d transition was also detected as an increase in absorbance at 525nm (Lau 
et al., 1974).  The CuGGHLis titration end-point was determined by fitting the absorbance of 
the more pronounced 250nm peak to a segmental linear regression model (Figure A9).  At 
the inflection point on the curve, and thus the titration end-point, a 1:1 molar ratio of metal 
to chelate was observed.  Further addition of CuCl2 led to a slight shift in the baseline (Figure 
A8), indicating that all GGHLis molecules were complexed and free Cu2+ possibly present in 





Figure A8: Titration of the GGHLis chelate with CuCl2.  
Absorbance (Abs) of buffer only is given in purple and GGHLis only in black.  Absorbance after 
sequential addition of 10µl volumes of CuCl2 is given in brown to red.  Titration was performed in 
buffer consisting of 20mM HEPES pH 7.5 and 100mM NaCl.  An increase in absorbance at 250nm 
indicates formation of the CuGGHLis complex.  The d-d transition is evident from an increase in 





Figure A9:  Establishing the titration end-point for the CuGGHLis complex.  
Complex formation was monitored as an increase in absorbance at 250nm and the data fitted to a 
segmental linear regression model using GraphPad Prism® v6.01.  The titration end-point was 




The second titration was performed up until this established endpoint to obtain a 1:1 molar 
ratio of metal to chelator (Figure A10) whereas the third titration was halted prior to the 
endpoint at a 1:1.1 metal to chelator molar ratio (Figure A11).  In both cases the lack of free 
copper ions was confirmed by the absence of absorbance at 750 – 800nm.  The third titration 
yielded a slight excess of chelate to further ensure that no free copper ions would be present 
during subsequent oxidative inactivation experiments.   
 
 
Figure A10: Titration of GGHLis with CuCl2 to prepare the CuGGHLis metallodrug used for binding 
affinity characterization.   
Copper addition was halted at a 1:1 molar ratio of metal to chelator. The zoomed in view in the right-





Figure A11: Titration of GGHLis with CuCl2 to prepare the CuGGHLis metallodrug used for 
characterization of catalytic inactivation. 
Copper addition was halted at a 1:1.1 molar ratio of metal to chelator. The zoomed in view in the right-







A14 His-Leu standard curve in HEPES assay buffer 
 
 
Figure A12: His-Leu standard curve prepared in HEPES pH 8.2 assay buffer (containing Brij at 0.05%).  




A15 Blue Silver Coomassie SDS-PAGE stain 
 
The colloidal Blue-Silver Coomassie stain was prepared according to the method of Candiano 
et al (Candiano et al., 2004).  A 200ml volume of stain was prepared by dropwise addition of 
20ml o-phosphoric acid (Sigma-Aldrich® Co.) to 20ml MilliQ deionized distilled water while 
stirring.  Twenty grams of ammonium sulphate was added while stirring.  Once dissolved, 
0.24g of Coomassie brilliant blue G250 was added and completely dissolved.  The volume 
was adjusted to 80% of the final volume with MilliQ deionized distilled water before addition 
of 40ml anhydrous methanol while stirring to obtain colloidal particles in greenish-blue 
solution.  The staining solution was stored in the dark at room temperature. 
 
After separation of the proteins by SDS-PAGE, the gel was washed three times for 10 minutes 
with MilliQ deionized distilled water to remove SDS.  The staining solution was added and 
incubated at room temperature with shaking to allow distribution of the colloidal particles.  
To achieve maximum staining, the gel incubations were performed overnight and de-stained 





A16 Reported versus published second order inactivation rate constants 
 
 
Table A2: Initial rates and second order catalytic inactivation rate constants (k2) at 37°C for N-domain 
in the presence or absence of CuGGHLis and redox co-reactants. 
Initial rates were calculated from the first-order exponential decay curves obtained from one time-
course experiment performed in triplicate and rate constants as k2 = (initial rate - background)/ 
[enzyme][CuGGHLis].  A comparison is given with the k2 values reported by Joyner et al at 37°C for 
two-domain sACE using a non-domain selective substrate. 
N-domain 
Initial rate (nM min-1) k2 for inactivation (M-1 min-1) 




















None 0.010 0.010 15 299  
Ascorbate 0.064 0.062 94 876 102 000 ± 6 000 












A17 System equilibration 
A17.1 N-domain energy, temperature, pressure, volume and density 
                                                          
                                                                                                 








                   
                   









                                
                                           
Figure A15:  Variation in N-domain temperature, energy, density, volume and pressure observed during 30ns production dynamics.  







A17.2 C-domain energy, temperature, pressure, volume and density 
 
                                       
                                                                                                          








            
  
                         








                                   
                                             
Figure A18:  Variation in C-domain temperature, energy, density, volume and pressure observed during 30ns production dynamics.  



















A17.4 Maintenance of C-domain Zn-coordination geometry 
 












A17.5 Stability of N-domain Cl- in the second pocket 
 
 
Figure A23:  Variation in chloride ion binding distances in the N-domain pocket 













Figure A24:  Variation in chloride ion binding distances in the C-domain pockets 




A18 Torsion angle analysis results 
A18.1 Population analysis of N-domain glycosidic torsion angles  
Table A3: Population of N-domain Asn-GlcNAc linkage torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses  
                        PNGs 
Torsion angle 








9 243±15 169±11 180±9 240±15 
NA 
25 248±11 165±7 174±7 254±10 
45 237±15 170±10 181±7 196±13 
82 250±17 177±10 305±10 297±18 
117 246±14 176±8 201±7 194±14 
131 251±16 176±13 195±17 (65%); 283±13 (35%) 68±16 (40%); 268±26 (60%) 
289 265±14 180±11 188±9 165±30 
416 255±17 184±10 191±10 189±20 











Table A4: Population of N-domain α(1-6) linkages’ torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses  
                       PNGs 
Torsion angle 








9 70±11 108±46 
NA 
49±10 (99,97%); 346 (0,03%) 
25 71±10 (99%);137±23% (1%) 170±38 55±10% (93%); 281±12 (7%) 
45 75±11 (95%); 160±13 (5%) 190±18 58±11 
82 76±12 94±12 50±8 
117 68±11 183±17 53±10 (99,9%); 311±31 (0,1%) 
131 76±12 96±20 50±9 (99,97%); 359 (0,03%) 
289 72±10 (99%); 155±14 (1%) 189±15 55±11 
416 68±10 (95%); 165±10 (5%) 180±18 57±11 (15%); 180±12 (85%) 










9 282±15 77±12 (23%); 166±15 (77%) 
NA 
49±10 (99,97%); 340 (0,03%) 
25 250±9 251±19 56±9 
45 256±28 73±13 (37%); 169±14 (63%) 42±12 (98%); 340±16 (2%) 
82 280±25 155±21 36±14 (99%); 343±19 (1%) 
117 242±39 171±15 43±11 (69%); 319±16 (31%) 
131 289±15 165±22 52±14 (99%); 345±13 (1%) 
289 281±15 165±23 44±11 (99,9%); 358±2 (0,1%) 
416 283±17 160±40 47±12 (99%); 324±16 (1%) 




Table A5: Population of N-domain α(2-3) linkages’ torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses (a: NeuAc on Manα1-3 Man arm; b: NeuAc on Manα1-6 Man arm) 
                       PNGs 
Torsion angle 









9 52±13 (61%); 313±13 (39%) 211±23 
NA NA 
25 56±13 (96%); 313±12 (4%) 228±27 
45 57±14 (85%); 313±13 (15%) 221±26 
82 57±13 (84%); 312±13 (17%) 221±26 
117 57±14 (76%); 313±12 (24%) 221±27 
131 56±14 (88%); 313±15 (12%) 220±27 
289 58±14 (91%); 314±12 (9%) 221±25 
416 54±16 (37%); 314±11 (63%) 217±18 










9 61±14 (81%); 313±12 (19%) 230±26 
NA NA 
25 59±14 (96%); 311±14 (4%) 221±27 
45 64±12 (80%); 312±11 (20%) 235±23 
82 54±14 (95%); 318±13 (5%) 224±25 
117 69±8 252±8 
131 58±14 (86%); 313±11 (14%) 222±29 
289 55±13 (80%); 314±13 (20%) 213±21 
416 53±12 (99,97%); 348 (0,03%) 215±28 




A18.2 Population analysis of C-domain glycosidic torsion angles 
Table A6: Population of C-domain Asn-GlcNAc linkage torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses  
                      PNGs 
Torsion angle 








36 227±12 172±10 177±7 199±11 
NA 
54 251±16 177±10 189±9 199±19 
73 266±14 187±9 182±7 130±16 
119 258±17 173±10 203±11 255±31 
301 255±17 177±10 191±11 (57%); 282±12 (43%) 215±26 












Table A7: Population of C-domain α(1-6) linkages’ torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses. 
                       PNGs 
Torsion angle 








36 68±15 182±14 
NA 
50±10 (99,6%); 295±12 (0,4%) 
54 74±13 181±14 57±11 (99,9%); 297±35 (0,1%) 
73 78±13 211±20 59±13 
119 76±13 107±22 53±9 
301 67±11 67±12 (85%); 172±17 (15%) 43±11 (99%); 309±14 (1%) 










36 287±9 196±10 
NA 
49±9 
54 289±10 158±22 49±11 (99,8%); 353±6 (0,2%) 
73 291±12 213±24 53±12 (99%); 342±17 (1%) 
119 277±22 171±16 42±13 (99,6%); 334±24 (0,4%) 
301 286±16 171±33 48±12 (99%); 312±27 (1%) 









Table A8: Population of C-domain α(2-3) linkages’ torsion angles during MD. 
Angles represented as mean ± standard deviation with population in parentheses.  (a: NeuAc on Manα1-3 Man arm; b: NeuAc on Manα1-6 Man arm) 
                      PNGs 
Torsion angle 









36 62±15 (87%); 313±11 (13%) 228±27 
NA NA 
54 58±13 (91%); 315±11 (9%) 225±26 
73 58±18 (89%); 312±12 (11%) 219±30 
119 56±13 (87%); 316±12 (13%) 220±26 
301 59±14 (80%); 313±11 (20%) 224±27 










36 55±12 (99,9%); 344±15 (0,1%) 213±22 
NA NA 
54 58±12 220±25 
73 61±12 231±22 
119 74±14 247±20 
301 66±15 (91%); 316±11 (9%) 233±24 




A19 Hydrogen bond analyses between glycans and the N- or C-domain 
 
 
Table A9: Glycan to N-domain hydrogen bonds. 
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies indicated 
in parentheses and acceptor residue names italicized.   
Donor glycan Donor sugar - acceptor residue (% frames) 
n2 
0SA O4 - Q30 OE1 (13.9) 
3LB O4 - Q545 OE1 (7.5) 
UYB C1 - R380 HH22 (5.7) 
0SA O4 - Q371 OE1 (5.5) 
n3 
0SA O9 - E49 OE1 (27.0) 
0fA O2 - N50 OD1 (24.8) 
0SA O8 - E49 OE2 (18.7) 
0SA O9 - E49 OE2 (18.4) 
0SA O8 - E49 OE1 (8.7) 
n4 0SA O8 - N203 OD1 (5.9) 
n5 0SA O7 - T482 OG1 (51.2) 
n7 
0SA O4 - G316 O (33.5) 
4YB O6 - E315 OE2 (14.6) 
4YB O6 - E315 OE1 (13.9) 
n8 
4YB N2 - E522 OE2 (22.0) 
VMB O4 - E522 OE1 (20.1) 
0SA O8 - Q575 OE1 (16.2) 
3LB O4 - E518 OE1 (14.4) 
0SA O4 - V560 O (14.0) 
3LB O6 - E518 OE2 (11.7) 
3LB O4 - E518 OE2 (11.3) 
3LB O6 - E518 OE1 (10.8) 
3LB O2 - Q575 OE1 (10.5) 
0SA O9 - E518 OE2 (9.6) 
VMB O4 - E522 OE2 (8.6) 
VMB C1 - E522 HB3 (5.8) 
                    0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc, UYB =1st core GlcNAc,  






















Table A10: N-domain to glycan hydrogen bonds. 
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies 
indicated in parentheses and acceptor residue names italicized.   
Acceptor glycan Donor residue – acceptor sugar (% frames) 
n2 
 
R340 NH2 - 4YB O2N (70.4) 
R340 NH1 - 4YB O2N (36.6) 
Q22 NE2 - UYB O2N (20.9) 
R541 NH2 - 0SA O1A (7.1) 
R541 NH2 - 0SA O1B (5.6) 
n3 
 
R52 NH1 - 0SA O1A (14.3) 
R52 NH2 - 0SA O1A (12.4) 
N50 ND2 - UYB O5 (10.6) 
R53 NH1 - 0fA O4 (8.5) 
R52 NH1 - 0SA O1B (6.2) 
R52 NH1 - 0SA O9 (5.7) 
R52 NH2 - 0SA O1B (5.1) 
n4 
 
R89 NH2 - 0fA O4 (17.4) 
N203 ND2 - 0SA O1B (13.4) 
N203 ND2 -0SAO1A (7.5) 
R89 NH1 - 0fA O4 (7.4) 
R89 NH2 - 0SA O1A (5.3) 
R89 NH1 - 0SA O1A (5.2) 
n5 
N480 ND2 - 0SA O4 (54.7) 
H483 NE2 - 3LB O4 (41.4) 
N480 ND2 - 0SA H4O (27.7) 
H483 NE2 - 3LB H4O (11.6) 
n7 
R344 NH1 - 0SA O4 (34.2) 
R344 NH1 - 0SA O1B (11.5) 
R344 NH2 - 0SA O1A (10.9) 
R344 NH1 - 0SA O1A (9.0) 
R344 NH2 - 0SA O1B (7.4) 
n8 
Q575 NE2 - 0SA O7 (25.0) 
Q579 NE2 - 0SA O7 (13.1) 
Q575 NE2 - 0SA O7 (11.8) 
Q568 NE2 - 4YB O4 (7.2) 
                                        0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc, UYB =1st core GlcNAc,  






























              
 
 
                 
 
 
               
 
 





























































































































     
 
 
   
 
 
   
 
 

















































































































Table A11: Glycan to C-domain hydrogen bonds. 
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies indicated 
in parentheses and acceptor residue names italicized.   
Donor glycan Donor sugar - acceptor residue (% frames) 
c1 
0SA O7 - E25 OE2 (35.4) 
0SA O7 - E25 OE1 (27.7) 
0SA O8 - E25 OE2 (8.7) 
0SA O8 - E25 OE1 (5.9) 
0SA O4 - Q47 OE1 (5.2) 
c2 
0SA O8 - E14 OE2 (14.2) 
0SA O8 - E14 OE1 (14.2) 
0SA O9 - E14 OE1 (9.7) 
0SA O4 - E62 OE1 (6.6) 
c3 
0SA O4 - N325 O (63.8) 
0fA O4 - E13 OE2 (35.6) 
0fA O4 - E13 OE1 (29.3) 
0SA O9 - D360 OD1 (9.2) 
c4 0SA O4 - G120 O (27.0) 
c5 0fA O4 - E28 OE2 (6.7) 
c6 
UYB O3 - S192 OG (37.7) 
4YB O6 - S192 OG (35.2) 
UYB N2 - D196 OD1 (29.9) 
UYB O3 - S192 HG (18.5) 
UYB O3 - D196 OD1 (12.8) 
UYB N2 - D196 OD2 (12.1) 
UYB O3 - D196 OD2 (11.1) 
                                        0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc, UYB =1st core GlcNAc,  
                                        VMB = 1st Man linked to core GlcNAc 
 
Table A12: C-domain to glycan hydrogen bonds. 
Hydrogen bonds present in more than 5% of the simulation are shown with the frequencies 
indicated in parentheses and acceptor residue names italicized.   
Acceptor glycan Donor residue – acceptor sugar (% frames) 
c1 
K48 NZ - 0SA O5N (15.9) 
Q47 NE2 - 0SA O4 (14.1) 
Q51 NE2 - 0SA O4 (13.7) 
K48 NZ - 0SA O5N (13.0) 
K48 NZ - 0SA O5N (12.9) 
Q51 NE2 - 0SA O4 (9.8) 
c2 
Q51 NE2 - 0fA O4 (10.0) 
K58 NZ - 0SA O7 (7.8) 
Q62 NE2 - 0SA O5N (7.4) 
K58 NZ - 0SA O7 (6.4) 
K58 NZ - 0SA O7 (6.0) 
c4 C122 N - 0SA O5N (21.8) 
c5 W31 NE1 - 0fA O4 (9.0) 
c6 
M551 N - UYB O2N (13.9) 
S192 N - 4YB H6O (13.3) 
S192 N - 4YB O6 (12.9) 
                                        0fA = Fuc, 0SA = NeuAc, 2MA = Man, 3LB = Gal, 4YB = GlcNAc, UYB =1st core GlcNAc,  



























































































































































A20 AQUA-DUCT statistics 
 
Table A13: Statistical analysis of the N-domain water flow. 
Entry and exit paths are described by rows and columns, respectively, with the number of water 
molecules given for each.  Water molecules that do not exit but remain in the scope region for the 
duration of simulation are given in red. 









 Prime Non-prime Flap 1 Flap 2 Scope Outliers Sum 






























Flap 2 1 (2.56%) 
1 
(2.56%)     
2 
(5.13%) 
Scope 1 (2.56%)      
1 
(2.56%) 




















Table A14: Statistical analysis of the C-domain water flow. 
Entry and exit paths are described by rows and columns, respectively, with the number of water 
molecules given for each.  Water molecules that do not exit but remain in the scope region for the 










 Prime Non-prime Flap 1 Flap 2 Scope Outliers Sum 



























Flap 1 1 (0.52%)      
1 
(0.52%) 
Flap 2 4 (2.09%) 
1 


















Outliers 1 (0.52%) 
2 
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